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Notch is a transmembrane receptor that mediates short-range signaling between
neighboring cells. Notch signaling has been implicated in various cellular and
developmental processes essential in the life of metazoans. Specifically, Notch signaling
plays a critical role in mammalian skin. Removal of Notch alleles in skin keratinocytes
has been associated with an array of phenotypes with varying severity based on the
identity and number of remaining Notch receptors. Phenotypes include carcinogenesis (in
the case of Notch1 loss), transformation of hair follicles to epidermal cysts and neonatal
lethality, the latter seen in the absence of all Notch signaling. Although these phenotypes
were previously described, the exact mechanisms underlying them have not been fully
understood. This dissertation focuses on obtaining mechanistic insights into some of the
observed phenotypes attained by analyses of the local and systemic changes downstream
of Notch signaling loss in the skin.
In order to examine the direct consequences of Notch loss in keratinocytes, we
first focused on intrinsic changes detected at postnatal day 9 in Notch-deficient epidermis
in vivo. Our findings helped establish that an additive function of Notch paralogs is
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required for proper epidermal differentiation and lipid biosynthesis in the epidermis,
which in turn lead to formation of a competent skin-barrier. We showed that these
functions were executed through both canonical (RBP-j-dependent) and non-canonical
Notch signals.
Accordingly, we discovered that the defective skin-barrier formed by Notch1deficient keratinocytes created a sub-acute wound-like microenvironment that explained
the tumor promotion seen in the absence of Notch1 in the skin. Therefore, skin
carcinogenesis is a non-cell autonomous consequence of Notch deletion in keratinocytes,
which represents the end result of a crosstalk between barrier-defective epidermis and its
underlying stroma.
Besides the intricate interaction between epidermis and its neighboring structures
in the skin, we uncovered that defects in epidermal barrier sets off a systemic alarm by
secreting thymic stromal lymphopoietin (TSLP), an epithelial-derived cytokine
implicated in pathogenesis of asthma and atopic dermatitis. TSLP was highly expressed
by Notch-deficient epidermis. Importantly, we were able to show that TSLP was both
required and sufficient to cause a lethal systemic B-lymphoproliferative disorder in
newborn or asthma in adult mice lacking Notch signaling in the skin.
Overall, this body of work outlines the direct cellular effects of Notch loss, and
describes the mechanisms connecting epidermal Notch deletion to its non-cell
autonomous local and systemic consequences.
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CHAPTER I

INTRODUCTION
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Notch, so named because of the notch that appears at the wing margin of flies
carrying mutation in Notch locus (Mohr, 1919), is a transmembrane receptor in a
evolutionarily conserved signaling pathway enabling short-range communications
between adjacent cells, thereby regulating several cellular processes including stem cell
renewal/fate selection, proliferation and differentiation (Artavanis-Tsakonas et al., 1999).
Given the importance of Notch signaling, dysregulation of this pathway has been linked
to human disorders ranging from developmental syndromes to cancer (Ball and Leach,
2003; Gridley, 2003; Radtke and Raj, 2003).
Notch Signaling in Vertebrates
Four Notch paralogs have been identified in mammalian cells (Favier et al., 2000;
Katoh and Katoh, 2007). Each Notch receptor is a single pass type I transmembrane
protein that has several structural domains (Figure 1.1A). The extracellular domain of
Notch contains 29-36 tandem epidermal growth factor (EGF)-like repeats (Rao et al.,
1995) and 3 cysteine-rich LIN-12/Notch (LNR) (Vardar et al., 2003). Following receptor
maturation, the extracellular and transmembrane segments of the Notch protein are held
together non-covalently by a heterodimerization (HD) domain (Sanchez-Irizarry et al.,
2004). The intracellular domain of Notch is composed of the RBP-j-AssociationMolecule (RAM) domain, tandem ankryin (ANK) repeats, transactivation domain (TAD),
a glutamine-rich domain (OPA), and a PEST domain (Gordon et al., 2008; Lubman et al.,
2004). Notch signaling is initiated upon binding of the Notch extracellular domain to its
ligands, DSL (Delta and Serrate/Jagged in Drosophila and vertebrate, Lag-2 in C.
elegans), that are expressed on the surface of the adjacent cells (Brou et al., 2000; Kopan,
2002; Mumm and Kopan, 2000). Several DSL ligands, Delta-like (1,3 and 4) and Jagged
2

(1and 2), have been identified in mammalian cells (Favier et al., 2000; Katoh and Katoh,
2007; Vargesson et al., 1998). Recent studies have shown that the LNR repeats and HD
domain of Notch together form an extracellular negative regulatory region (NRR),
adopting an autoinhibitory conformation and keeping the the metalloprotease cleavage
site of Notch buried in the absence of ligand (Gordon et al., 2007). Ligand-bound Notch
undergoes a substantial conformational change within NRR thereby exposing this
metalloprotease cleavage site (Gordon et al., 2007). The intermediate peptide created
after this proteolytic cleavage (NEXT: Notch extracellular truncation) is cleaved by the !secretase enzyme within the transmembrane domain to release the Notch intracellular
domain (NICD) (De Strooper et al., 1999; Struhl and Greenwald, 2001). !-secretase is
composed of four subunits: Presenilin, Nicastrin, Aph1 and Pen2 (Wolfe, 2008).
Presenilins (Presenilin (PS) 1 and 2) form the catalytic pocket of !-secretase and are
required for generation of NICD (De Strooper et al., 1999). The NICD that is released
from the plasma membrane translocates into the nucleus and binds to its DNA-binding
partner, RBP-j (also called CSL: CBF1 or RBP-j in vertebrates, Su(H) in Drosophila,
Lag-1 in C. elegans) (Pursglove and Mackay, 2005; Schroeter et al., 1998). NICD
replaces the co-repressor proteins associated with RBP-j on DNA to form a NICD/RBP-j
complex (Tamura et al., 1995; Tani et al., 2001). Mastermind (MAM/Lag3) protein binds
to the NICD/RBP-j interface, which leads to recruitment of other members of the
transcription-activating complex like p300 on promoters of target genes (Fryer et al.,
2002). This complex activates a large array target genes in a context-dependent manner.
Among the best-studied direct targets of Notch signaling are HES and HERP family of
transcription factors (Iso et al., 2003). On some Notch pathway targets (the so-called
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permissive Notch targets), loss of RBP-j and with it, displacement of co-repressor
proteins from the target gene promoter is sufficient for activation (Koelzer and Klein,
2006; Morel et al., 2001; Morel and Schweisguth, 2000). This overall pathway is called
“canonical” Notch signaling (Figure 1.1B). Despite the lack of genetic evidence in
vertebrates, an RBP-j-independent (“non-canonical”) Notch signaling pathway in
vertebrates has also been proposed (Rangarajan et al., 2001). In this context, NICD is
thought to associate with another DNA-binding partner besides RBP-j to regulate the
transcription of RBP-j-independent Notch target genes like involucrin in epidermal
keratinocytes (Rangarajan et al., 2001).

Skin Biology
One of the organs in which Notch signaling is known to be active is the
mammalian skin. Skin is composed of epidermis and its underlying dermis. Skin also
contains appendages that include hair follicles, sweat glands, and sebaceous glands
(Figure 1.2A). The skin composition allows for keratinocytes, melanocytes, dermal
fibroblasts, resident immune cells, nerve cells, blood vessels and circulating
hematopoietic cells to engage in an intricate interaction sustaining organ integrity
(Morasso and Tomic-Canic, 2005). Skin appendages also contribute to the maintenance
of this organ. Three Notch paralogs (Notch1, Notch2 and Notch3) are expressed in
epidermal and hair follicular keratinocytes (Figure 1.2B; (Pan et al., 2004; Rangarajan et
al., 2001)). Therefore, the skin architecture provides an ideal system in which to study
how Notch signaling regulates the homeostasis of a multi-compartmental organ.
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Epidermis is an ectoderm-derived tissue that is first composed of a single basal
layer and an overlying periderm during early embryonic life of mammals (Li et al., 2003;
M'Boneko and Merker, 1988). Later, basal layer keratinocytes undergo stratification to
form spinous, granular and cornified layers of the epidermis (Figure 1.2A), which takes
place around embryonic day 15.5 (E15.5) in mice (Fuchs and Raghavan, 2002). Several
signaling pathways have been implicated to regulate epidermal stratification. Among
them, p63, a p53 family member, plays a critical role in this process. Although p63
maintains the proliferative potential of basal keratinocytes in mature epidermis, its
expression is required for the initiation of epidermal stratification in embryonic life
(Koster and Roop, 2004; Mills et al., 1999). Another key molecule involved in epidermal
stratification is IKK, which has a pro-differentiation role in keratinocytes. Loss of IKK is
associated with hyperproliferation and impaired differentiation in mouse epidermis (Hu et
al., 2001; Li et al., 1999; Takeda et al., 1999).
Adult epidermis maintains its stratified composition through a dynamic
equilibrium between proliferation and terminal differentiation. Keratinocytes in the basal
layer maintain contact with the basement membrane through their hemidesmosomes,
which contain integrins "6#4 (Fuchs and Raghavan, 2002). The epidermal stem cells and
proliferative progenitor cells reside in the basal layer of the epidermis (Clayton et al.,
2007). A subset of basal layer cells enter the differentiation program, lose their integrin
"6#4 expression, detach from the basement membrane and give rise to the upper spinous
layer. Spinous cells execute the terminal differentiation program and ascend to the
granular and cornified layers (Fuchs and Raghavan, 2002; Jamora and Fuchs, 2002).
These layers form the epidermal barrier that prevents foreign agents from entering into
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and water loss from the organism (Segre, 2006). The signs of skin-barrier formation are
evident in the spinous layer where keratinocytes that have exited the cell cycle start to
accumulate a dense network of keratin intermediate filaments. In the granular layer,
deposition of lipids and filaggrin-mediated assembly of keratin filaments to generate
macrofibrils result in a more resilient barrier. Starting in the granular layer, cornified
envelop protein precursors assemble beneath the plasma membrane and their irreversible
cross-linkage by transglutaminase enzymes leads to formation of an insoluble sac around
the keratin filaments in the cornified layer. This elaborate protein scaffold is tightly
sealed by lipid deposition. If a defect arises in executing the keratinocyte terminal
differentiation program, several compensatory mechanisms, including dermal fibroblast
activation, immune cell infiltration and reactive epidermal hyperplasia, will come into
effect in order to limit the adverse consequences of skin-barrier defects (Segre, 2006).

Notch Signaling and Skin Development
Notch signaling in keratinocytes is thought to regulate skin development and
maintenance in at least 4 distinct compartments:
(1) Notch signaling controls keratinocyte proliferation, commitment and
differentiation decisions in the intact epidermis and in cultured keratinocytes
through its intricate interaction with several signaling molecules such as p63
(Nguyen et al., 2006; Nickoloff et al., 2002; Nicolas et al., 2003; Okuyama et
al., 2004; Rangarajan et al., 2001). In this context, Notch activation acts as a
switch in basal layer keratinocytes, inducing their exit from proliferation and
their entrance into differentiation as they migrate upward into the spinous
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layer. During this process, Notch represses the basal layer-specific genes like
integrin "6#4 to facilitate the detachment of keratinocytes from the basement
membrane. In addition, Notch indirectly activates the expression of spinous
genes including keratin 1 and 10 through Hes1 upregulation (Blanpain et al.,
2006). In suprabasal keratinocytes, Notch promotes the transition from
spinous to granular layer in part through activating Ascl2, an Achaete/Scuterelated basic helix-loop-helix (bHLH) transcriptional activator (Moriyama et
al., 2008). Collectively, these functions of Notch ensure proper epidermalbarrier formation. Therefore, the global loss of Notch signaling in epidermal
keratinocytes results in a severely impaired skin barrier and death at birth due
to dehydration (Blanpain et al., 2006). Importantly, mice that lack Notch
signaling only in a portion of their epidermis and can retain enough liquid to
survive after birth, still die before weaning with a relatively mild skin
phenotype (Pan et al., 2004).
(2) Notch signaling is implicated in regulation of the stem cell niche in the
epidermis (Estrach et al., 2008; Estrach et al., 2007; Lowell et al., 2000;
Thelu et al., 2002). It has been proposed that Delta1 marks the clusters of
stem cells in the basal layer of the epidermis and its interaction with Notch
on the neighboring cells induces the differentiation of the Notch-expressing
cells.
(3) Notch plays a critical role in differentiation and maintenance of skin
appendages (Lin and Kopan, 2003; Lin et al., 2000; Pan et al., 2004;
Uyttendaele et al., 2004; Vauclair et al., 2005). During hair follicle
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development, Notch signaling regulates the proper terminal differentiation of
the inner root sheath cells, but it is not required for fate selection during the
process of embryonic hair follicle formation (Pan et al., 2004). In addition,
Notch plays a critical role in preserving the proliferative capacity of hair
follicle progenitors in the bulb by maintaining the balance between
transforming growth factor (TGF)-# and insulin-like growth factor (IGF)
signaling pathways in the bulb microenvironment (Lee et al., 2007).
(4) Notch has also been suggested to be directing the differentiation choices by
adult hair follicle stem cells in the bulge (Yamamoto et al., 2003). Loss of
Notch/RBP-j in adult hair follicles leads to transformation of the hair follicles
to epidermal keratin cysts. Based on indirect lineage-tracing methods, it
appears that Notch is required in hair follicle stem cells in the bulge to
choose the hair follicle fate, and in the absence of Notch signaling these cells
choose the alternative epidermal fate. This fate switch is thought to underlie
the transformation of adult RBP-j/Notch-deficient hair follicles into keratin
cysts.

Notch Signaling and Skin Carcinogenesis
Notch signaling dysregulation has been associated with several cancers in mice
and humans (Radtke and Raj, 2003). In most cases, Notch functions as a proto-oncogene
and its excessive activation drives tumorigenesis (Radtke et al., 2006; Weng and Aster,
2004). For instance, activating mutations in HD and PEST domains of Notch1 has been
found in more than 50% of patients with T-cell acute lymphoblastic leukemia (T-ALL)
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(Demarest et al., 2008; Weng et al., 2004). Unlike its prominent oncogenic activity,
Notch overexpression is suggested to limit the growth of a few tumor cell types
(Kunnimalaiyaan et al., 2006; Sriuranpong et al., 2001; Zheng et al., 2007). More
importantly, Notch has been demonstrated to suppress tumorigenesis in skin
keratinocytes (Nicolas et al., 2003).
Studies on mice lacking Notch1 in epidermal keratinocytes have conclusively
demonstrated that loss of Notch1 stimulates tumor formation in the mouse skin (Nicolas
et al., 2003). Even in the absence of any treatment, Notch1-deficient skin develops
spontaneous tumors overtime. The majority of these tumors are benign papillomas but a
few of them progress to invasive basal cell carcinomas (BCCs). The development of BCC
is associated with activation of the Hedgehog (HH) pathway (Hutchin et al., 2005), and
the Gli2 overexpression in the epidermis of Noch1-/- mice supports this connection.
Using the two-stage chemical carcinogenesis model of skin carcinogenesis (DMBA/TPA;
(Kelly-Spratt et al., 2004; Weinberg et al., 1999; Yuspa, 1994)), it has been shown that
all Notch1-/- animals develop at least one papilloma over a 25-week follow-up period (no
lethality within this window was reported in a largely resistant mixed 129/C57BL6
background) with a subset of these papillomas at high risk for malignant conversion to
squamous cell carcinoma (SCC) with elevated nuclear #-catenin (Nicolas et al., 2003).
DMBA acts by inducing mutations in the H-ras gene (Yuspa, 1994); it is thought that
loss of Notch predisposes cells to H-ras-mediated transformation by linking deregulation
of the cell cycle with loss of differentiation (Dotto, 2008). Interestingly, it has been
shown that p53, a master regulator of the cell cycle, binds to and activates Notch1
expression in keratinocytes, which could point to the tumor-suppressing role of Notch1 in
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the face of p53-activating DNA damage (Lefort et al., 2007). Experiments with cultured
epidermal keratinocytes suggest several differentiation-promoting mechanisms to explain
how Notch activity in mouse keratinocytes suppresses tumorigenesis:
(1) Notch1 activates cyclin/CDK inhibitor p21WAF1/Cip1 either directly via RBP-jbinding (Rangarajan et al., 2001) or indirectly as a consequence of Hes1mediated inhibition of calcipressin, which releases NFAT to activate
p21WAF1/Cip1 (Mammucari et al., 2005; Nicolas et al., 2003; Rangarajan et al.,
2001). p21WAF1/Cip1 is thought to mediate the growth inhibitory role of Notch1
in keratinocytes.
(2) p21WAF1/Cip1 and Hes1 cooperate to inhibit Wnt3A and Wnt4, leading to a
decrease in #-catenin activation (Devgan et al., 2005; Nicolas et al., 2003).
Loss of Notch1 thus leads to elevated #-catenin activity.
(3) Notch1 activation in suprabasal keratinocytes, through modulation of
interferon signaling, acts to down-regulate p63 and thus promote
differentiation (Nguyen et al., 2006). Loss of Notch therefore results in p63
overexpression and increased keratinocyte proliferation.
(4) Notch1 seems capable of sustaining NF$B signals (Nickoloff et al., 2002;
Osipo et al., 2008; Shin et al., 2006) further promoting the differentiation
signal. In the absence of Notch signaling this differentiation pathway is
impaired.
(5) Notch1 up-regulates caspase 3 expression, which promotes the differentiation
of keratinocytes (Okuyama et al., 2004). Therefore, low levels of caspase 3 in
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the absence of Notch can contribute to the lack of differentiation and
accumulation of cancer-prone proliferative keratinocytes.
(6) The Rho-GTPase effectors, ROCK1/1 and MRCK" kinases, are under
negative regulation by Notch/HES (Lefort et al., 2007). These molecules are
found to be up-regulated in tumors (Sahai and Marshall, 2002). Therefore,
their up-regulation in Notch-deficient skin may contribute to the tumor
phenotype.
To summarize, the tumor suppressor activity of Notch1 may reflect its ability to
antagonize keratinocyte proliferation through one or more of the above mechanisms: its
ability to activate p21WAF1/Cip1, reduce Wnt/#-catenin and p63 signaling, and enhance
NF$B signaling (Devgan et al., 2005; Nguyen et al., 2006; Nicolas et al., 2003). Some of
these Notch1 tumor-suppressing mechanisms have also been described in human
keratinocytes.
Although these mechanisms confirm the complexity of Notch signaling in
promoting epidermal differentiation, they are based primarily on studies in vitro and may
not account for the mechanisms responsible for the tumorigenic effect of Notch1 loss in
vivo. In fact, several mouse studies have presented data that dampens the significance of
these proposed mechanisms in vivo. For instance, the skin of p21-/- mice has normal
thickness and, unlike Notch1-/- mice, these animals do not develop spontaneous skin
tumors (Philipp et al., 1999; Topley et al., 1999; Weinberg et al., 1999). In addition, the
mechanistic explanation involving activation of #-catenin is not entirely consistent with
the observations made by several groups in vivo. First, Wnt and Notch cooperate or
antagonize each other in a context-dependent manner. If Notch1 was a key and an early
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negative regulator of Wnt activity in the epidermis, loss of Notch signaling should result
in specific alterations in vertebrate skin development, including induction of ectopic hair
follicles (Gat et al., 1998). However, there is no evidence for an increase in the density of
hair follicles in Notch signaling-deficient skin (Pan et al., 2004; Vauclair et al., 2005).
Second, Wnt signaling promotes entry of bulge stem cells into the follicular program and
is required for this process (DasGupta and Fuchs, 1999; DasGupta et al., 2002; Huelsken
et al., 2001; Merrill et al., 2001; Niemann et al., 2002). If Notch signaling repressed Wnt
activity, loss of RBP-j would promote selection of the follicular program (Lo Celso et al.,
2004; Van Mater et al., 2003). Instead, RBP-j loss promotes entry into the epidermal
program (Yamamoto et al., 2003). Third, an important contradiction is that epidermal
cells with activated #-catenin produce ectopic hair follicles in adult skin (Silva-Vargas et
al., 2005) and tumors with deregulated #-catenin activity form unique and rare hair
follicle tumors (pilomatricomas) both in mice (Gat et al., 1998) and humans (Haskell et
al., 2005; Kajino et al., 2001). However, no ectopic follicles are detected in adult Notch1/- skin and Notch1-/- cancers are epidermal in nature (i.e., basal cell carcinomas (BCC)
and squamous cell carcinomas ((SCC) (Nicolas et al., 2003)). Furthermore, caspase 3
expression is not altered in RBP-j-deficient skin. Thus, the molecular mechanism that
links the pro-differentiation effects of Notch1 to tumor suppression is still controversial,
and it is important to extend the previous observations and find the exact mechanism
mediating Notch1 tumor-suppressing function in the skin.
To advance the mechanistic understanding of Notch signaling effects in relation
to the phenotypes described above, we have studied a comprehensive series of mutant
mice that lack Notch in their skin. Using a bulge-specific Cre line, we show that loss of
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Notch signaling in hair follicle stem cells does not impair the ability of these cells to
choose the hair follicle fate, therefore the transformation of Notch-deficient hair follicles
to epidermal keratin cysts is primarily the consequence of a terminal differentiation
defect and aberrant hair shaft formation (chapter II). By comparing the consequences of
Notch signaling deletion in hair follicles and epidermis, we pinpoint the importance of
non-cell autonomous signaling pathways in mediating the effects of Notch loss (chapter
III). Given the significant non-cell autonomous effects associated with Notch loss, we
have reexamined the carcinogenesis phenotype observed in Notch1-deficient skin. While
there is no dispute that Notch1 possesses tumor-suppressing activity in keratinocytes, we
have explored in detail the early and direct consequence(s) of Notch loss that lead(s) to
skin tumorigenesis. The primary cellular consequence of Notch deletion in keratinocytes
is a defect in epidermal-barrier formation. We demonstrate that the skin-barrier defect
caused by deleting Notch1 leads to a wound-like environment in the skin, which could
explain the tumorigenic effects of Notch loss (chapter IV). We extend these analyses to
show that Notch-deficient barrier-defective epidermis evokes a systemic lethal Blymphoproliferative disorder in newborn mice by overexpressing thymic stromal
lymphopoietin (TSLP; chapter V). TSLP overexpression persists during adult life, and we
demonstrate that the high systemic levels of epidermal-derived TSLP predispose mice to
asthma, potentially explaining the development of asthma in patients with skin-specific
barrier defects (chapter VI).
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Figure 1.1. Canonical Notch signaling pathway (adopted from (Lubman et al., 2004)).
(A) Schematic structure of Notch protein that demonstrates the various domains of this
transmembrane receptor. Upon binding to the ligand presented by a neighboring cell,
Notch undergoes its second (S2) cleavage (not shown) and loses most of its extracellular
domain. Next, S3 cleavage by !-secretase in the transmembrane domain (scissor) releases
Notch intracellular domain (NICD) into cytoplasm. EGF: epidermal growth factor-like
repeats; LNR: cysteine-rich LIN-12/Notch; HD: heterodimerization domain; RAM: RBPj-Association-Molecule domain; ANK: tandem ankryin repeats; TAD: transactivation
domain; OPA: a glutamine-rich domain. (B) Schematic diagram showing the replacement
of co-repressor complex on RBP-j (CSL) by NICD and assembly of transcription
activating complex and transcription of target genes. This active transcriptional complex
falls apart as NICD gets degraded.
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Figure 1.2
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Figure 1.2. Mammalian skin and its appendages (modified from (Fuchs and Raghavan,
2002)). (A) Schematic picture of skin. Note the organization of epidermal and hair
follicular keratinocytes in distinct layers. (B) The depiction of hair follicle/epidermal
layers in which Notch proteins are found to be expressed/activated.
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CHAPTER II

Notch Signaling In Bulge Stem Cells Blocks Epidermal Fate
Selection but Is Not Required for Selection of Hair Follicle
Fate
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SUMMARY
Notch signaling plays an important role in hair follicle maintenance, and it has been
suggested that Notch is also required for follicular fate selection by adult hair follicle
stem cells in the bulge. Here we demonstrate that instead, Notch signaling in bi-potential
bulge stem cells or their uncommitted descendents acts to suppress the epidermal fate
choice thus ensuring follicular fate selection. To examine the role of Notch signaling in
adult hair follicle stem cells, we used Krt1-15-CrePR1 transgenic line to delete RBP-j or
all Notch proteins specifically in the bulge stem cells. We conclusively determined that in
the absence of Notch signaling, bulge stem cell descendents retained their capacity to
execute the follicular differentiation program but failed to maintain it due to their genetic
deficiency. The defect in terminal differentiation caused the diversion of Notch-deficient
hair follicles to epidermal cysts, and the presence of wild-type cells could not prevent this
conversion. Importantly, our analysis revealed that a functional Notch signaling pathway
was required to block bulge stem cells from migrating into, and assuming the fate of
interfollicular epidermis. Taken together, our findings yield detailed insight into the
function of Notch signaling in hair follicle stem cells and explain the mechanism causing
the replacement of Notch-deficient adult hair follicles by epidermal cysts.
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INTRODUCTION
The mammalian hair follicle continuously cycles through three distinct phases: (1)
anagen of variable length (regenerative/proliferative phase), (2) catagen, a short
destructive phase during which the lower part of the hair follicle containing the
proliferating and keratogenous zones is removed, and (3) telogen (resting phase) (MullerRover et al., 2001). The quiescent hair follicle stem cells reside in the bulge located in the
permanent part of the hair follicle near the arrector pili muscle attachment site (Blanpain
and Fuchs, 2006; Cotsarelis et al., 1990). During each hair cycle, a few bulge stem cells
respond to signals from dermal papilla, divide, and give rise to new progenitor cells that
reside in the hair matrix. This highly proliferative structure surrounds the dermal papilla
at the base of the bulb and generates the new anagen hair shaft (Hardy, 1992; Millar,
2002). Matrix cells undergo cell division and terminal differentiation to form outer root
sheet (ORS), inner root sheet (IRS), cuticle, cortex and medulla of the hair (Legue and
Nicolas, 2005). An elaborate network of signaling pathways regulates the hair follicle
morphogenesis and maintenance (Fuchs and Horsley, 2008; Millar, 2002). A component
of this network, the Notch signaling pathway, is involved in the maintenance of the
follicular structure but not in cell fate selection during hair follicle morphogenesis (Pan et
al., 2004). In addition, it ensures optimal proliferative environment in the matrix during
first anagen by suppressing TGF-# and activating Kit ligand (Lee et al., 2007) .
Notch regulates keratinocytes proliferation, commitment, and differentiation
decisions in an intact skin or in culture (Blanpain et al., 2006; Lee et al., 2007; Pan et al.,
2004; Rangarajan et al., 2001). In response to ligand binding, Notch receptors undergo
sequential proteolysis by two enzymes (ADAM metalloprotease followed by !-secretase)
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to release the active Notch intracellular domain fragment (NICD), which translocates into
the nucleus, binds to RBP-j, and nucleates the recruitment of a transcription-activating
complex (Lubman et al., 2004). This overall schema is dubbed “canonical” Notch
signaling. Part of Notch function in epidermal keratinocytes is mediated by a poorly
defined, RBP-j-independent signal (Demehri et al., 2008; Rangarajan et al., 2001).
Although Notch receptors do not function during hair germ induction or cell fate
acquisition within the embryonic hair follicle, they are required to complete terminal
differentiation in IRS cells. In the anagen hair follicle bulb, 3 Notch receptors are
expressed in partially overlapping domains (Pan et al., 2004). Each follicle is derived
from 2-4 multi-potent bulge stem cells (Jaks et al., 2008; Kopan et al., 2002), which give
rise to oligo-lineage hair follicular progenitors (Legue and Nicolas, 2005)

located

adjacent to dermal papilla in the matrix. Notch proteins are not expressed in these oligolineage progenitors (Kopan and Weintraub, 1993; Pan et al., 2004; Powell et al., 1998).
Notch1 is expressed and activated in mitotically active IRS and cortex precursors (Jing et
al., 2009; Pan et al., 2004) while Notch2 and Notch3 are expressed in their post-mitotic
descendents, respectively (Pan et al., 2004). In the absence of Notch signaling, a hair
shaft still forms and contains properly positioned cells expressing markers for each fate
(Pan et al., 2004). However, since IRS cells fail to properly adhere to each other,
follicular architecture cannot be maintained leading to the transformation of these
aberrant hair follicles into epidermal cysts during the first anagen by over-proliferating
ORS cells (Pan et al., 2004).
Partial reduction in Notch signaling has also been associated with the conversion
of hair follicles to epidermal cysts in adults (Figure 2.1; (Vauclair et al., 2005; Yamamoto
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et al., 2003)). However, it is unclear whether the switch from a hair follicle to an
epidermal unit during the hair cycle in adult Notch-deficient animals reflects (1)
epidermal fate selection by Notch-deficient hair follicle stem cells in the bulge or (2)
terminal differentiation defects caused by loss of Notch proteins in committed hair
follicle progenitors that lead to aberrant hair shaft formation and to conversion of the hair
follicle into epidermal cyst. Previous studies support the former possibility by
demonstrating that mosaic loss of Notch signaling by RBP-j removal in hair follicles
result in reduced follicular regeneration during postnatal life due to fate switch at the
level of RBP-j-deficient bulge stem cells (Yamamoto et al., 2003). In addition, fate
mapping of the cells that have experienced Notch1 activation in mice mark the cells in
the bulge, which subsequently contribute descendents to the hair follicles (Vooijs et al.,
2007), consistent with a role for Notch1 in the bulge.
To differentiate between these possibilities, we used the inducible, stem-cellspecific Krt1-15-CrePR1 transgenic line (Ito et al., 2005) to remove Notch pathway
components in hair follicle stem cells. We determined that Notch signaling is not required
for stem cells to select and execute the follicular program; it instead plays an inhibitory
role in preventing bulge stem cells from differentiating into epidermal cells. Therefore,
our findings describe the role of Notch signaling in adult hair follicle stem cells, where it
acts to ensure a follicular choice in bi-potential stem cells or in their uncommitted
descendents.
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RESULTS AND DISCUSSION
Notch signaling is not required for follicular fate determination of bulge stem cells
To directly examine the possibility that Notch was required for follicular fate
selection during hair regeneration, we used Krt1-15-CrePR1 transgenic animals (Ito et
al., 2005) to remove canonical Notch signaling specifically in bulge stem cells in
adulthood, and ask if bulge stem cells lacking Notch signaling could produce daughters
choosing the hair follicle fate. RBP-j (Yamamoto et al., 2003) deletion was induced by
topical application of RU486 onto the skin of postnatal day 50 (P50) Krt1-15-CrePR1;
RBP-jflox/flox; Rosa26R (K15-RBP-jCKO) mice at the beginning of the second telogen. 14
days later, we activated bulge cells by depilation to induce a new hair cycle, and 14 days
after that we harvested the skin to examine the extent of labeling within the regenerating
hair follicles (Figure 2.2A). If Notch signaling were required to select/execute the
follicular fate, RBP-j-deficient lacZ-positive cells would not be able to enter the follicular
program. Contrary to this prediction, X-gal and antibody stainings conclusively showed
that blue RBP-j-deficient stem cells contributed descendents to hair matrix progenitors as
well as to AE13-expressing cortex and cuticle cells (Figure 2.2B, C and D). To rule out
the possibility that depilation overcame Notch deficiency, we repeated the experiment by
topically treating skin with RU486 (to induced Cre-mediated RBP-j deletion in the bulge)
and waited for the next spontaneous anagen before harvesting the skin (Figure 2.3A). As
seen with follicles regenerating after depilation, hair follicles spontaneously entering
anagen contained blue RBP-j-deficient cells (Figure 2.3C). Therefore, canonical Notch
signaling is not required for hair follicle fate selection by descendents of bulge stem cells.
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The analysis of a complete allelic series of mice lacking Notch signaling
components in their hair follicles revealed a tight inverse correlation between Notch
dosage in follicular keratinocytes and the level of hair follicle distortion (Figure 2.4A and
4B). Importantly, we have noticed that Msx2-Cre/+; RBP-jflox/flox hair follicles displayed a
milder disruption at P9 than that seen with total loss of Notch receptors or !-secretase,
which led to epidermal keratin cysts formation during the first anagen (Figure 2.4A and
B)(Pan et al., 2004). Similar to hair follicles retaining some Notch activity (Msx2-Cre/+;
Notch1flox/flox; Notch2flox/+; Notch3+/- or N1N2hN3hCKO) that formed epidermal cysts
only in the second anagen (Figure 2.4C and Figure 2.1), Msx2-Cre/+; RBP-jflox/flox
follicles did not form epidermal cysts in the first anagen and retained a recognizable
follicular morphology at P9 (Figure 2.4). As shown in previous studies (Demehri et al.,
2008; Rangarajan et al., 2001), we determined that RBP-j-independent Notch signals
contributed to hair follicle maintenance (Figure 2.5). Thus, to address the concern that the
demonstrated ability of RBP-j-deficient bulge stem cells to choose a follicular fate was
preserved by RBP-j-independent Notch signal(s), we generated mice lacking all Notch
proteins in bulge stem cells (Krt1-15-CrePR1; Notch1flox/flox; Notch2flox/flox; Notch3-/-;
Rosa26R or K15-N1N2N3CKO). Following the Cre induction/hair depilation protocol
(Figure 2.2A), we were able to show that Notch-deficient stem cells were also fully
capable of giving rise to daughters contributing to hair follicle structures (Figure 2.2E).
This finding demonstrates that neither arm of Notch signaling is required for stem cells to
choose the follicular fate.
Although Notch-deficient bulge stem cells (blue) migrated down and formed
anagen hair follicle progenitors and differentiated hair keratinocytes, the defect in
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maintaining terminal differentiation resulted nonetheless in formation of aberrant hair
shafts (Figure 2.2B, E, F, 2.3C and 2.4). To study the long-term consequences of Notch
loss in bulge stem cells, we deleted RBP-j (K15-RBP-jCKO) or Notch receptors (K15N1N2N3CKO) by topical application of RU486 onto the skin during the second telogen,
and monitored the hair phenotype overtime by successive histological analyses (Figure
2.6). In the absence of Notch signaling, hair follicles transformed eventually into keratin
10- and loricrin-positive epidermal cysts (Figure 2.6B and C) following the destruction of
anagen hair follicles in K15-RBP-jCKO and K15-N1N2N3CKO skin. Such cysts were
predominantly located deep in the dermis (Figure 2.6B). Hair follicles are polyclonal,
derived from 2-4 stem cells (Jaks et al., 2008; Kopan et al., 2002), and not all bulge cells
undergo Notch/RBP-j deletion with our topical application paradigm. Thus, most follicles
are chimeric, containing descendents of Notch/RBP-j-deficient stem cells as well as wildtype descendent of stem cells that are Notch signaling competent. Importantly, a
significant number of keratin cyst-forming cells contained intact Notch signaling,
demonstrating that the “field effect” of aberrant hair shafts formed by Notch/RBP-jdeficient keratinocytes was sufficient to set them on the path to become epidermal cells
(Figure 2.6B). Accordingly, inactivation of Notch signaling in most bulges resulted in
complete alopecia within 10 weeks (Figure 2.6D) despite the presence of many stem cells
that did not experience Cre activation. Importantly, K15-N1N2N3CKO hair loss was
much more severe than that of RU486-treated Krt1-15-CrePR1; Notch1flox/flox; Rosa26R
(K15-N1CKO) mice (Figure 2.6D and 2.7). Considering that Notch3 is a null allele and
Notch1&3-deficient hair follicles are indistinguishable from Notch1-deficient hair
follicles (Pan et al., 2004), the severity of K15-N1N2N3CKO hair phenotype confirms
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that deletion of Notch2 and Notch1 occurred in these Notch3-deficient bulge cells. In
conclusion, replacement of Notch-deficient hair follicles by epidermal cysts is a
secondary byproduct of terminal differentiation defects that cannot be rescued by normal
cells and does not reflect a defective hair follicle fate selection process. These findings
show that the function of Notch signaling during hair regeneration is similar to its role
during hair morphogenesis.

Removal of the Notch signaling pathway exposes the bi-potentiality of bulge stem
cells
To examine the developmental potential of Notch signaling-deficient bulge stem
cells, we mapped the cell lineages derived from these cells in K15-RBP-jCKO skin
following the induction of Cre-mediated gene deletion (Figure 2.8A). Importantly, a
significant number of bulge-derived RBP-j-deficient blue cells migrated upward and
generated K10+ K6- interfollicular epidermal cells in the isthmus and epidermis (Figure
2.8B, C and D). 39% of K15-RBP-jCKO hair follicles (78 of 200) counted on X-galstained 5µm skin cross-sections contained blue RBP-j-deficient cell above the bulge
region (Figure 2.9). Similar evidence for epidermal fate selection by K15-N1N2N3CKO
bulge stem cells was also observed after RU486 treatment (data not shown). The
migration of Notch/RBP-j-deficient bulge cells into the epidermis preceded the secondary
effects of an aberrant hair shaft formation: bulge-derived Notch/RBP-j-deficient cells
were already present in interfollicular epidermis as hair follicles spontaneously entered
anagen (Figure 2.8). At this point, epidermal thickness, hair follicle structure and dermal
cellularity are normal. In addition, staining the skin sections with CD45 pan-leukocyte
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marker confirmed that there was no inflammation present at this early stage when
epidermal migration of Notch/RBP-j-deficient bulge cells is well underway (Figure
2.8E). Furthermore, the occasional presence of bulge-derived RBP-j-deficient cells in
isthmus of otherwise normal looking hair follicles (i.e. club hairs of telogen hair follicles,
Figure 2.3B and 2.10) demonstrated that the upward migration of Notch/RBP-j-deficient
bulge cells started before the hair follicles entered anagen. Considering that under similar
circumstances wild-type bulge stem cells do not choose an epidermal fate (Figure 2.8 and
2.9 (Ito et al., 2005; Levy et al., 2005)), these observations demonstrate that Notch
signaling acts to prevent hair follicle stem cells or their uncommitted descendents from
randomly adopting the epidermal fate. How wounds reverse this block (Ito et al., 2005)
remains an interesting question to be investigated.
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CONCLUSIONS
In summary, and in contrast to Wnt signaling (Huelsken et al., 2001), neither arm
of Notch signaling is required for follicular fate selection by bulge stem cells. Instead,
RBP-j-dependent Notch signals restrict bulge cells (or their uncommitted, migratory
descendents) to the follicular fate: In addition to cells selecting the follicular fate, a
substantial fraction of Notch/RBP-j-deficient stem cells produce descendents that
spontaneously choose the epidermal fate and migrate upwards, joining the interfollicular
epidermis and producing epidermal cells deficient in terminal differentiation. The hair
follicles formed by Notch-deficient stem cells properly associate with dermal papilla,
produce a bulb expressing hair keratins, but fail to maintain the identity of IRS cells and
medulla (Pan et al, 2004). Thus, both during hair follicle development and regeneration,
Notch contributes to terminal differentiation. The progressive transformation of hair
follicles to epidermal cysts caused by stepwise reduction of Notch dosage is the direct
result of aberrant hair shaft disintegration due to increasingly defective terminal
differentiation.
This report identifies Notch signaling as a novel regulator of bulge stem cell fate
selection, acting to constrain this bi-potential cell to the hair follicle fate. The ability of
Notch/RBP-j-deficient stem cells to enter both hair follicle and epidermal fates under
normal homeostatic state with similar probability indicates a stochastic fate selection
process. This is in contrast to the classical role for Notch in fate selection as seen in the
fly neuroectoderm, where a default fate (sensory organ precursor fate) is selected by all
Notch-deficient cells due to the presence of a dominant factor (achaete-Scute proteins)
(Simpson, 1997). The identities of molecules governing this stochastic fate selection
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process in bulge stem cells, and the details of how Notch constrains the fate choice,
remain obscure.
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EXPERIMENTAL PROCEDURE
Mice
We generated the following strains of mice lacking the components of Notch signaling
pathway in skin keratinocytes using Msx2-Cre transgene (Pan et al., 2004).
Msx2-Cre/+; Notch1flox/flox (N1CKO)
Msx2-Cre/+; Nocth1flox/flox; Notch2flox/+ (N1N2hCKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3+/- (N1N2hN3hCKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3-/- (N1N2hN3CKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox (N1N2CKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox; Notch3-/- (N1N2N3CKO)
Msx2-Cre/+; PS1flox/flox; PS2-/- (PSDCKO)
Msx2-Cre/+; RBP-jflox/flox (RBP-jCKO)
Msx2-Cre/+; PS1flox/flox; PS2-/-; RBP-jflox/flox (PSDRBP-jCKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox ; RBP-jflox/flox (N1N2RBP-jCKO)
For the hair follicle stem cell studies, Krt1-15-CrePR1; RBP-jflox/flox; Rosa26R (K15RBP-jCKO), Krt1-15-CrePR1; RBP-jflox/+; Rosa26R (Control), Krt1-15-CrePR1;
Notch1flox/flox; Notch2flox/flox; Notch3-/-; Rosa26R (K15-N1N2N3CKO), Krt1-15-CrePR1;
Notch1flox/+;

Notch2flox/+;

Notch3-/-;

Rosa26R

(control),

and

Krt1-15-CrePR1;

Notch1flox/flox; Rosa26R (K15-N1CKO) were used (Ito et al., 2005). All the mice were
kept in the animal facility under Washington University animal care regulations.
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Lineage analysis
To induce Cre-mediated floxed gene deletion in Krt1-15-CrePR1 system, mice were
shaved and treated topically with 1% RU486 (Sigma, St. Louis, MO) dissolved in 70%
ethanol for 5 consecutive days starting at the beginning of the second telogen (~P50). A
subgroup of animals was depilated mechanically using Hair Remover Wax Strip Kit (Del
Laboratories, Uniondale, NY). At indicated time points, dorsal skin is collected and
analyzed.

Histology and Imunohistochemistry
For Hematoxylin and eosin (H&E) staining, skin samples from various mutant and wild
type animals where fixed in 4% paraformaldehyde in PBS, and paraffin-embedded tissues
were sectioned at 5µm. Staining for #-galactosidase activity (X-gal staining) was
performed on whole mount skin samples as previously described (Kopan et al., 2002).
Skin sections that are only X-gal stained were counterstained with Nuclear Fast Red
(Vector Laboratories, Burlingame, CA). X-gal stained paraffin-embedded skin samples
were used for immunohistochemical analysis. Anti-hair follicle keratin (AE13) antibody
(a kind gift from Dr. Tung-Tien Sun, New York University), anti-RBP-j antibody (clone
T6709, Institute of Immunology Co., Tokyo, Japan), anti-Keratin 10 antibody (Covance
Research Products, Princeton, NJ), anti-Keratin 6 antibody (Abcam, Cambridge, MA),
anti-Loricrin antibody (Covance Research Product), or anti-panleukocytic marker (CD45;
BD PharMingen, San Diego, CA) was used. After treatment with biotinylated secondary
antibody, HRP-conjugated streptavidin (Vectastain ABC kit, Vector Laboratories,
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Burlingame, CA) and DAB substrate kit (Pierce, Rockford, IL) were applied to visualize
the signal. No counterstaining was performed in immunohistochemical staining.
Immunofluorescence staining was conducted on paraffin-embedded skin samples using
the combination of anti-Keratin 10 antibody (Covance Research Products) and antiLoricrin antibody (Covance Research Product). Fluorochrome-Conjugated secondary
antibodies were used to visualize the signals and DAPI nuclear stain was used as the
counterstain.
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FIGURES

Figure 2.1
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Figure 2.1. Hair follicles lacking partial Notch signaling gradually transform into
epidermal cysts in adult mice. (A) Ventral images of adult compound mutant mice
demonstrate progressive alopecia in the Msx2-Cre expression domain. As more alleles
are lost, visible keratin cysts (white arrows) appear to replace hair follicles. All mice are
photographed at P120 except Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3-/(N1N2hN3CKO) mouse, which is 60 days old. (B) Immunofluorescence and H&E
staining reveals that Notch1-deficient adult hair follicles in Msx2-Cre/+; Notch1flox/flox
(N1CKO) revert to epidermal differentiation program (asterisks) late in the life of the
animal (scale bar: 50µm).

51

Figure 2.2
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Figure 2.2. Hair follicle stem cells lacking total Notch signaling are capable of choosing
a follicular fate. (A) Diagram describing the timeline/cohorts used to delete RBP-j (or
Notch) in adult hair follicle stem cells, induce the hair cycle, and examine the behavior of
anagen hair follicles 14 days after hair cycle induction. Note that topical application of
RU486 started when animals were at ~P50 and the following analyses are performed at
the end of the experimental period (i.e. 28 days after the last RU486 treatment). (B) X-gal
staining shows blue RBP-j-deleted bulge cells in Krt1-15-CrePR1; RBP-jflox/flox; Rosa26R
(K15-RBP-jCKO) and control hair follicles that are not depilated and hence are still in
telogen phase of the hair cycle. Depilated hairs, however, have entered anagen. Blue
RBP-j-deleted cells in K15-RBP-jCKO hair follicle have migrated down to the bulb and
are detectable in all layers of anagen hair follicle. (C) AE13 (cortex and cuticle marker)
staining confirms that blue RBP-j-deleted keratinocytes in K15-RBP-jCKO undergo
follicular differentiation program. The inset shows the normal pattern of AE13 staining in
an anagen hair follicle (counterstained with Hematoxylin). (D) Immunohistochemistry
staining for RBP-j demonstrates that blue cells in K15-RBP-jCKO anagen hair follicle
are in fact depleted of RBP-j protein. (E) Bulge stem cells deleted for all Notch receptors
can differentiate into hair follicle keratinocytes and are detectable in anagen hair using Xgal staining on Krt1-15-CrePR1; Notch1flox/flox; Notch2flox/flox; Notch3-/-; Rosa26R (K15N1N2N3CKO) skin after Cre/hair induction as outlined in “A”. (F) Pictures from back
skin of K15-RBP-jCKO and control mice highlight the aberrant hair shafts made by
keratinocytes derived from RBP-j-deficient stem cells. The genotype of control mice is
shown in “A” (scale bar: 25µm).
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Figure 2.3
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Figure 2.3. RBP-j-deficient bulge stem cells give rise to keratinocytes forming the
anagen hair follicle in absence of exogenous hair cycle induction. (A) Diagram
describing the timeline used to treat 50- day-old K15CrePGR/+; RBP-jflox/flox; Rosa26R
(K15-RBP-jCKO) and control animals with RU486 in order to delete RBP-j in adult hair
follicle stem cells at beginning of second telogen phase. The hair follicles are examined
35 days later at the point when some have entered the anagen phase of a new hair cycle.
The status of telogen hair is also documented 14 days after RU486 treatment
(arrowhead). Note that no hair induction step is included. (B) X-gal staining shows blue
bulge cells in K15-RBP-jCKO and control telogen hair follicles 14 days after Cre
activation. Arrow points to a blue cell in the isthmus. (C) After 35 days, hair follicles
have entered anagen. X-gal staining demonstrates that blue RBP-j-deleted cells in K15RBP-jCKO hair follicle have contributed to all layers of anagen hair follicle (scale bar:
25µm).
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Figure 2.4
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Figure 2.4. Stepwise deletion of Notch pathway components in hair follicle keratinocytes
results in progressive hair follicle deterioration culminating in transformation into
epidermal keratin cysts. (A) H&E-stained skin sections from a comprehensive allelic
series of Notch-deficient mice at P9 demonstrate the progressive hair follicle destruction,
which is most evident in mice lacking total Notch signaling (N1N2N3CKO and
PSDCKO) with densely packed keratin cysts beneath the epidermis. Note that RBP-jdeficient hair follicles have milder phenotype than those lacking total Notch signaling
(scale bar: 100µm). (B) A scoring system that is devised to generate quantitative measure
of hair follicle destruction (e.g. 0: intact hair follicle and 10: keratin cyst) confirms the
inverse correlation between Notch dosage and the level of hair follicle deterioration. The
destruction level of RBP-jCKO hair follicles (asterisk) is similar to that of
N1N2hN3CKO. Hair follicles in 3 random 100X microscope fields are scored and the
average score + standard deviation is presented as a bar graph. (C) Immunofluorescence
staining for keratin 14 and loricrin (an epidermal-specific marker) shows the
transformation of Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3+/- (N1N2hN3hCKO)
hair follicles to fully-formed epidermal keratin cysts (asterisks) in the second anagen
(P35; scale bar: 50µm). Abbreviations: Msx2-Cre/+; Notch1flox/flox (N1CKO), Msx2Cre/+;

Notch1flox/flox;

Notch2flox/+ (N1N2hCKO),

N1N2hN3hCKO,

Msx2-Cre/+;

Notch1flox/flox; Notch2flox/+; Notch3-/- (N1N2hN3CKO), Msx2-Cre/+; Notch1flox/flox;
Notch2flox/flox

(N1N2CKO),

Msx2-Cre/+;

Notch1flox/flox;

Notch2flox/flox;

Notch3-/-

(N1N2N3CKO), Msx2-Cre/+; RBP-jflox/flox (RBP-jCKO), and Msx2-Cre/+; PS1flox/flox;
PS2-/- (PSDCKO).
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Figure 2.5
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Figure 2.5. Evidence of bifurcation in Notch signaling pathway downstream of !secretase. (A) The RBP-j-deficient hair follicles display a milder disruption than that seen
with loss of Notch receptors (Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox or N1N2CKO) or
!-secretase (Msx2-Cre/+; PS1flox/flox; PS2-/- or PSDCKO). This would be expected in a
linear pathway if a few critical permissive Notch targets were de-repressed upon RBP-j
loss, ameliorating the phenotype (Koelzer and Klein, 2006). Alternatively, the Notch
pathway might have an RBP-j-independent yet !-secretase-dependent arm that
contributed to the severity of the hair phenotypes observed in Notch-deficient hair follicle
(Demehri et al., 2008). To distinguish between these possibilities, mice with !-secretase
and RBP-j deletion in hair follicles are examined (Msx2-Cre/+; PS1flox/flox; PS2-/-; RBPjflox/flox or PSDRBP-jCKO (Demehri et al., 2008)). In this genetic combination, if derepressed Notch targets are important in hair follicle maintenance, they will suppress the
PSDCKO phenotype, and the PSDRBP-jCKO hair will display a milder, RBP-jCKO-like
phenotype (Koelzer and Klein, 2006). On the other hand, if RBP-j-independent targets of
Notch contribute to hair follicle maintenance, PSDRBP-jCKO hair follicles will have the
PSDCKO phenotype. A combination of both effects will generate an intermediate
phenotype. PSDRBP-jCKO mice display hair phenotype similar to PSDCKO, a result
supporting the assertion that RBP-j-independent signals downstream of Notch activation
contribute to hair follicle homeostasis (Demehri et al., 2008; Rangarajan et al., 2001). To
confirm that these RBP-j-independent signals are regulated by Notch, mice lacking
Notch1, Notch2, and RBP-j in hair follicles (Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox;
RBP-jflox/flox or N1N2RBP-jCKO) are examined. As expected, these mice have hair
phenotype similar to N1N2CKO, which is more severe than that of RBP-jCKO mice
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(scale bar: 100µm). (B) Immunohistochemical staining for RBP-j shows that RBP-j
protein is absent in PSDRBP-jCKO skin at P9 (scale bar: 50µm).
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Figure 2.6
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Figure 2.6. Hair follicles that are derived for Notch/RBP-j-deficient stem cells transform
into epidermal keratin cysts. (A) Diagram outlining the experimental approach used to
delete RBP-j or Notch in adult hair follicle stem cells during the second telogen (~P50)
and examine the status of hair follicles in the subsequent anagen phase. Note that no
depilation step is included. (B) X-gal stained skin sections collected 50 days after the last
RU486 treatment demonstrate the replacement of hair follicles by keratin cysts in K15RBP-jCKO skin. Note that RBP-j-expressing (pink) cells also contribute to this epidermal
structure. Same transformation happens with K15-N1N2N3CKO hair follicles (data not
shown). The genotype of control mice is shown in “A”. (C) Expression of Keratin 10
(suprabasal epidermal marker) and loricrin (granular layer marker within a LacZ-positive
cyst; inset) confirms that K15-RBP-jCKO keratinocytes forming the keratin cysts have
undergone epidermal differentiation program. (D) 10 weeks after RU486 treatment, K15N1N2N3CKO mice show severe alopecia with numerous keratin cysts visible on the back
skin. Keratin cysts formation in K15-N1N2N3CKO and/or barrier defects associated with
loss of Notch proteins in bulge-derived epidermal keratinocytes lead to an intense dermal
inflammation in these mice (Figure 2.7). RU486 treated Krt1-15-CrePR1; Notch1flox/flox;
Rosa26R (K15-N1CKO) mice have a mild hair loss phenotype compared to similarly
treated age-matched controls (Krt1-15-CrePR1; Notch1flox/+; Notch2flox/+; Notch3-/-;
Rosa26R) (scale bar: 25µm).
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Figure 2.7
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Figure 2.7. Mice lacking all Notch receptors in the bulge stem cells develop keratin cysts
and intense inflammation 10 weeks after RU486-mediated gene deletion. CD45 staining
of X-gal-stained skin from animals described in Figure 2.6 shows a marked infiltration of
immune cells in the dermis of K15-N1N2N3CKO animal. Note that K15-N1CKO
animals contain much less CD45+ leukocytes in their dermis at this point relative to K15N1N2N3CKO mice. No counterstaining is performed (scale bar: 25µm).

64

Figure 2.8
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Figure 2.8. Hair follicle stem cells lacking Notch signaling contribute to epidermal
homeostasis under normal conditions. (A) Diagram describing the approach used to
delete RBP-j in adult hair follicle stem cells during the second telogen (~P50) and
determine their fate 35 days later without depilation. (B) X-gal staining of the skin shows
that blue cells migrate up from bulge to form epidermis in K15-RBP-jCKO animals. Note
that no blue clone emanating from hair follicles is found in the RU486 treated control
animals (counterstain: Nuclear Fast Red). (C) RBP-j antibody staining confirms that blue
cells in K15-RBP-jCKO are RBP-j-deficient. (D) Immunohistochemical staining with
Keratin 6 (ORS marker) and Keratin 10 (epidermal marker) demonstrate that blue RBP-jdeficient bulge stem cells have differentiated into epidermal keratinocytes. (E) Leukocyte
content of K15-RBP-jCKO dermis is comparable to that of control 35 days after Cre
induction. CD45 pan-leukocyte marker is used to demonstrate the absence of
inflammation in K15-RBP-jCKO skin at the point that RBP-j-deficient bulge cells have
migrated into epidermis. Note that in “C, D and E” no counterstaining is performed, and
genotype of control mice is shown in “A” (scale bar: 25µm).
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Figure 2.9
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Figure 2.9. 35 days after RU486 treatment, K15-RBP-jCKO anagen hair follicles contain
RBP-j-deficient blue cells above the bulge region (dotted line), which are not found in
control animals. The hair follicles with streak of blue cells extending into the epidermis
are counted and their percentage over the total number of blue-cell-containing anagen
hair follicles is calculated (scale bar: 25µm).
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Figure 2.10
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Figure 2.10. Following RU486 application, blue RBP-j-deficient bulge cells migrate
upward toward epidermis in hair follicles that have not yet entered anagen. X-gal staining
shows blue bulge cells in K15-RBP-jCKO hair follicle, which is in telogen 35 days after
Cre activation according to the induction protocol described in Figure 2.5A. Arrows
highlight blue cells in the isthmus (scale bar: 25µm).
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CHAPTER III

Bi-compartmental communication contributes to the
opposite proliferative behavior of Notch1-deficient hair
follicle and epidermal keratinocytes
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SUMMARY
Notch1-deficient epidermal keratinocytes become progressively hyperplastic and
eventually produce tumors. In contrast, Notch1-deficient hair matrix keratinocytes have
lower mitotic rates, resulting in smaller follicles with fewer cells. Investigation into the
underlying mechanism for these phenotypes revealed significant changes in the TGF-#
and IGF signaling pathways, which have not been previously shown to be downstream of
Notch signaling. TGF-# ligands were elevated in Notch1-deficient keratinocytes, which
correlated with elevated expression of several targets, including the diffusible IGF
antagonist IGFBP3 in the dermal papilla. Diffusible stromal targets remained elevated in
the absence of epithelial TGF-# receptors, consistent with paracrine TGF-# signaling.
Overexpression of IGF1 in the keratinocyte reversed the phenotype, as expected if
Notch1 loss altered the IGF/IGFBP balance. Conversely, epidermal keratinocytes
contained less stromal IGFBP4 and may thus be primed to experience an increase in IGF
signaling as animals age. These results suggest that Notch1 participates in a bicompartmental signaling network that controls keratinocytes homeostasis and
proliferation within the skin.
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INTRODUCTION
During skin organogenesis, keratinocytes and the underlying mesenchymal cells
engage in reciprocal and sequential communication events that result in formation of the
hair follicles, the interfollicular epidermis, the sebaceous glands, and the sweat glands
(Hardy, 1992; Millar, 2002; Sengel, 1976). Migratory melanocytes, and the Merkel and
Langerhans cells later join in to form a community of specialized cells that together
perform a unique set of physiological functions. Despite their shared origin, hair follicles
and epidermal keratinocytes diverge to execute unique differentiation programs and, in
the adult, replenish themselves from distinct stem cell populations (Alonso and Fuchs,
2003; Ito et al., 2005). Epidermal stem cells are restricted to the innermost (Basal) layer
and are the only epidermal cells that proliferate in the adult under normal circumstances
(Clayton et al., 2007). Asymmetric basal cell divisions result in one cell withdrawing
from the cell cycle, commencing a terminal differentiation program and a journey
outwards towards the skin surface (Lechler and Fuchs, 2005). Differentiation is
manifested by unique gene expression profiles that distinguish the Spinous layer,
Granular layer, and Cornified layer (Fuchs and Raghavan, 2002; Jamora and Fuchs,
2002).
In the hair follicle, keratinocytes surround a teardrop shaped core of
mesenchymal cells (dermal papilla, DP) in a structure called the bulb. In contrast to the
epidermis, the proliferation zone within the bulb contains many cells that are not in direct
contact with a basement membrane although the lineage-restricted stem cells do maintain
contact with the DP (Legue and Nicolas, 2005). As hair matrix keratinocytes exit the cell
cycle, they differentiate into several different cell layers (outer and inner root sheath,
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cortex and medulla; (Hardy, 1992; Millar, 2002; Sengel, 1976)). In the third week of life,
murine hair follicles start to cycle, i.e., they undergo a period of destruction, rest and
regeneration, which continues throughout adult life (Muller-Rover et al., 2001; Stenn and
Paus, 2001). The hair shaft is actively produced during anagen phase. During the
destructive catagen phase, the bottom two thirds of each hair follicle undergoes
apoptosis; only the upper third of the follicle, the stem cell niche (bulge) and DP remain
intact. Catagen lasts ~ 3 days, followed by the resting phase (telogen) of variable length.
Subsequent entry into anagen is believed to begin when signals from DP activate stem
cells in the bulge (Stenn and Paus, 2001).
Notch signaling promotes selection of the hair fate by activated bulge stem cells
(Yamamoto et al., 2003) and plays an important role in maintenance of the follicle, in
particular the inner root sheath fate (Pan et al., 2004). Notch proteins (Notch 1-4 in mice
and humans) are transmembrane receptors activated by transmembrane ligands on
neighboring cells (Kopan, 2002). Binding of Notch to its ligand leads to its cleavage by !secretase and translocation of the Notch intracellular domain (NICD) into the nucleus,
where NICD binds to CSL (CBF1/RBPjk, Su(H), and Lag-1). CSL is a transcriptional
repressor bound with other nuclear factors to the promoter region of particular genes.
Association of NICD with CSL transiently converts CSL from transcription repressor to
transcription activator, resulting in activation of downstream targets (Fryer et al., 2004;
Mumm and Kopan, 2000).
In the embryonic mouse epidermis, NICD1 is ubiquitous in supra-basal
keratinocytes selecting the spinous fate (Blanpain et al., 2006; Lin and Kopan, 2003; Pan
et al., 2004); after birth, NICD1 is detected transiently in a small fraction of spinous cells
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(YP and RK, unpublished observations). This pattern of Notch1 activation is consistent
with its proposed role in suppressing proliferation and promoting differentiation via cell
autonomous modulation of targets that may include Wnt, p21cip1, K1, K10, Hes1 and p63
(Blanpain et al., 2006; Devgan et al., 2005; Mammucari et al., 2005; Nguyen et al., 2006;
Okuyama et al., 2004; Rangarajan et al., 2001). In addition, keratinocytes deficient in
Notch1 are sensitive to chemical carcinogenesis, establishing Notch1 as a tumor
suppressor in the epidermis (Nicolas et al., 2003). Although the role of Notch2 in the
epidermis is thought to be minimal (Rangarajan et al., 2001), loss of Notch1 and 2, RBP-j
or presenilin (the catalytic component of !-secretase) results in more severe epidermal
phenotypes (Blanpain et al., 2006; Pan et al., 2004), indicating that Notch2 also
contributes to epidermal differentiation.
The contribution of Notch signaling to follicular and epidermal homeostasis can
result from both cell autonomous and cell non-autonomous effects. Both are consistent
with the role of Notch as a transcriptional modulator: the former is built on the proven
ability of Notch to modulate the transcriptional landscape within keratinocytes (Blanpain
et al., 2006; Devgan et al., 2005; Nguyen et al., 2006), while the latter posits that some of
the transcripts altered by Notch encode cell surface or secreted molecules that would
impact neighboring cells (Lin et al., 2000; Pan et al., 2004). In this report, we
demonstrate that Notch1 plays contrasting roles in keratinocyte proliferation within the
hair follicles and the epidermis, attributed in large part to previously underappreciated
cell non-autonomous signals. We provide evidence that TGF-# signaling is elevated in
Notch1-deficient hair matrix keratinocytes, correlating with reduced keratinocyte mitotic
rates. In addition, we demonstrate that the impact on the epithelial cell cycle is not
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dependent on autocrine TGF-# reception in the keratinocyte but on paracrine signaling to
neighboring fibroblasts. The fibroblast, in turn, controls keratinocyte proliferation by
modulating Insulin-like growth factor (IGF) signaling: in the hair follicle, IGF binding
protein 3 (Igfbp3) levels were elevated in the DP, while in the epidermis, Igfbp4 protein
was reduced. Increasing the IGF/IGFBP ratio by IGF1 overexpression in Notch1deficient skin restored the cell numbers in the hair matrix. Thus, diffusible epithelial
TGF-# and stromal IGFBP act downstream of Notch1 in a bi-compartmental signaling
network within the skin. When perturbed by Notch loss, this paracrine loop could
contribute to epidermal keratinocyte hyperproliferation in a manner analogous to the
vicious cycle seen in bone metastasis.
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RESULTS AND DISCUSSION
The bulbs of Notch1-deficient hair follicles contain fewer keratinocytes
Conditional deletion of Notch1 in Msx2Cre;Notch1flox/flox (N1CKO) mice produced
chimeric skin with two different patterns of gene loss in hair follicles, previously
described as anagen-deleted and embryo-deleted (Figure 3.1A and (Pan et al., 2004)). As
the names imply, embryo deleted (emN1) epidermis and follicles are derived from cells
that experienced a pulse of Cre activity at E9.5 and thus lack Notch1 from that point
onwards. Anagen deleted (anN1) follicles express Cre recombinase in the mid-bulb
region a few days after the start of the growth phase (anagen); Notch1 is thus only
removed in the upper bulb (Figure 3.1A). We observed that emN1 follicles are
substantially shorter than anN1 or wild type follicles (Figure 3.1B and C). Because anN1
follicles are wild type in appearance, we concluded that growth-related Notch1 functions
are required in the proximal, actively proliferating matrix during hair morphogenesis
(Figure 3.1B and C; (Pan et al., 2004)).
Closer inspection of hair bulbs at P9 revealed that the portion below the most
proximal melanin granules (marked by a dashed red line in Figure 3.1D) was shorter in
the emN1 follicles compared to wild type or anN1 follicles (Fig. 3.1D). Cell size in all
genotypes was not altered. Instead, fewer cells were detected in Notch1-deficient
follicles: emN1 hair follicles had only 44.69 ± 8.92 cells, whereas wild type (75.32 ±
10.30) and anN1 (69.86 ± 14.17) hair follicles had nearly twice as many cells (Figure
3.1E). Notch1-deficient epidermis did not display any observable hyperplasia at this age,
but the epidermis of older mice did (Figure 3.1F and G; (Nicolas et al., 2003; Rangarajan
et al., 2001)). We thus conclude that in contrast to the epidermis, where the number of
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Notch1-deficient epidermal keratinocytes increase as mice age (Nicolas et al., 2003;
Rangarajan et al., 2001), fewer Notch1-deficient keratinocytes formed the hair bulb.
Therefore, Notch1 loss leads to differential effects on related keratinocyte populations.

Notch1-deficient hair matrix cells have decreased mitotic rates
During catagen, hair bulbs involute and regress quickly (within three to four days)
through a combination of cell cycle arrest and apoptotic cell death (Dry, 1926; Lindner et
al., 1997; Muller-Rover et al., 2001; Weedon and Strutton, 1981). One trivial explanation
for reduced keratinocyte numbers in emN1 bulbs is accelerated catagen onset, as
observed in mice with global epithelial deletion of Notch1 (K14-Cre; Notch1flox/flox and
K5-CreERT; Notch1flox/flox (Vauclair et al., 2005)). To ask if reduced cell numbers in emN1
hair bulbs reflected early catagen onset at P9, we examined emN1 skin at P9, P13, P17,
and P22 (Figure 3.2A). If catagen had started at P9, the lower two thirds of the follicles
would have been lost by P13. Instead, characteristic follicular catagen destruction was not
detected before P17 in all genotypes, indicating that Notch1 deficient skin in N1CKO
mice did not exhibit accelerated entry into catagen (Figure 3.2A).
Early catagen (stage II) follicles contain, on average, 4 or more TUNEL-positive
cells ((Lindner et al., 1997), Figure 3.2B and C). While we observed a few Notch1deficient follicles containing >2 TUNEL positive cells, which is characteristic of
morphologically distinct catagen stage I (Muller-Rover et al., 2001), more than 40% of
emN1 hair follicles lacked TUNEL-positive cells. Moreover, the average number of
TUNEL positive cells was significantly lower in emN1 follicles at P9 compared to that
seen at P16, which is already undergoing catagen based on morphology (1.34 vs 4.18,
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respectively, p< 0.005; Figure 3.2C). Given that no further morphological changes were
detected, we concluded that the increased apoptotic cell death in emN1 follicles at P9 did
not indicate catagen onset nor could it explain the reduced cell number seen in TUNELnegative emN1 hair follicles.
Another possible explanation for the lower cell numbers in emN1 follicles is a
reduced proliferation rate. To examine mitotic rates at P9, we labeled mitotic cells with
Ki67 (red in Figure 3.2D) and S-phase cells by BrdU-incorporation (green in Figure
3.2D) following a 30-minute BrdU pulse-label (Chenn and Walsh, 2002). The proportion
of S-phase cells in the cycling population (BrdU+/Ki67+) was determined for the hair
follicles and the epidermis of mutant and wild type mice. Interestingly, emN1 hair
follicles displayed a reduced progenitor-labeling index (27.07±1.99%) compared with
anN1 (36.26±1.33%) and wild type (35.28±0.71%) follicles (Figure 3.2E), which
correlated with the cell numbers in these follicles. Therefore, the lower cell numbers
within Notch1-deficient hair bulbs is likely due to a delayed cell cycle, with a small
contribution from increased apoptotic cell death. Interestingly, P9 epidermal
keratinocytes did not display any difference in the progenitor-labeling index (Figure
3.2E) indicating that the proliferation defect in epidermal keratinocytes is progressive,
evident only as the animals age.

Altered IGF signaling in Notch1-deficient hair follicles
Our microarray analyses revealed that transcripts for IGF signaling modulators
(Igfbp2, 3, and 4) are elevated in Notch1-deficient hair bulbs, as is the IGF receptor
(Table 3.1 and Figure 3.3A). Indeed, pathway analysis of transcripts altered in emN1
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relative to wild type follicles confirmed that the vast majority of possible protein
networks were anchored around IGFBPs (data not shown). IGF signaling promotes cell
proliferation by reducing the length of G1 phase (Edmondson et al., 2003), the inverse of
the phenotype we observed in Notch1-deficient hair follicles (Figure 3.2). Diffusible IGF
binding proteins (IGFBPs) antagonize the mitogenic (Baserga et al., 1997; Firth and
Baxter, 2002) and antiapoptotic (Butt et al., 1999; Resnicoff and Baserga, 1998) activity
of IGF1 by sequestering it from its receptors (Edmondson et al., 2003; Firth and Baxter,
2002).
To ask if changes in IGF signaling underlie the Notch1 phenotype, we attempted
to confirm the observed changes in IGFBP expression in the microarray at the tissue
level. IGFBP2 expression was detected in the nuclei of hair matrix cells, and no change
in its distribution was evident at the protein level in Notch1-deficient hair follicles
(Figure 3.3B). Strikingly, while IGFBP3 mRNA and protein were undetectable in wild
type hair follicles, their expression was evident in DP fibroblasts but not the keratinocytes
of Notch1-deficient hair follicles (Figure 3.3B).
IGFBP3 is a diffusible molecule and its ectopic expression in hair follicles leads
to decreased hair length and bulb volume (Weger and Schlake, 2005b), a phenotype
strikingly similar to Notch1-deficient hair follicles (Figure 3.1 and 3.2). Conversely,
ectopic expression of IGF1 promotes hair growth and follicular elongation (Su et al.,
1999a; Su et al., 1999b; Weger and Schlake, 2005a). Importantly, mice overexpressing
both IGF1 and IGFBP3 are normal (Weger and Schlake, 2005a), indicating that
IGF/IGFBP3 balance is an important regulator of follicular keratinocyte proliferation.
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To determine if IGF1 overexpression (and thus a higher IGF/IGFBP ratio) can
rescue Notch1-deficient hair follicles, we generated Msx2-Cre;Notch1flox/flox;Ivl::IGF1
mice (Weger and Schlake, 2005a) and analyzed the morphology of their hair follicles at
P9. The cell numbers in Notch1-deficient, IGF1-expressing hair follicles increased
(Figure 3.3C and D), indicating that an imbalance between IGF ligand and IGFBPs was
indeed a contributing factor to the phenotype of Notch1-deficient follicles.
As described above, a change in protein expression in one compartment (Notch1
loss in keratinocytes) led to a change in another compartment (IGFBP3 gain in DP). It is
important to note that dermal fibroblasts and DP did not experience Msx2-Cre activity (as
evident from lack of LacZ expression in Msx2-Cre; Rosa26R skin; Figure 3.1A and data
not shown). In addition, they do not express Notch1 mRNA or protein (Figure 3.8 and
3.10), and are even separated from Notch1 expressing cells by a basement membrane and
a layer of keratinocytes lacking Notch1 proteins. Therefore, a longer G1 in Notch1deficient matrix keratinocytes likely involves a cell non-autonomous mechanism (e.g.,
elevation of Igfbp3 in the DP) perhaps in combination with a cell-autonomous
mechanism (e.g., elevated expression of Igfbp2, cytostatic and proapoptotic genes). We
again turned to the array information in search for candidate molecules that can
participate in bi-compartmental communication.

Changes in epithelial TGF-# ligands lie downstream of Notch1 and may contribute to the
skin phenotype

Components of the TGF-# signaling pathway, which has been shown to induce
IGFBPs and cyclin kinase inhibitors (CKIs) and thus promote G1 arrest (Firth and
Baxter, 2002; Jetten et al., 1986; Moustakas et al., 2002), were also altered in N1CKO
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skin. Transcription of the ligands Tgfb1 and Tgfb2, the receptor Tgfbr2 (itself a target of
TGF-# signaling (Cui et al., 1995)), the co-receptor Tgfbr3 (Brown et al., 1999), as well
as the TGF-# targets Col1a2 (Inagaki et al., 1994) and Thbs1, were all elevated in the
emN1 hair bulb (Table 3.1 and Figure 3.4A). The ligands TGF-#1 and TGF-#2 and the
receptors TGF-#RI and TGF-#RII were all expressed in the hair follicle (Figure 3.5 and
(Paus et al., 1997)). These receptors were also expressed in DP (Figure 3.5) while Col1a2
was specifically expressed in dermal fibroblasts (Zheng et al., 2002). Because TGF-#mediated signaling can act both as an autocrine and a paracrine signal, this pathway is
capable of activating transcription of Igfbp2 in keratinocytes (Moustakas et al., 2002;
Scandura et al., 2004), as well as that of Igfbp3 in neighboring cells (Guo et al., 1995;
Martin and Baxter, 1991).
To ask if autocrine reception of TGF-# plays a role in hair matrix homeostasis, we
removed the essential type II receptor Tgfbr2 in all Notch1-deficient keratinocytes by
generating Msx2Cre;Tgfbr2flox/flox (TGFßR2CKO) and Msx2Cre;Notch1flox/flox; Tgfbr2flox/flox
(N1TGFßR2CKO) mice. Only dermal fibroblasts and DP cells in these compound mice
retain the ability to respond to TGF-# ligands via TGF-#RII, yet the skin of
TGFßR2CKO mice is indistinguishable from wild type (data not shown and Figure 3.6).
Importantly,

hair

follicles

from

N1TGFßR2CKO

and

N1CKO

mice

were

morphologically identical, and qRT-PCR analysis confirmed that the expression of Tgfb1,
Tgfb2, Tgfbr3, Igfbp2, Igfbp3, Col1a2, and CKIs remained elevated in N1TGFßR2CKO
emN1 hair bulbs (Figure 3.4B). These observations indicate that (1) even though a block
in TGF-# signaling in bulb keratinocytes has not been demonstrated, TGF-#RII-mediated
TGF-# signals do not regulate the proliferation/apoptosis of hair matrix keratinocytes
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cell-autonomously, and (2) elevated Igfbp2 or CKI mRNA levels may not be a
consequence of autocrine TGF-# signaling in the hair matrix. Collectively, our results
described thus far are consistent with the hypothesis that Notch1 regulates hair matrix
proliferation both autonomously, by preventing expression of proapoptotic and cytostatic
genes, and non-autonomously, by establishing a bi-compartmental feed-back loop. Loss
of Notch1 in transit amplifying keratinocytes induced TGF-# ligands, which were
recognized by DP cells. As a possible consequence of TGF-# signaling, diffusible
IGFBP3 was produced in DP cells to inhibit follicular IGF signaling and suppress the
proliferation of follicular keratinocytes.

Differential impact of Notch1 loss on hair follicle and epidermal keratinocytes:
underlying mechanisms?
In Notch1-deficient skin, the proliferation of epidermal keratinocytes increases
progressively until a hyperplastic skin phenotype is evident, whereas follicular
keratinocytes are hypoplastic, resulting in a shorter hair shaft (Figure 3.1). To gain further
insight into the basis of the differential response in these related keratinocyte populations,
we compared the epidermal and follicular expression of selected Notch targets. The
mRNA levels of Nrarp and Heyl (Krebs et al., 2001; Lamar et al., 2001), were reduced in
the epidermis and in the hair follicle (Figure 3.7C and 3.8A). Transcripts of these targets
overlap with Notch1 in the hair follicle (Figure 3.8B). In contrast, epidermal Hes1 and
p21Cip1 protein levels were reduced in Notch1-deficient epidermal keratinocytes (Figure
3.7A and B) whereas their expression was unchanged in Notch1-deficient hair follicles
(Figure 3.8 and 3.9). Moreover, Hes1 protein, a well-studied Notch target, did not overlap
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with Notch1 mRNA (Figure 3.8B) or protein (Figure 3.10). Instead, it overlapped with
the expression domain of Notch2 and Notch3 (see (Pan et al., 2004) for details). p21Cip1
mRNA overlapped with Hes1 supporting an indirect activation mechanism whereby Hes1
impacts the Calcineurin/NFAT pathway (Mammucari et al., 2005). We conclude that
p21Cip1 is likely a target of Hes1 (but not Notch1) in both the epidermis and the hair
follicle, and that Hes1 acts as a Notch1 target only in the epidermal keratinocytes. In the
hair follicle, its expression may be regulated by other Notch paralogs (Notch2 or
Notch3). These data agree with a recent demonstration that vertebrate cellular context
affects usage of targets by individual Notch proteins in a manner yet to be explained
(Cheng et al., 2007). These differences constitute a cell autonomous contribution to the
distinct proliferative behavior of hair follicles and epidermal keratinocytes in response to
Notch1 loss.
To our knowledge, this is the first report to place Notch1 upstream of TGF-#
signaling in any cell type. While at this time we can only speculate how TGF-# ligands
responded to Notch1 loss, the broad spectrum of co-regulated TGF-# response genes
confirm that this pathway is perturbed in response to Notch1 loss. Another striking
molecular difference between epidermis and hair follicles is the response of the stromal
compartment to TGF-#, specifically, in regulating the expression of IGFBP3 and
IGFBP4. In Notch1-deficient hair follicles, induction of IGFBP3 underlies the follicular
phenotype in N1CKO animals. Overexpression of IGFBP4 can decrease growth of
prostate cancer (Durai et al., 2006); Igfbp4 mRNA was also up regulated in the follicle
(Figure 3.3A) and may have also contributed to down regulation of IGF1. In contrast,
Igfbp4 mRNA was significantly down regulated in Notch1-deficient dermis (Figure 3.7A
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and B; (Batch et al., 1994)). We thus posit that the differential modulation of IGF
signaling as a consequence of changes in stromal IGFBP levels may underlie the
difference in the response of epidermis and hair follicles to Notch1 loss. Thus, the
contribution of Notch signaling to differential follicular and epidermal homeostasis
results from both cell autonomous (differential target selection) and cell non-autonomous
effects (differential stromal response to the same diffusible factors), the latter mediated
possibly by TGF-# (Li et al., 2004; Liu et al., 2001).
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Conclusions
The response of wild type stromal cells to signals produced by mutant epithelial
neighbors critically contributes to cancer (Krtolica and Campisi, 2002; Krtolica and
Campisi, 2003). We demonstrate that Notch1 contributes to an elaborate network of
signaling pathways that monitor and control proliferation in the skin. The effects of
Notch1 loss in the skin is reminiscent of the transformation of cells adjacent to Notchdeficient clones in Drosophila (Moberg et al., 2005; Thompson et al., 2005; Vaccari and
Bilder, 2005). Our observations suggest that the skin tumorigenesis due to Notch loss is
in part mediated by elevation in ligands that elicit stromal responses, similar to the
‘vicious cycle’ that promotes bone metastasis in several solid cancers (Mundy, 2002;
Roodman, 2004). In a broader context, the role of Notch signaling in tumor suppression
may reflect both an autonomous function in promoting keratinocyte differentiation and a
non-autonomous function within a signaling network that regulates keratinocyte
proliferation.
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EXPERIMENTAL PROCEDURE
Production and Analysis of Single and Compound Mutant Mice
The generation of Tgfbr2flox(Yang et al., 2004), Msx2-Cre (Sun et al., 2000), Ivl::IGF1
(Weger and Schlake, 2005a), and N1CKO (Msx2-Cre;Notch1

flox/flox

) (Pan et al., 2004)

mice were described previously.
N1IGF1
Ivl::IGF1

females

were

crossed

with

NICKO

males,

and

the

F1

Msx2-

Cre/+;Notch1flox/+;Ivl::IGF1 male offspring were then crossed with F1 Notch1flox/+;
Ivl::IGF1 females to produce Msx2-Cre/+;Notch1flox/flox;Ivl::IGF1 offspring.
N1TGFßR2CKO
Tgfbr2flox/flox

males

and

females

were

similarly

used

to

generate

Msx2-

Cre/+;Notch1flox/flox;Tgfbr2flox/flox for analysis.
PCR conditions and protocols used for genotyping will be provided upon request.

Histology, In situ Hybridization (ISH), and Immunohistochemical Analysis
To obtain stereoscopic images, 9-day-old (P9) skins in PBS were torn as strips across the
caudal-rostral axis with fine forceps and photographed with an Olympus SZH10 stereo
dissecting microscope. For hematoxylin/eosin staining, ISH, and immunohistochemical
analyses, skins were fixed in 4% paraformaldehyde in PBS, embedded in paraffin and
sectioned at 5µm thickness. ISH was performed as described (Pan et al., 2004) with
probes prepared using cDNAs either generated by RT-PCR or from the following
sources: Cdkn1a (IMAGE 3495942), Nrarp (IMAGE 6439916), and Notch1 (Kopan and
Weintraub, 1993). The primer sequences for RT-PCR are available upon request. For
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each reaction, a corresponding sense transcript was used as a negative control.
Immunohistochemical analysis was performed as described previously (Lin et al., 2000;
Pan et al., 2004). For BrdU staining, animals were intraperitoneally administered with
100µg BrdU/g body weight and sacrificed after 30 minutes. Immunohistochemical
analyses with AE13, BrdU, and Ki67 antibodies were performed as described (Lin and
Kopan, 2003; Lin et al., 2000). Other antibodies used were Hes1 (rabbit, 1:1000; kindly
provided by Dr. Sudo (Ito et al., 2000), Igfbp2 (goat, 1:200; R and D systems AF797),
Igfbp3 (goat, 1:200; R and D systems AF775), and p73 (mouse, 1:1000; Labvision
ER15). For #-galactosidase (rabbit, 1:1000, 5 Prime ! 3 Prime, Inc) antibody staining,
skins were fixed in periodate-lysine-paraformaldehyde, cryoprotected with 30% sucrose
in PBS overnight, embedded in OCT, and sectioned at 7µm thickness. Sections were
counterstained with DAPI.

Cell counting and progenitor cell labeling index
For hair matrix cell counting, paraffin sections were stained with DAPI and photographed
under both UV and visible light. The two pictures were overlapped and nuclei located
below the most proximal melanin granules were counted from each hair follicle. For each
genotype, >20 hair follicles in proper longitudinal orientation were counted to calculate
average and standard deviation. For progenitor cell labeling index, BrdU- and Ki67positive cells were counted from >20 hair follicles per mouse, using three mice for each
genotype. In all cases, significant differences between means were determined by twotailed Student's t-test.
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TUNEL (Terminal deoxynucleotide transferase dUTP-digoxigenin nick end labeling) staining

Frozen unfixed dorsal skins were embedded in OCT, and 10µm sections were prepared
for TUNEL assay. TUNEL assay was performed as described (Lindner et al., 1997). The
number of TUNEL-positive cells per follicle was counted from >60 longitudinally
sectioned, properly oriented follicles from each individual (anN1 and emN1 follicles
from N1CKO mice at P9; wild-type follicles at P9 and P16), and 3 different individuals
were used. Statistical significance was determined by two-tailed Student's t-test.

Isolation of hair bulbs and epidermis, total RNA extraction, and microarray
analyses
For hair bulb isolation, fresh P9 skin samples were immediately immersed in RNAlater
(Ambion, TX) and individual hair follicles were collected using a fine tungsten needle
and precisely cut with a 26G syringe needle (Becton Dickinson and Company, NJ) at the
level twice the distance between the tip of the bulb and the melanin granules (Figure
3.9A). For epidermis preparation, a patch of P9 dorsal skin was harvested and flashfrozen with dry ice, and the epidermis was isolated by scraping it off the skin using a cold
scalpel. Isolated hair bulbs and epidermis samples were then subjected to total RNA
isolation using QIAGEN RNeasy Micro Kit (QIAGEN Sciences, MD) according to the
manufacturer’s protocol. For hair bulb microarray analyses, 50-100ng of total RNA was
collected from emN1 and anN1 follicles isolated from the same N1CKO mouse (total of
two mice) and from two wild type littermates. After double-round amplification/labeling
procedures, the cRNA products were hybridized to Affymetrix MOE430v2 chips. All
protocols

were

conducted

at

the

Washington
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University

Genechip

Facility

(http://www.siteman.wustl.edu/internal.aspx?id=238). Affymetrix microarray suite 5.0
and dChip software (http://www.dchip.org) were used for expression profile comparisons
and GO (Gene Ontology)-based classification. The data discussed in this publication have
been

deposited

in

NCBIs

Gene

Expression

Omnibus

(GEO,

http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession
number

GSE6867.

Ingenuity

(https://analysis.ingenuity.com)

and

David2

(http://niaid.abcc.ncifcrf.gov/) were used for pathway analyses.

cDNA preparation and Quantitative RT-PCR
Total RNA from hair bulbs and epidermis was used for cDNA preparation using
QIAGEN Sensiscript RT Kit (QIAGEN Sciences, MD) according to the manufacturer’s
protocol. The cDNA was amplified with SYBR-Green PCR Master Mix (Applied
Biosystems, CA) and gene-specific exon-exon junction spanning primers using the
ABI7700 sequence detection system (Applied Biosystems, CA) or the MyIQ iCycler
(Bio-rad, CA). Normalizations across samples were performed using hypoxanthine
guanine

phosphoribosyl

transferase

1

(hprt1)

or

glyceraldehyde-3-phosphate

dehydrogenase (gapdh) primers. The differences between samples and controls were
calculated using the Comparative CT (2-!!CT) Method. The histograms in Figures show the
mean ± s.e.m. of two or three independent experiments for hair follicles and of five
independent experiments for epidermal samples, each of which was performed in
triplicate. All qRT-PCR primers were tested for the presence of nonspecific primer
dimers and for linear amplification. The identity of the qRTPCR amplicons was validated
by DNA sequencing or restriction enzyme digestion of the amplicon. Primer sequences
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and qRT-PCR conditions are available upon request.

Immunoblotting
Frozen epidermal samples were immediately lysed in NP40 lysis buffer (1% NP-40,
150mM NaCl, 10% glycerol, 1mM EDTA, 20mM Tris, pH 8.0) containing protease and
phosphatase inhibitors and analyzed by SDS-PAGE/Western blotting. The following
primary antibodies were used: "-tubulin (mouse, 1:1000; Sigma-Aldrich B-5-2),
CyclinD1 (rabbit, 1:1500; Santa Cruz sc-718), IGFBP4 (rabbit, 1:5000; kindly provided
by Dr. Chernausek, Cincinnati Children’s Hospital), p15 (rabbit, 1:200; Santa Cruz sc612), p21 (mouse, 1:100; Santa Cruz sc-6246) and anti-TGF-#2 (rabbit, 1:200; Santa
Cruz sc-90). Western blot quantification was performed using Quantity One software
(Bio-Rad Laboratories, CA). The histograms in Figures show mean ± s.e.m. of two or
three independent epidermal lysates per genotype.
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FIGURES
Figure 3.1
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Figure 3.1. Notch1 loss leads to reduced cell numbers in hair follicles but expansion
of epidermal keratinocytes.
(A) LacZ immunohistochemistry on Msx2Cre;Notch1flox/flox;Rosa26R/+ skin. Note that
LacZ staining displays the area of Notch1 deletion. Scale Bar 50µm.
(B) Stereoscopic side view of the anagen-deleted (anN1) (left) and embryo-deleted
(emN1) (right) skin at P9. Scale Bar 300µm.
(C) Stereoscopic view magnified from (B) after dissection. Wild type (left, blue box),
anN1 (middle, yellow box), emN1 (right, red box). Arrows indicate guard hairs. Scale
Bar 200µm.
(D) Histological view of (B) and (C). Different genotypes designated as in (C). Nuclei
were stained with DAPI. Scale Bar 20µm.
(E) Average number of hair matrix cells (below the red line in D) per hair follicle. (* p <
0.00001). Error Bars represent s.d.
(F-G) H and E staining of P9 (F) and P453 (G) skin. Note the epidermal hyperplasia in
older emN1 skin (G). Scale Bar 40µm.
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Figure 3.2
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Figure 3.2. Notch1 loss causes decreased mitotic rates and a slight increase in
apoptosis, but not acceleration in catagen onset.
(A) H and E staining of anN1, emN1, and wild type skin at P9, 13, 17, and 22. Note that
hair cycling was not altered in Notch1-deficient hair follicles. Scale Bar 200µm.
(B) TUNEL staining of emN1 and anN1 (P9), and wild type hair follicles (P9 and P16catagen).
(C) Average number of TUNEL-positive cells per hair follicle in each genotype shown in
(B). (* p < 0.05 for both WT vs emN1 and anN1 vs emN1; ** p < 0.05 for both WT vs
WT(cat) and anN1 vs WT(cat); *** p < 0.005).
(D) Immunofluorescence staining of BrdU (green) and Ki67 (red). Scale Bar 20µm
(E) Progenitor labeling index of anN1, emN1, and wild type hair follicles and epidermis.
(* p <0.01 for anN1 vs emN1 and WT vs emN1). Error Bars represent s.d.
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Figure 3.3
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Figure 3.3. Altered IGF/IGFBP equilibrium in the hair matrix of Notch1-deficient
hair follicles.
(A) qRT-PCR of IGF signaling components. Error bars represent s.e.m. (B)
Immunohistochemistry (IGFBP2 and 3) and in situ hybridization (IGF1R, IGFBP3
insets) of IGF signaling components on hair follicles. DAPI was used to label nuclei
during antibody staining. Arrows indicate DP-specific IGFBP3 immunoreactivity. Note
the mRNA and protein expression of Igfbp3 in dermal papilla, where Notch1 is not
expressed. Scale Bars 40µm. (C) Histological comparisons of the hair follicles from the
genotypes specified. Note that the matrix size is restored in emN1;Ivl-IGF1 follicles.
Scale Bars 200µm (skin H and E staining); 50µm (follicular H and E and DAPI staining)
(D) Average number of hair matrix cells (below the red line in C) per hair follicle. Error
Bars represent s.d.
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Figure 3.4
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Figure 3.4. Notch1 loss alters the expression of the diffusible TGF-# ligand.
(A) qRT-PCR of TGF-# signaling components and a downstream target (Col1a2). (B)
qRT-PCR of the genes specified using Notch1- and Tgfbr2-deficient hair bulbs. Error
bars represent s.e.m.
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Figure 3.5
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Figure 3.5. mRNA expression patterns of TGF-# and IGF signaling components.
TGF-#1 is expressed in hair matrix while TGF-#2 is only in proximal hair matrix. TGF-#
receptors are found in the matrix as well as the dermal papilla (Arrows). IGFBP2 and 3
are found in dermal fibrobalsts and epidermal basal keratinocytes, respectively. Scale
Bars 50µm.
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Figure 3.6
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Figure 3.6. TGF-# signaling in epithelial cells do not participate in Notch1-deficient
phenotype.
(A) Histological (H&E staining) and stereoscopic view of the genotypes specified. Note
that no observable difference between the presence and absence of Tgfbr2. Scale Bars
200µm. (B) Semi-quantitative PCR of genomic DNA from plucked hairs from wild-type,
anagen-deleted and embryo-deleted Msx2-Cre;Notch1flox/flox;Tgfbr2flox/flox (anN1;TbR2 and
emN1;TbR2, respectively) using primers specific for Notch1 and Tgfbr2 floxed alleles.
Nrarp primer sets were used as a positive control. Note the absence of Tgfbr2 floxed
allele in emN1;TbR2 hairs.
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Figure 3.7
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Figure 3.7. Monitoring the epidermal expression of genes altered in Notch1-deficient
hair follicles.
(A) Western blot analyses of P9 epidermal cell lysates from embryo-deleted N1CKO
mouse (N1EP) and its wild type littermate (WTEP). (B) Quantification of the western
data from (A). (C) qRT-PCR of Notch1 and its targets, Hes1, HeyL, and Nrarp, using P9
epidermal total RNA. Error bars represent s.e.m. * p = 0.05; ** p < 0.001.
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Figure 3.8
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Figure 3.8. Monitoring epidermal Notch targets for their expression in the hair
follicles.
(A) qRT-PCR for Notch1, Nrarp, Hes1, and Heyl. Note that Hes1 expression was
sustained in emN1 hair follicles. Error bars represent s.e.m.
(B) mRNA (Notch1, Nrarp, and Cdkn1a) and protein (Hes1) expression in skin. Hes1
(red) expression is found in differentiating hair matrix and epidermal suprabasal cells.
AE13 is a marker for follicular cortex and cuticle. Nuclei were stained with DAPI. Scale
bars 40µm.
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Figure 3.9
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Figure 3.9. Reduced mitotic rates in hair follicles correlates with elevated expression
of cytostatic and proapoptotic genes.
(A) Microdissection of hair bulbs from emN1 or anN1/wild type follicles (grouped for
this image as they have the same morphology). Scale Bars (left) 100µm; (right) 200µm.
(B) qRT-PCR of G1 cyclins, CKIs, gasdermin1, and Scotin using total RNA isolated
from micro-dissected samples shown in (A). Error bars represent s.e.m.
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Figure 3.10

122

Figure 3.10. Confirmation of Notch1 deficiency in IGF1 rescued hair follicles.
Immunohistochemical analyses with full-length Notch1 (1:50, rabbit, Abcam ab27526)
and cleaved Notch1 (V1744, 1:100, rabbit, Cell Signaling, #2421) antibodies. Note the
absence of Notch1 and V1744 immunoreactivity in emN1 and emN1;Ivl-IGF1 follicles.
Scale bars, 50µm.
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TABLES
Table 3.1
Probe Set ID

Gene Symbol

Gene Title

emN1 vs
anN1 (1)

emN1 vs
anN1 (2)

qRT-PCR
validation

Cell Cycle / Growth / Proliferation
1456022_at

B230339E18Rik

RIKEN cDNA B230339E18 gene

-2.32

-1.74

1418971_x_at

Bcl10

B-cell leukemia/lymphoma 10

1.56

1.62

1418970_a_at

Bcl10

B-cell leukemia/lymphoma 10

1.62

1.62

1422477_at

Cables1

Cdk5 and Abl enzyme substrate 1

2.5

1.63

1441938_x_at

Cables1

Cdk5 and Abl enzyme substrate 1

2.01

1.92

1455869_at

Camk2b

2.56

2.3

1449145_a_at

Cav1

Calcium/calmodulin-dependent protein
kinase II, beta
caveolin, caveolae protein 1

2.98

3.23

1417327_at

Cav2

caveolin 2

3.31

2.29

1417419_at

Ccnd1

cyclin D1

-2.37

-2.32

NC

1448698_at

Ccnd1

cyclin D1

-1.5

-1.79

NC

1417649_at

Cdkn1c

cyclin-dependent kinase inhibitor 1C (P57)

2.43

2.22

"

1449152_at

Cdkn2b

1.72

1.83

"

1450944_at

Cspg4

cyclin-dependent kinase inhibitor 2B (p15,
inhibits CDK4)
chondroitin sulfate proteoglycan 4

3.53

1.94

1423341_at

Cspg4

chondroitin sulfate proteoglycan 4

4.9

3.12

1448823_at

Cxcl12

chemokine (C-X-C motif) ligand 12

6.22

4.19

1421117_at

Dst

dystonin

2.96

2.39

1419431_at

Ereg

epiregulin

2.87

2.88

1416268_at

Ets2

E26 avian leukemia oncogene 2, 3' domain

1.78

1.78

1438883_at

Fgf5

fibroblast growth factor 5

-1.56

-2.57

1416855_at

Gas1

growth arrest specific 1

2.3

2.78

1417399_at

Gas6

growth arrest specific 6

2.52

2.1

1459211_at

Gli2

GLI-Kruppel family member GLI2

1.58

1.6

1446086_s_at

Gli2

GLI-Kruppel family member GLI2

2.08

1.61

1419292_at

Htra3

serine protease HTRA3

2.33

4.63

1454159_a_at

Igfbp2

insulin-like growth factor binding protein 2

5.8

7.05

"

1458268_s_at

Igfbp3

insulin-like growth factor binding protein 3

8.03

4.05

"

1423062_at

Igfbp3

insulin-like growth factor binding protein 3

6.4

5.98

"

1437406_x_at

Igfbp4

insulin-like growth factor binding protein 4

1.51

1.75

"

1423757_x_at

Igfbp4

insulin-like growth factor binding protein 4

1.74

1.85

"

1423756_s_at

Igfbp4

insulin-like growth factor binding protein 4

1.89

1.89

"

1423584_at

Igfbp7

insulin-like growth factor binding protein 7

2.58

1.96

1421066_at

Jak2

Janus kinase 2

1.63

1.51

1421317_x_at

Myb

myeloblastosis oncogene

1.86

2.37

1450194_a_at

Myb

myeloblastosis oncogene

2.22

2.56

1422818_at

Nedd9

2.09

1.53

1438157_s_at

Nfkbia

1.5

1.8

1448306_at

Nfkbia

neural precursor cell expressed,
developmentally down-regulated gene 9
nuclear factor of kappa light chain gene
enhancer in B-cells inhibitor, alpha
nuclear factor of kappa light chain gene
enhancer in B-cells inhibitor, alpha

1.89

2.25
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1421917_at

Pdgfra

1.56

1.84

Pmp22

platelet derived growth factor receptor,
alpha polypeptide
peripheral myelin protein

1417133_at

2.11

1.99

1438251_x_at

Prss11

protease, serine, 11 (Igf binding)

2.29

2.35

1416749_at

Prss11

protease, serine, 11 (Igf binding)

2.47

2.55

1447830_s_at

Rgs2

regulator of G-protein signaling 2

5.19

3.54

1419248_at

Rgs2

regulator of G-protein signaling 2

6.32

3.63

1419247_at

Rgs2

regulator of G-protein signaling 2

5.96

3.84

1418448_at

Rras

Harvey rat sarcoma oncogene, subgroup R

2.1

1.95

1456212_x_at

Socs3

suppressor of cytokine signaling 3

6.63

2.13

1455899_x_at

Socs3

suppressor of cytokine signaling 3

2.73

2.21

1421943_at

Tgfa

transforming growth factor alpha

4.31

3.28

1423250_a_at

Tgfb2

transforming growth factor, beta 2

3.45

1.83

"

1450923_at

Tgfb2

transforming growth factor, beta 2

3.36

2.23

"

1450922_a_at

Tgfb2

transforming growth factor, beta 2

3.15

2.86

"

1426397_at

Tgfbr2

transforming growth factor, beta receptor II

2.23

2.16

"

1460302_at

Thbs1

Thrombospondin 1

3.46

3.06

Programmed Cell Death
1456022_at

B230339E18Rik

RIKEN cDNA B230339E18 gene

-2.32

-1.74

1418971_x_at

Bcl10

B-cell leukemia/lymphoma 10

1.56

1.62

1418970_a_at

Bcl10

B-cell leukemia/lymphoma 10

1.62

1.62

1421392_a_at

Birc3

baculoviral IAP repeat-containing 3

2.17

1.77

1454880_s_at

Bmf

Bcl2 modifying factor

1.9

1.69

1417040_a_at

Bok

Bcl-2-related ovarian killer protein

1.57

1.71

1416855_at

Gas1

growth arrest specific 1

2.3

2.78

1435040_at

Irak3

interleukin-1 receptor-associated kinase 3

2.56

2.79

1421066_at

Jak2

Janus kinase 2

1.63

1.51

1420640_at

Jmy

junction-mediating and regulatory protein

1.53

1.66

1454974_at

Ntn1

netrin 1

4.22

2.89

1423986_a_at

Scotin

scotin gene

1.91

1.73

1450036_at

Sgk3

serum/glucocorticoid regulated kinase 3

2.11

1.62

1418011_a_at

Sh3glb1

SH3-domain GRB2-like B1 (endophilin)

1.66

1.56

1433699_at

Tnfaip3

1.71

1.59

1416926_at

Trp53inp1

1.81

1.72

1452325_at

Trp73

tumor necrosis factor, alpha-induced protein
3
transformation related protein 53 inducible
nuclear protein 1
transformation related protein 73

4.19

3.28

1460302_at

Thbs1

thrombospondin 1

4.2

3.65

1421811_at

Thbs1

thrombospondin 1

3.64

5.04

1415855_at

Kitl

Kit ligand

-3.24

-2.63

"

"

Others

Table 3.1. Continued
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"

Table 3.1. Genes altered in Notch1-deficient proximal hair bulbs classified under the
GO categories of cell growth, cycle, proliferation, and programmed cell death.
622 genes differentially regulated in Notch1-deficient proximal bulbs were classified by
GO terms. “emN1 vs anN1 (1)” and “emN1 vs. anN1 (2)” indicate two different
microarray experiments. Validated genes by qRT-PCR were marked as “!” and the genes
with no significant change as “NC”.
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CHAPTER IV

Notch1 loss causes skin carcinogenesis by creating a tumorpromoting stromal microenvironment
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SUMMERY
Notch1 is a proto-oncogene in several organs. In skin, however, Notch1 deletion leads to
tumor formation, suggesting that within this specific cellular context Notch1 acts as a
tumor suppressor. Here we demonstrate that Notch1 loss acts as a non-cell autonomous
tumor promoter in the skin through a wound-like microenvironment created by barrier
defects in Notch1-deficient epidermis. Using mice with chimeric pattern of Notch1
deletion, we determined that Notch1-expressing keratinocytes in this microenvironment
readily formed epidermal tumors, showing that Notch1 was insufficient to suppress this
tumor-promoting effect. Accordingly, loss of other Notch paralogs that impaired the skin
barrier also predisposed Notch1-expressing skin to carcinogenesis, confirming that the
tumor-promoting effect of Notch1 loss involves a crosstalk between barrier-defective
epidermis and its stroma. This distinguishes the "tumor suppressor" activity of Notch1
from classical tumor suppressors. In contrast to the current dogma, we demonstrate
unequivocally that the non-cell autonomous consequences of defective barrier formation
are responsible for the tumor-promoting effects of Notch1 loss in the skin. Thus,
individuals with clinical sub-acute skin-barrier defects may be more prone to
carcinogenesis upon exposure to initiating carcinogens like UV rays. As Notch1 deletion
in skin tumors enhanced their progression to invasive carcinomas, patients with benign
hyperplasic skin lesions receiving !-secretase inhibitor therapy may also be at additional
risk. More broadly, given the clinical reality that chronic injury causatively effects the
development of several human carcinomas, Notch1-deficient mice with mild skin-barrier
defects can serve as a novel experimental model in which to study the tumor-promoting
elements of chronic injury/wound and develop relevant therapies.
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INTRODUCTION
Notch signaling is implicated in many developmental and cellular processes
including carcinogenesis (Artavanis-Tsakonas et al., 1999; Radtke et al., 2006). Notch
proteins are transmembrane receptors activated upon binding of transmembrane ligands.
Activation involves two proteolytic cleavages culminating in the release of the Notch
Intracellular Domain (NICD), a transcription regulator, into the nucleus (Lubman et al.,
2004). Based on its role in most cancers involving Notch signaling (e.g. T-acute
lymphoblastic leukemia), Notch1 is found to be a proto-oncogene, driving carcinogenesis
cell autonomously when hyperactivated or hyperstabilized (Radtke et al., 2006; Weng et
al., 2004). In contrast, an opposite role for Notch1 is observed in skin keratinocytes,
where it acts as a “tumor suppressor” (Koch and Radtke, 2007; Nicolas et al., 2003). The
mechanism enabling Notch1 to deliver this unique function in the skin remains
controversial.
The vertebrate skin is a barrier-forming organ in which keratinocytes form a
highly organized, stratified epithelium protecting the internal milieu from the outside
environment. To achieve this, proliferating keratinocyte progenitors that reside within the
innermost (basal) layer of the epidermis constantly divide and replenish the upper barrierforming layers (Clayton et al., 2007). Cells exiting the basal layer commit to terminal
differentiation in the upper spinous layer, and, under normal conditions, complete their
differentiation program, giving rise to granular and cornified layers (Fuchs and
Raghavan, 2002; Jamora and Fuchs, 2002). Three Notch paralogs (Notch1, 2 & 3) are
expressed in the epidermis and their activation is evident in suprabasal keratinocytes,
where they are thought to cooperate in regulating proper epidermal differentiation
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(Mammucari et al., 2005; Moriyama et al., 2008; Nguyen et al., 2006; Pan et al., 2004;
Rangarajan et al., 2001). Importantly, reduction in Notch signaling within keratinocytes
impairs their ability to execute the terminal differentiation program, resulting in
formation of a defective skin-barrier and death if the areas involved are sufficiently large
(Blanpain et al., 2006; Demehri et al., 2008).
One of the major adverse consequences of Notch loss in epidermis is the
development of skin tumors (Nicolas et al., 2003; Proweller et al., 2006), which has
evoked the use of the term tumor suppressor to specifically describe the role of Notch1 in
the epidermis (Nicolas et al., 2003). However, the exact mechanism underlying Notch1
tumor suppressor function and the specific role of other Notch paralogs present in the
same microenvironment (i.e. Notch2 & 3) are not fully understood. It has been previously
proposed that the tumor suppressor activity of Notch1 may reflect its ability to antagonize
keratinocyte proliferation through one or more of the following mechanisms not shared
by other Notch paralogs: Notch1 ability to activate p21wAF1/Cip1, suppress Gli2 expression,
up-regulate caspase 3 expression, reduce Wnt/#-catenin signaling, and reduce p63
signaling (Devgan et al., 2005; Nguyen et al., 2006; Nicolas et al., 2003; Okuyama et al.,
2004). Most of these findings were established in pre-cancerous hyperplastic epidermis of
Notch-deficient animals (Nicolas et al., 2003; Proweller et al., 2006) and did not address
the early changes following Notch loss. In addition, some of these conclusions were
based on in vitro studies with isolated keratinocytes (Devgan et al., 2005; Nguyen et al.,
2006; Nicolas et al., 2003), failing to take into account the complexity of the skin
microenvironment including the contribution of other skin components to carcinogenesis.
Notably, in vivo studies have revealed that loss of Notch signaling during embryogenesis
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induces epidermal hypoplasia and low proliferative capacity in the keratinocytes,
proposing that reactive hyperplasia accounts for the late epidermal hyperproliferation
detected in adult Notch-deficient skin (Blanpain et al., 2006; Demehri et al., 2008). This
also implies that the molecular changes outlined above may reflect secondary events
following tumor formation in Notch-deficient mice.
To address the mechanism underlying tumor development in Notch1-deficient
skin, we have taken an in vivo approach using the multistage skin chemical
carcinogenesis model (Kelly-Spratt et al., 2004; Weinberg et al., 1999; Yuspa, 1994;
Zoumpourlis et al., 2003). In this well-established carcinogenesis model, treating the skin
with an initiating carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA), results in an
activating mutation in the H-ras gene and creation of “initiated cells”. Thereafter, the
continual exposure of the skin to a tumor promoting agent, tetradecanoylphorbol acetate
(TPA), leads to expansion of the initiated cells and eventually, to tumor development
(Figure 4.2C).
For our analysis, we took advantage of two Cre-expressing transgenes: K14CreERT
transgene (Vasioukhin et al., 1999) to generate mice in which we could control the timing
of Notch1 deletion in the epidermis relative to DMBA treatment, and Msx2-Cre transgene
to generate mice with chimeric pattern of Notch1 deletion exclusively in the skin
keratinocytes (Demehri et al., 2008; Pan et al., 2004). Msx2-Cre is ectopically expressed
at E9.5 in clusters of ectodermal cells, prior to the onset of dorsal skin morphogenesis.
After E13, Cre expression is never again detected in the epidermis. This chimeric pattern
of Cre expression creates three types of epidermal territories: (1) clones of epidermal
cells on dorsal and ventral midline with complete deletion of Notch1-floxed alleles
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showing alopecia; (2) Territories with functional proteins expressed from un-deleted
floxed alleles exhibiting normal epidermal and hair growth; and (3) Border regions
between the two in which cells of both genotypes mingle (Figure 4.1). This chimeric
animal model permits a direct comparison of cells with identical genetic background,
other than the deleted allele(s), in the same microenvironment. Using this system, we
have identified several long-range signaling pathways affected by Notch1 loss in
keratinocytes, which exert their effects on their neighboring cells (Lee et al., 2007), and
may be part of the early changes associated with loss of Notch1 in the skin that precede
tumor development. These pathways include TGF-#" which may also contribute to Notch1
“tumor suppressor” function in the epidermis by altering stroma and/or the immune cells
in a non-cell autonomous manner (Lee et al., 2007).
Our in vivo studies demonstrated unequivocally that the tumor-promoting effect
of Notch1 loss in the skin was delivered non-cell autonomously through a wound-like
microenvironment created in response to the defective skin barrier formed by Notch1deficient keratinocytes, underscoring the intricate interplay between the stromal and
epithelial compartments in tumorigenesis. In accordance with the additive function of
three Notch paralogs in regulating proper epidermal differentiation/skin-barrier formation
(Blanpain et al., 2006; Demehri et al., 2008; Rangarajan et al., 2001), we were able to
document a tight inverse correlation between Notch dosage in the epidermis and the
severity of epidermal hyperplasia/carcinogenesis in the complete allelic series of Notchdeficient animals. In addition, a prominent tumor phenotype was associated with deletion
of both Notch2 and Notch3 in skin keratinocytes challenging the notion that Notch1 had a
unique, cell autonomous tumor suppressor function (Nicolas et al., 2003; Rangarajan et
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al., 2001). Therefore, the chronic wound-like skin-barrier defect associated with loss of
Notch signaling in the skin facilitates tumor development and presents a novel system in
which to study stromal-induced carcinogenesis and develop therapies that may be
relevant to a wide array of cancers.
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RESULTS
Animals with chimeric loss of Notch1 in the epidermis develop skin tumors
As reported in animals with 4-hydroxytamoxifen (4-OHT)-induced deletion of
Notch1 in the epidermis (K5CreERT; Notch1flox/flox or K5ERT-N1CKO; (Nicolas et al.,
2003)), most of 20-month-old Msx2-Cre; Notch1flox/flox (Msx2-N1CKO) mice
spontaneously developed 1 to 4 skin tumors each (Figure 4.2A). These lesions were
predominantly composed of benign papillomas; however, a small but significant subset of
tumors (10%, n=4 out of 41 spontaneous tumors characterized) progressed to basal cell
carcinoma (BCC; Figure 4.2B). To study the mechanism linking Notch1 loss to skin
carcinogenesis in an in vivo setting that permitted analysis of mutant and wild-type cells
in the same environment, we examined the response of Msx2-N1CKO animals to the
multistage chemical skin carcinogenesis model (Figure 4.2C). Treating 6- to 10-week-old
Msx2-N1CKO and wild-type (Notch1flox/flox) littermates with a single initiating dose of
DMBA, followed by a twice-weekly dose of TPA for 14 weeks (Nicolas et al., 2003),
resulted in development of more than 20 papillomas/mouse in all DMBA/TPA-treated
Msx2-N1CKO animals, whereas none of the control animals developed any papillomas
after 25 weeks of follow-up (n=10 for each group, p <0.0001, Figure 4.2D and E). These
results reproduce the tumor phenotype reported in K5ERT-N1CKO mice (Nicolas et al.,
2003) and now establish that Notch1 loss, even in a fraction of epidermal cells, is
sufficient to sensitize the animals to chemical carcinogenesis.
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Notch1 loss primarily acts as a tumor promoter in the epidermis
Utilizing the multistage chemical skin carcinogenesis model, we next tested the
impact of Notch1 loss on distinct stages of skin tumor development (Zoumpourlis et al.,
2003). The appearance of spontaneous tumors on Msx2-N1CKO skin could reflect a role
for Notch1 in initiation, in which case tumors would be expected to develop earlier in
Msx2-N1CKO mice exposed to TPA alone. However, 6- to 10-week-old Msx2-N1CKO
animals treated only with high dose of the promoting agent (TPA) twice weekly for 25
weeks (n=10, Figure 4.3A) did not develop any tumors, indicating that deletion of Notch1
did not act as a tumor initiator, nor did its loss lead to the activation of one. Accordingly,
we were unable to detect an elevated Gli2 expression (Nicolas et al., 2003) or elevated
Wnt/#-catenin signaling (seen at 6 weeks of age or older; (Nicolas et al., 2003; Proweller
et al., 2006)) in 2-week-old Notch-deficient skin (Figure 4.4). However, given that the
direct Notch1 targets in skin keratinocytes, Hes1 and Hey1, are repressors of HDM2
(Huang et al., 2004), Notch1 loss might have led to elevated MDM2 and destabilization
of p53. This could facilitate H-ras-mediated transformation of DMBA-treated
keratinocytes and enhance adduct fixation by lowering p53 levels (Zhao et al., 2006). In
addition, Notch1 loss could contribute to tumor initiation by lowering p21WAF1/Cip1
expression in keratinocytes (Nicolas et al., 2003; Rangarajan et al., 2001). Therefore, we
next examined the possibility that Notch1 loss contributed to the fixation rate of DMBAinduced DNA mutation in basal keratinocytes, thus enhancing tumor initiation.
To address this, we treated 6- to 10-week-old K14CreERT; Notch1flox/flox
(K14ERT-N1CKO) animals with 4-OHT (red pins in Figure 4.3B) to remove Notch1
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either before (OHT! DMBA! TPA or ODT) or after (DMBA! OHT! TPA or DOT)
DMBA exposure (black triangle). In the ODT cohort, 4-OHT injections were started 9
days before DMBA application; in the DOT group, 4-OHT injections began 4 days after
DMBA application (Figure 4.3B). Both cohorts were then treated with TPA for 14 weeks
(blue pins, Figure 4.3B). Importantly, as judged by time to tumor onset, both cohorts
displayed a similarly elevated susceptibility to carcinogenesis over the 4-OHT-treated
controls (K14CreERT; Notch1flox/+), indicating that Notch1 loss did not contribute to a
p21WAF1/Cip1- or p53-controlled checkpoint (Figure 4.3C and Table 4.1). Although
animals in which deletion of Notch1 was completed before DMBA treatment developed
more tumors in the final two weeks of the follow-up period, both cohorts had comparable
tumor counts during the first 23 weeks that were significantly higher than the wild-type
tumor count (Figure 4.3D and Table 4.1). Because our animals were kept in an outbred
background with variable strain susceptibility, we performed nested ANOVA to
determine if the variations among litters’ background strain susceptibility or gender
affected the tumor phenotype. This analysis confirmed that the differences reported in
this study were solely conferred by the presence or absence of Notch1 (Table 4.2 and
4.3). Collectively, these data suggest that the main consequence of Notch1 loss is in
tumor promotion. This conclusion was further confirmed by showing that 100% of Msx2N1CKO mice treated only once with DMBA (n=10) developed tumors, whereas wildtype controls (Notch1flox/flox; n=10) did not, effectively demonstrating that Notch1 loss can
substitute for TPA (p <0.0001, Figure 4.3E, F, Table 4.1 and 4.3).
In the K14CreERT genetic background, a subset of papillomas from DMBA/TPAand 4-OHT-treated K14ERT-N1CKO mice progressed to invasive squamous cell
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carcinoma (SCC) (Figure 4.5; also reported by (Nicolas et al., 2003)). Therefore, we
examined the impact of Notch1 loss specifically on malignant progression.
Intraperitoneal injection of 4-OHT into K14ERT-N1CKO and control mice after
completion of the DMBA/TPA protocol (DTO) did not alter tumor numbers (Figure 4.6A
and B). Interestingly, malignant conversion of papillomas to metastatic SCC was seen
only in Notch1-deficient animals (Figure 4.6C and D). On average, 50% of Notch1deficient tumors progressed to SCC, which metastasized and necessitated euthanasia of
the moribund mice (Figure 4.6E). Together, these in vivo cancer studies indicate that the
primary role of Notch1 in suppressing skin tumors is in blocking tumor promotion and
progression; the latter could be associated with reduction in p53 (Huang et al., 2004) or
with elevated activity of Wnt and HH signaling in hyperplasic, Notch1-deficient cells
(Nicolas et al., 2003).

Notch1 loss and HPV E6/E7 protein expression have a synergistic effect in inducing
skin carcinogenesis
It has been proposed that Notch1 expression is controlled in part by p53, which
has been shown to bind Notch1 promoter in keratinocytes (Lefort et al., 2007). According
to this paradigm, Notch1 functions downstream of p53 to suppress tumorigenesis. Studies
on human papillomavirus (HPV) in cervical keratinocytes have shown that viral E6mediated degradation of p53 results in strong reduction in Notch1 expression in HPVpositive cervical carcinomas, therefore, loss of p53 could have a dominant tumorigenic
phenotype masking the effects of Notch1 loss in keratinocytes (Dotto, 2008). To directly
test this hypothesis, we generated animals that lacked Notch1 and expressed HPV E6/E7
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oncogenes in epidermal keratinocytes

(Msx2-Cre; Notch1flox/flox; K14-HPV16tg/+ or

Msx2-N1CKO;K14-HPV). Importantly, Msx2-N1CKO;K14-HPV mice developed
multiple spontaneous SCCs and BCCs at the age when no tumor was found in their K14HPV16tg/+ (K14-HPV) or Msx2-N1CKO littermates, demonstrating that Nocth1 and p53
do not function in a linear pathway (Figure 4.7). Instead, the oncogenic consequence of
Notch1 deletion synergized with that of HPV oncogenes (e.g. p53 degradation) to cause
an early-onset severe skin carcinogenesis.

Notch1-deficient epidermis creates a microenvironment promoting carcinogenesis
The tumor-promoting effect of Notch1 deletion can be mediated either by cell
autonomous changes in the initiated cells (the cells that acquired H-ras mutations), by
non-cell autonomous signals emanating from the surrounding environment that is
responding to transforming growth factor beta (TGF-#) and other signals produced by
Notch1-deficient keratinocytes (Lee et al., 2007), or a combination of both. To determine
which of these possibilities best describes the contribution of Notch1 loss to
carcinogenesis, we re-analyzed Msx2-N1CKO mice in which wild-type skin territories
were also exposed to DMBA/TPA (Figure 4.2). In this analysis, we focused on
intracomparison of adjacent territories of wild-type and Notch1-deficient skin within
individual Msx2-N1CKO animals (Figure 4.8A). If Notch1 acted as a tumor suppressor,
Notch1-expressing initiated cells would not be able to form tumors. The Rosa26R
reporter transgene present in some DMBA/TPA-treated Msx2-N1CKO mice allowed us
to document that in contrast to this prediction, a substantial number of white, Crenegative papillomas formed adjacent to the blue, Cre-positive territory, consistent with
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development of Notch1-expressing tumors in Msx2-N1CKO; Rosa26R animals (Figure
4.8B). To confirm that tumors can arise from initiated cells that did not experience
Notch1 deletion, we performed direct amplification of the Notch1 locus in tumor DNA
randomly collected from DMBA/TPA-treated Msx2-N1CKO animals to estimate how
many cells underwent Notch1 deletion. This analysis confirmed that a significant subset
of papillomas contained more than 99% genome equivalents contributed by wild-type
cells (Figure 4.8C and Figure 4.9) and thus arose from tumor initiating cells that did not
experience deletion of Notch1. 33 out of 91 tumors analyzed (36%) in DMBA/TPAtreated Msx2-N1CKO mice contained >99% wild-type cells (i.e. Notch1 deletion was
undetectable by PCR with conditions sufficient to detect deletion only in 1% of genome
equivalents). All the tumors examined were benign exophytic papillomas. Because none
of the wild-type littermates used in this study (n=10) developed any tumors, this finding
demonstrates that loss of Notch1 provides a promoting, non-cell autonomous signal that
can support tumor formation from nearby initiated cells independent of their Notch1
status. Given the global nature of Cre activation in K14ERT-N1CKO mice (Vasioukhin
et al., 1999), we could not examine if progression to SCC was a strict cell autonomous
consequence of Notch1 loss.

Epidermal differentiation/barrier formation defects can explain tumor promotion
upon Notch1 loss
Previous studies have shown that loss of Notch signaling in the skin causes
impaired epidermal differentiation, which in turn results in defective skin-barrier
formation (Figure 4.10) (Blanpain et al., 2006; Demehri et al., 2008). After birth, the
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reactive epidermal hyperplasia masks the physical consequences of skin-barrier
impairments (i.e. dye penetration or transepidermal water loss) to ensure survival in
terrestrial life (Kuramoto et al., 2002). Nonetheless, thymic stromal lymphopoietin
(TSLP) overexpression, a general biomarker for skin-barrier defects, can serve as a
reliable indicator for postnatal barrier impairments (Demehri et al., 2008). Based on this
criteria, a mild barrier defect is also detectable in Msx2-N1CKO skin after birth (Demehri
et al., 2008). The persistence of this barrier defect in adult Msx2-N1CKO skin was
confirmed by documenting that TSLP levels remained elevated in the serum of 6- to 8month-old Msx2-N1CKO mice (Figure 4.11 (Demehri et al., 2008)). Severe barrier
defects in Notch pathway-deficient skin present initially as an epidermal hypoplasia that
resembles a chronic wound, thus recruiting an array of cellular responders to repair the
site of the breach and resulting in the development of a reactive epidermal hyperplasia
overtime (Blanpain et al., 2006; Segre, 2006). Accordingly, Msx2-N1CKO epidermis
was mildly hypoplastic at birth, but exhibited a significant stromal hyperplasia as early as
postnatal day 9 (P9; Figure 4.12A; black and green bars mark average epidermal and
stromal thickness, respectively). Following the proliferative changes in the dermis,
significant epidermal hyperplasia developed in adult mutants (Figure 4.12A and 4.13;
(Lee et al., 2007)). Importantly, epidermal hyperplasia extended beyond Notch1-deleted
territories and into adjacent, Notch1-expressing epidermal regions (Figure 4.12B),
indicative of a non-cell autonomous proliferative mechanism.
The major stromal responses to a breach in the skin barrier include infiltration of
immune cells, activation of fibroblasts and angiogenesis, all of which provide
proliferative signals to keratinocytes as part of an integrated wound healing/barrier repair
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response (Segre, 2006; Werner et al., 2007). To determine the contribution of immune
cells to reactive epidermal hyperplasia and tumor promotion in Msx2-N1CKO skin
(Proweller et al., 2006), we examined the number and composition of dermal leukocytes
in Msx2-N1CKO skin. An increase in CD45+ leukocytes was evident in Msx2-N1CKO
skin as early as P9 (Figure 4.12C), which was due predominantly to accumulation of
CD4+ T cells in the dermis of Msx2-N1CKO mice (Figure 4.12D and Figure 4.14).
Prominent increase in number of CD4+ T cells in dermis and peripheral blood of adult
Msx2-N1CKO mice together with serum IgE elevation (Figure 4.15) is reminiscent of a
mild atopic dermatitis (AD)-like allergic inflammation, which represents a typical
immune response to skin-barrier defects (Segre, 2006). In addition, dermal mast cells,
another component of AD-like inflammation (Navi et al., 2007), were significantly
increased in Msx2-N1CKO skin (Figure 4.16). Mast cell activation has been shown to
enhance skin carcinogenesis (de Visser et al., 2005). Therefore, to examine if mast cell
activity was critical for tumor promotion, we impaired mast cells and neutrophils
function by generating Msx2-N1CKO mice deficient for cathepsin C (dipeptidyl
peptidase I; DPPI (Pham, 2006)). DMBA/TPA treatment of Msx2-Cre; Notch1flox/flox;
DPPI-/- (Msx2-N1CKO;DPPI-/-), Msx2-N1CKO, DPPI+/- and wild-type littermates
demonstrated that mast cells did not play a dominant role in tumor promotion since the
inhibition of mast cell/neutrophil function did not completely ameliorate the tumor
promoting effect of the stroma in Notch1-deficient background (Figure 4.12E and F).
When nested ANOVA was applied to account for the contribution of gender-based
differences, a trend toward delayed tumor onset, and a significant reduction in tumor
counts at 20 weeks after DMBA treatment, were detected in Msx2-N1CKO;DPPI-/-
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relative to Msx2-N1CKO mice (Table 4.3D). Thus, mast cells contribute to tumor
promotion, but loss of this contribution can be largely overcome by other tumorpromoting factors.
Msx2-N1CKO epidermis overproduces TGF-#1 and TGF- #2 (Lee et al., 2007),
the major diffusible keratinocytes factors that recruit Gr-1+CD11b+ myeloid suppressor
cells (Yang et al., 2008) and activate dermal fibroblasts (Werner et al., 2007). Gr1+CD11b+ myeloid suppressor cells, which promote carcinogenesis by suppressing
immunosurveillance apparatus including cytotoxic CD8+ T cells (Bronte et al., 2000),
were increased in spleen of adult Msx2-N1CKO (Figure 4.17). Activated fibroblasts are
also known to play an important role in tumor promotion (Orimo and Weinberg, 2006);
therefore, stromal hyperplasia in Msx2-N1CKO skin could reflect, in part, the presence
of activated fibroblasts. These cells would in turn secrete matrix-modifying proteins and
mitogens leading to epidermal hyperproliferation, establishing a “vicious cycle” (Lee et
al., 2007). In agreement with a vicious cycle involving TGF-# signaling (Werner et al.,
2007), Msx2-N1CKO dermal fibroblasts were increased relative to wild type at P9 and 1
year of age, acquiring a myofibroblast phenotype as indicated by the expression of "smooth muscle actin ("-SMA) in dermis of adult Notch1-deficient mice (Figure 4.12G,
H, and 4.18). To determine if activated dermal fibroblasts contributed to epidermal
proliferation in Msx2-N1CKO skin, we examined the expression levels of two fibroblastderived epidermal mitogens: keratinocyte growth factor (KGF or FGF-7) and stromal
cell-derived factor 1 (SDF-1 or CXCL-12) (Szabowski et al., 2000; Werner et al., 2007).
These factors were modestly but significantly up-regulated in Notch1-deficient skin as
early as P9 (1.6 fold, p <0.001; Figure 4.12I). SDF-1 mRNA remained elevated in 6- to
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8-month-old Msx2-N1CKO skin relative to wild-type littermates, confirming the
persistent overexpression of this factor overtime (Figure 4.19). Of note, the dermal
vasculature also showed increased branching and dilation in P9 and adult Msx2-N1CKO
skin, underscoring the gestalt of non-cell autonomous events contributing to the tumor
phenotype (Figure 4.12G and J). Taken together, the consequences of persistent skinbarrier

defects

in

Msx2-N1CKO

mice

create

a

wound-like,

proliferative

microenvironment capable of driving epidermal hyperplasia and carcinogenesis overtime
(Alberts et al., 2002; Eming et al., 2007; Parkinson, 1985).

All Notch paralogs involved in barrier formation also participate in suppressing
skin carcinogenesis
Loss of either Notch2 (Msx2-Cre; Notch2flox/flox or Msx2-N2CKO) or Notch3
(Notch3-/- or N3KO) in the skin had no phenotypic consequences, and accordingly, no
spontaneous epidermal tumors appeared over the entire life span of these animals (n>10
for each genotype; Figure 4.20A). Furthermore, the response of Notch2- or Notch3deficient mice to DMBA/TPA carcinogens was indistinguishable from the wild-type
littermates, reflecting their respective strain’s baseline susceptibility (Figure 4.20B and
C). This result could reflect a unique contribution of Notch1 to tumor suppression,
perhaps by maintaining p21WAF1/Cip1 expression (Devgan et al., 2005; Nguyen et al., 2006;
Nicolas et al., 2003; Okuyama et al., 2004). Alternatively, if tumor promotion is mainly a
consequence of an impaired epidermal differentiation/barrier formation (the “defective
barrier” hypothesis), the lack of tumor susceptibility upon the deletion of Notch2 or
Notch3 could be because their loss did not compromise the skin barrier.
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To differentiate between these possibilities, we first accessed the contribution of
Notch2 and Notch3 to the Notch1 “tumor suppressor” function by analyzing an allelic
series in which Notch2 and Notch3 alleles were progressively removed on the Msx2N1CKO background. Removal of Notch2 and Notch3 in Notch1-deficient skin
exacerbates the barrier defects (Demehri et al., 2008). In agreement with the defective
barrier hypothesis, this stepwise removal of Notch2 and Notch3 alleles in Msx2-N1CKO
animals resulted in progressive enhancement of epidermal hyperplasia at P9 (Figure
4.21A and B). We also noticed a tight correlation between time to spontaneous tumor
onset and global Notch dose in keratinocytes (Figure 4.21C). This demonstrates the
existence of an additive function for Notch paralogs in suppressing skin tumors as long as
the overall Notch dosage is reduced below a threshold; however, it does not determine
whether or not Notch1 makes a unique contribution to tumor suppression in addition to
its shared effect on proper skin-barrier formation.
To examine if Notch1 has any unique tumor suppressing activity, which should be
sufficient to prevent tumor formation in barrier-impaired skin, we generated animals
lacking Notch2 and Notch3 while expressing Notch1 (Msx2-Cre; Notch2flox/flox; Notch3-/or

Msx2-N2N3CKO).

P9

Msx2-N2N3CKO

epidermis

overexpressed

TSLP,

demonstrating that keratinocytes lacking Notch2 and Notch3 formed a defective skinbarrier (Figure 4.22A). TSLP overexpression persisted in adult Msx2-N2N3CKO mice
and was accompanied by serum IgE elevation that signified the development of a
subacute AD-like inflammation in response to persistent barrier defects in these animals,
similar to what was found in Msx2-N1CKO mice (Figure 4.22B, C, 4.11 and 4.15).
Importantly, Msx2-N2N3CKO epidermis retained normal expression of p21wAF1/Cip1,
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confirming the unique role of Notch1 in maintaining its expression (Figure 4.22A;
(Nicolas et al., 2003)). Nonetheless, deletion of Notch2 in the skin of Notch3 null animals
resulted in skin hyperplasia (Figure 4.22D), and development of spontaneous Notch1expressing skin tumors in adult life (Figure 4.22E and F). As predicted from the defective
barrier hypothesis, exposure of Msx2-N2N3CKO mice to DMBA/TPA resulted in a
significantly higher tumor burden than that seen in control littermates (Figure 4.22G and
H). In addition, Msx2-N2N3CKO tumors progressed to SCC (Figure 4.22I), arguing that
blocking tumor progression is also a shared function of the Notch pathway. Taken
together, these findings indicate that the presence Notch1 or p21wAF1/Cip1 is not sufficient
to protect barrier-defective skin from chemical carcinogens and instead demonstrates that
the tumor phenotype mirrors the progressive defects in barrier formation and keratinocyte
differentiation.
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DISCUSSION
The fundamental observation that Notch1 deletion in epidermal keratinocytes
causes skin carcinogenesis is a clear deviation from Notch1’s role as a proto-oncogene in
several other organs (Koch and Radtke, 2007). The limitations of in vitro studies led us to
examine the mechanism underlying Notch1 tumor suppressing activity in mice that
lacked Notch1 in a global or chimeric pattern in their epidermis. Using a novel approach
to test the effect of Nocth1 deletion on DMBA-driven initiation by deleting Notch1 either
before or after DMBA treatment in the K14CreERT system, we established that Notch1
resembled most tumor suppressors in that its loss was not involved in the initiating event
of multistage skin carcinogenesis (Zoumpourlis et al., 2003). However, Notch1 loss could
effectively substitute for TPA in the chemical carcinogenesis paradigm, establishing
unequivocally that its loss acts as a tumor-promoting event. Delaying Notch1 deletion in
K14CreERT mice until after the tumor-promotion stage of carcinogenesis demonstrated
that late deletion of Notch1 contributed to malignant progression of benign papillomas, a
phenotype that is observed upon loss of p53 but not loss of p21WAF1/Cip1 (Weinberg et al.,
1999), a specific Notch1 target in the skin (Rangarajan et al., 2001). Taken together, we
have conclusively determined that the main effect of Notch1 loss is to provide the
initiated cells with a proliferative signal to form tumor and proceed to invasive
carcinoma.
The proliferative signal that lies downstream of Notch1 loss could be originated
from within the initiated cells, substantiating Notch1 role as a classical tumor suppressor
in skin keratinocytes (Nicolas et al., 2003). Alternatively, this signal could be delivered
by the skin microenvironment reacting to Notch1 loss in the epidermis (Lee et al., 2007;
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Orimo and Weinberg, 2006; Vauclair et al., 2007; Watt et al., 2008). The system we
studied allowed us to distinguish between these two possibilities; the chimeric pattern of
Notch1 deletion by Msx2-Cre created neighboring territories of Notch1-expressing and
Notch1-deficient keratinocytes coexisting in the same microenvironment. Examining a
large number of tumors isolated from DMBA/TPA-treated Msx2-N1CKO mice clearly
demonstrated that tumors comprised mostly of Notch1-expressing cells were as likely to
form as tumors comprised predominantly of Notch1-deleted cells in the same
environment. Thus, Notch1 loss in the epidermis generates a non-cell autonomous signal,
promoting carcinogenesis from any initiated cell exposed to the microenvironment
conditioned by Notch1-deficient keratinocytes. This finding emphasizes the importance
of the environment as an active contributor to tumor development (Bissell and Radisky,
2001) by showing that it can be the primary source of proliferative signals to initiated
cells.
To determine the identity of the tumor-promoting microenvironment formed as a
consequence of Notch1 deletion in keratinocytes, we reexamined the earliest effects of
Notch1 loss on the skin. As previously shown, loss of Notch signaling leads to impaired
keratinocytes proliferation/differentiation culminating in epidermal cell loss and defective
skin-barrier function at birth (Blanpain et al., 2006; Demehri et al., 2008; Rangarajan et
al., 2001). Therefore, we examined the hypothesis that Notch1-deficient skin
encompassed a chronic wound-like microenvironment developing in response to barrier
defects, which were the direct consequence of Notch1 deletion in the epidermis (Blanpain
et al., 2006; Demehri et al., 2008). Indeed, the dermis of Notch1-deficient skin contained
the critical components of an activated stroma responding to the breach in the skin barrier
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including inflammatory cell infiltrate, activated fibroblasts and expanded vasculature
(Mueller and Fusenig, 2004). To further demonstrate that the tumor promoting effect of
Notch1 loss was the consequence of an activated stroma responding to a general breach in
the skin barrier, we showed that mice lacking Notch2 and Notch3 in their epidermis also
developed skin tumors. This Notch1-independent tumor phenotype confirms that Notch1
has a tumor suppressing function distinct from classical tumor suppressors in the skin,
revising the mechanistic model based on the assumption that oncogenic changes, specific
to Notch1 loss (Rangarajan et al., 2001), are the initial events required to cause skin
carcinogenesis. Thus, the tumors in Notch1-deficient skin are the end product of a
complex interaction between a barrier-defective epidermis and its underlying stroma,
which creates a tumor-promoting feed-forward loop (Figure 4.23). Accordingly, we
predict that any mouse model with chronic skin-barrier defects will also be prone to skin
carcinogenesis.
Fibroplasia, angiogenesis and inflammation are stromal elements intimately
linked to wound repair (Martin, 1997). These cellular changes are also closely associated
with neoplastic transformation (Bissell and Radisky, 2001; Mueller and Fusenig, 2004). It
is proposed that the microenvironment of the non-healing wound/defective skin barrier
could be a risk factor for carcinogenesis (Eming et al., 2007). This association is
supported by chemical carcinogenesis studies showing that tumors grow at the edges of
skin wounds (Parkinson, 1985). In addition, it is suggested that chronic injury can
predispose various organs to cancer (Bissell and Radisky, 2001), and there are clinical
evidence linking chronic skin wounds to BCC and SCC (Nguyen and Ho, 2002). For
instance, leg ulcers significantly increase the risk of SCC in patients (Baldursson et al.,
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1995). Nonetheless, experimental evidence establishing that stromal changes in chronic
wound microenvironment can drive skin carcinogenesis is lacking (Eming et al., 2007).
Therefore, Msx2-N1CKO and Msx2-N2N3CKO skin present a novel model
demonstrating that a lengthened stromal attempt to repair a non-healing wound or a
persistent skin-barrier defect predisposes the skin to carcinogenesis. We speculate that the
plurality of the cellular effectors (i.e. Fibroplasia, angiogenesis and inflammation)
responding to breach in skin-barrier collectively contribute to tumor promotion in this
model.
We have previously identified several of these factors. Matrix metallopeptidases
(MMP8 and MMP9) are elevated in Notch1-deficient skin at P9 as is osteopontin (OPN
(Demehri et al., 2008)). All these stromal-derived factors are potential tumor promoters
(Pazolli et al., 2008; van Deventer et al., 2008). In addition, dermal fibroblasts in Notch1deficient skin are overproducing SDF-1 and KGF that directly stimulate keratinocytes
proliferation; this is reminiscent of carcinoma-associated fibroblasts known to promote
tumor development from a non-tumorigenic cell population (Bhowmick et al., 2004;
Orimo and Weinberg, 2006). Furthermore, accumulation of immune cells and
development of AD-like inflammation in Notch-deficient skin, triggered by
cytokines/chemokines released from barrier-defective epidermis (Demehri et al., 2008;
Segre, 2006; Yoo et al., 2005), have been shown to promote skin carcinogenesis
(Johansson et al., 2008). From this large pool of tumor-promoting stromal cells/factors
present in Notch1-deficient skin, we examined the contribution of a single component
(Mast cells), which has been previously deemed critical in skin carcinogenesis (Coussens
et al., 1999; de Visser et al., 2005; Tlsty and Coussens, 2006), and asked if the
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components listed above act redundantly or are all required individually. Our results are
consistent with the possibility that removal of any single stromal component would not
significantly alter the tumor-promoting effect of the wound microenvironment.
Therefore, we propose that the tumor promotion in Notch1-deficient skin results from the
additive contributions of fibroplasia, angiogenesis and inflammation. Taken together,
Notch1 and Notch2/3-deficient mice demonstrate that stroma of a chronic skin wound is
analogous to tumor stroma, and can be used to determine the specific contribution of each
stromal component to tumor development, a worthy question that falls outside the scope
of the current study.
In conclusion, the persistent barrier defects in Notch-deficient skin, which
resembles chronic wounds, recruit several mesenchymal components necessary to repair
the barrier. In turn, the vascularized and growth-factor-rich stroma provides initiated cells
with nutrients and proliferative signals that can directly promote tumor formation. Thus,
Notch1 is not a classical tumor suppressor that solely exerts its effects cell autonomously
(e.g. promotes cell death or cell cycle arrest). Notch-deficient mice provide instead a
suitable system in which to dissect out the molecular mediators and the cellular
interactions that are responsible for oncogenic effect of chronic wound/tumor stroma.
Based on such an analysis, novel therapeutic targets can be identified in the tumor
microenvironment that will be useful in developing molecular therapies for cancers of
skin and perhaps other organs (Albini and Sporn, 2007).

150

EXPERIMENTAL PROCEDURES
Generation of mutant mice
The following mutant strains of mice were generated following the protocol described
previously (Pan et al., 2004).
Msx2-Cre/+; Notch1flox/flox (Msx2-N1CKO)
Msx2-Cre; Notch1flox/flox; K14-HPV16tg/+
Msx2-Cre; Notch1flox/flox; DPPI-/K14CreERT; Notch1flox/flox (K14ERT-N1CKO)
Msx2-Cre/+; Notch2flox/flox (Msx2-N2CKO)
Notch3-/- (N3KO)
Msx2-Cre/+; Notch2flox/flox; Notch3-/- (Msx2-N2N3CKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/+ (Msx2-N1N2hCKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3+/- (Msx2-N1N2hN3hCKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3-/- (Msx2-N1N2hN3CKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox (Msx2-N1N2CKO)
Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox; Notch3-/- (Msx2-N1N2N3CKO)
Msx2-Cre/+; RBP-jflox/flox (Msx2-RBP-jCKO)
Msx2-Cre/+; PS1flox/flox; PS2-/- (Msx2-PSDCKO)
All our animals are maintained in mixed C57BL/6 and CD1 genetic backgrounds, which
are overall resistant to DMBA/TPA skin carcinogenesis. In some experiments, remnant
contribution from 129sv and FVB strains may also be present. In all cancer experiments,
age-matched littermates were compared, and nested ANOVA used to confirm that strainbased differences did not confound our analysis.
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All the mice were maintained in Washington University animal facility according to
animal care regulations. In studies related to spontaneous carcinogenesis and longevity,
mice were monitored regularly for onset, number and size of tumors and any sign of
failure to thrive. Moribund mice are euthanized and skin, tumors, and lymph nodes are
harvested.

Chemical Skin Carcinogenesis Studies
For DMBA/TPA experiments in Msx2-Cre background, mutant mice and their agematched littermate controls were treated with standard protocols for skin chemical
carcinogenesis models as previously described (Nicolas et al., 2003). We included similar
number of males and females in each genotype/treatment cohort and used nested
ANOVA to confirm that gender-based differences did not confound our analysis. Mice
were shaved under anesthesia 2 days prior to treatment with DMBA to ensure the hair
follicles are in telogen, and on day 0, each mouse received 25µg of DMBA (Sigma, St.
Louis, MO) topically, followed by topical treatment with TPA (4µg per mouse; Sigma)
twice weekly starting on day 7. Animals were treated with TPA for 14 weeks, closely
monitored for another 10 weeks and tumor indices were recorded over the whole
experimental/follow-up period (Figure 4.2C). As many of these experiments were
conducted on Msx2-Cre-expressing mice and Msx2-Cre-negative littermates served as
controls, we performed a separate DMBA/TPA experiment comparing Msx2-Cre/+;
Notch1flox/+ and Notch1flox/+, and confirmed that Msx2-Cre expression itself had no impact
on skin carcinogenesis (data not shown). In DMBA-only experiment, Msx2-N1CKO and
wild-type littermates received a single dose of DMBA (150µg) each. In TPA-only
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experiment, each Msx2-N1CKO or wild-type mouse received 18µg of TPA twice weekly
for 25 weeks.
DMBA/TPA experiments in K14CreERT background were more complex and the
methods used are outlined in Figure 4.3B and 4.6B. Briefly, five consecutive days of
intraperitoneal 4-hydroxytamoxifen (4-OHT; Sigma) injections (0.5mg per 10gram body
weight (Nicolas et al., 2003)) at specific points before DMBA (ODT), after DMBA
(DOT) or after TPA (DTO) treatment were used to delete Notch1. These experiments
contained proper controls that included K14CreERT; Notch1flox/+ mice treated with 4OHT to induce the nuclear translocation of Cre and K14CreERT; Notch1flox/flox mice
treated with carrier alone (90% sunflower oil + 10% ethanol).

Histology and Imunohistochemistry
For Hematoxylin and eosin (H&E), toluidine blue and immunostaining using paraffinembedded tissue sections, skin, tumor and lymph node samples from various mutant and
wild-type animals where fixed in 4% paraformaldehyde in PBS, dehydrated with ethanol
and embedded in paraffin, which were then sectioned at 5µm. X-gal staining was done on
the skin prior to fixation with 4% paraformaldehyde as previously described (Pan et al.,
2004). The diagnosis of tumor types (papilloma, BCC or SCC) is performed by a
Dermatopathologist on H&E-stained tumor sections. Immunohistochemical analysis was
performed on paraffin-embedded tissue samples using anti-epidermal keratin (AE1; a
kind gift from Dr. Henry Sun, NYU), anti-panleukocytic marker (CD45; BD
PharMingen, San Diego, CA) or anti-cleaved-Notch1 (V1744, Cell Signaling, Danvers,
MA) antibody. Following treatment with biotinylated secondary antibody, HRP-
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conjugated streptavidin (Vectastain ABC kit, Vector Laboratories, Burlingame, CA) and
DAB substrate kit (Pierce, Rockford, IL) were used to visualize the signal. In case of
AE1

and

CD45

staining,

sections

were

counterstained

with

Hematoxylin.

Immunofluorescence staining was performed on paraffin-embedded skin samples using
the combination of anti-Keratin 6 (K6; Abcam, Cambridge, MA) and anti-Keratin 14
(K14; Covance Research Products, Princeton, NJ) antibodies or anti-"-smooth muscle
actin ("-SMA; Sigma) and anti-murine panendothelial cell antigen (MECA-32; BD
PharMingen) antibodies. For #-catenin immunofluorescence staining, the pan #-catenin
antibody (BD PharMingen) detecting total #-catenin levels was used. Secondary
antibodies were labeled with Alexa Fluor 488 (Invitrogen, Carlsbad, CA) or Cy3
(Jackson ImmunoResearch Laboratories, West Grove, PA). Sections were counterstained
using DAPI nuclear stain, which was in the mounting media (Vector Laboratories).

Flow cytometry (FC)
Single cell suspensions from dermis, peripheral blood and spleen were prepared for FC
analysis as described (Demehri et al., 2008). For dermal cell preparation, skin of adult
Msx2-N1CKO and wild-type controls were chopped with Brinkmann Tissue Chopper
(ON, Canada). The tissues were then treated with crude collagenase (Sigma) for 90min at
37°c and filtered to obtain signal cell suspensions. The following antibodies were used
for FC analysis: anti-CD45 conjugated to peridinin chlorophyll-a protein-cyanin 5.5
(PerCP-Cy5.5), anti-CD4, anti-CD8, anti-B220, anti-Ly-6G, anti-Gr-1 conjugated to
phycoerythrin (PE) and anti-CD11b conjugated to fluorescein (FITC; all from BD
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PharMingen). Stained cells were studied using BD FACScan Flowcytometer (Cytek
Development), and the data were analyzed using FlowJo software (Ashland, OR).

ELISA
Serum TSLP concentrations were measured using Quantikine mouse TSLP kit (R&D
Systems, Minneapolis, MN). Serum IgE was measured using Mouse IgE ELISA kit
(Immunology Consultants Laboratory Inc., Newberg, OR).

Immunoblotting
Epidermal samples were collected in NP40 lysis buffer as previously shown (Lee et al.,
2007; Nicolas et al., 2003) Protein lysates were run on SDS-PAGE after adjusting for
protein concentration and analyzed using anti-active #-catenin antibody (ABC, Upstate
Biotechnology, Lake Placid, NY) and total #-catenin (BD PharMingen).

Dye penetration assay
To detect defect in skin-barrier function (Hardman et al., 1998), intact E18.5 embryos
were stained in X-gal (pH 4.5) for 12hr at 37°C. After X-gal staining, the embryos were
washed in PBS three times and photographed with a digital camera.

PCR
Conventional PCR for Notch1 allele was performed on genomic DNA isolated from skin
tumors of DMBA/TPA-treated Msx2-N1CKO mice using KlenTaq10 (DNA Polymerase
Technology, St. Louis, MO) supplemented with 1.3M final concentration of betaine
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(amplification cycles=32). Primers used to amplify the wild-type (Notch1+) and floxed
Notch1 alleles (Notch1flox) were: 5’-TGGAAGCTACTGACTTAGTAGGGGGAAAAC3’ and 5’-GCAAGCATGAAGTGGTCCAGGGTGTGAGTG-3’. To detect Cre-mediated
deletion of Notch1 allele (Notch1!# the following set of primers were used: 5’TGGCCTGCCTGTCTGGAACAACAGTTCAGG-3’

and

5’-

ACCCTTGCCTCAGTTCAAACACAAGATACG-3’.

qRT-PCR
qRT-PCR was performed on mRNA isolated from skin and epidermis of Msx2-N1CKO,
Msx2-N2N3CKO and their wild-type littermates as previously described (Lee et al.,
2007). The primers used are: Notch1: 5’-GCCCTTGCTCTGCCTAAC-3’ and 5’CTGCAGACACAGGCTTCAGT-3’; Notch2: 5’-GGACTGCCAATACTCCACCT-3’
and 5’- ACAGGCATCTGTCCACTGAC-3’; stromal cell-derived factor 1 (SDF-1): 5’GAAAGGAAGGAGGGTGGCAG-3’

and

5’-TCCCCGTCTTTCTCGAGTGT-3’;

keratinocyte growth factor (KGF or FGF-7): 5’-CTGGCCTTGTCACGACCTGTTTCT3’ and 5’-CCCTTTCACTTTGCCTCGTTTGTC-3’; thymic stromal lymphopoietin
(TSLP):

5’-CCAGGCTACCCTGAAACTGA-3’

and

5’-

TCTGGAGATTGCATGAAGGA-3’; p21WAF1/Cip1: 5’-CTGGTTCCTTGCCACTTCTT3’ and 5’-GGCTGTGACTGCTTCACTGT-3’.

Statistical analysis
The cancer studies presented in this report were conducted using mice maintained in
outbred genetic backgrounds, resembling human population. Therefore, in each study
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age-matched littermates are used as controls to minimize the effect of susceptibility
differences due to genetic background on tumor phenotype observed. Prior to conducting
the experiments, we used power analysis to estimate the number of mice needed in each
group to reach statistical significance (Table 4.4). In addition, we applied basic
population genetics tools to confirm that the differential tumor parameters we measured
were conferred by status of gene (e.g. Notch1) deletion and not by heritable factors
(strain) or gender.

Specifically, gMouse (Circusoft, Hockessin, DE) maintained

information from which we generated a comprehensive pedigree for the animals
participated in each cancer study (Figure 4.24), and used nested ANOVA (SPSS,
Chicago, IL) to determine if the genetic background differences between the families
(litters) made any significant contribution to the variations in the two main tumor
parameters measured: time to tumor onset and weekly tumor counts. This analysis
allowed us to exclude any effect of between-family and between-gender differences and
make certain that the significant differences observed in tumor outcomes were solely
attributable to the gene (e.g. Notch1) removed.
“Time to tumor onset” and “survival” data were analyzed using log rank test to determine
significant differences. Tumor counts and other quantitative measurements were assessed
using Student’s t-test as the tests of significance. These quantitative data are presented as
mean + standard deviation for each measured parameter.
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FIGURES

Figure 4.1

166

Figure 4.1. Msx2-cre expression in dorsal ectoderm creates a chimeric pattern of gene
deletion. Based on the pattern of hair phenotype in Msx2-Cre/+; Notch1flox/flox (Msx2N1CKO) skin, closed circles (red) identify genetically distinct, Notch1 deleted regions,
and dashed circles (black) mark Notch containing territories, reflecting the chimeric
pattern of Cre-mediated Notch1 deletion observed in neonate (P9) and adult (P60) mice.

167

Figure 4.2
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Figure 4.2. Msx2-N1CKO mice develop skin tumors spontaneously and in response to
treatment with chemical carcinogens. (A) Lifelong monitoring of 20 Msx2-Cre/+;
Notch1flox/flox (Msx2-N1CKO) mice and their wild-type littermates (n=20) reveals the
development of spontaneous skin tumors in 90% of the mutant animals (p <0.0001, log
rank test). (B) The majority of tumors that spontaneously form in Notch1-deficient skin
are benign papillomas (left); however, a subset of these tumors progress to BCC (right).
This representative Msx2-N1CKO mouse has 2 papillomas and 1 BCC at P593 (scale
bar: 500µm). (C) Schematic diagram outlining the standard DMBA/TPA treatment
protocol used for skin carcinogenesis studies. Note that two days prior to treatment with
carcinogen (DMBA; black arrowhead) the back skin of the animals are shaved to ensure
the hair follicles are in telogen phase hair cycle. (D) Treating 6- to 10-week-old Msx2N1CKO and their wild-type littermates with DMBA/TPA chemical skin carcinogenesis
model (described in ”C”) results in papilloma formation in all Notch1-deficient mice. In
contrast, no papilloma is formed in the wild-type littermates in this resistant background.
Papillomas appear starting 6 weeks post initiation in Msx2-N1CKO animals (n=10 for
each group; p <0.0001, log-rank test). (E) Upon DMBA/TPA treatment, the average
number of papillomas per each tumor-bearing mutant mouse increases progressively over
the 25-week follow-up period. Beginning at 20 weeks post initiation, >50% of Msx2N1CKO mice have more than 20 papillomas (*: p <0.05, student’s t-test). These findings
are confirmed in additional independent experiments.
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Figure 4.3
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Figure 4.3. Epidermal deletion of Notch1 leads primarily to skin tumor promotion. (A)
Treating Msx2-N1CKO and wild-type skins with high dose of TPA (18µg per mouse)
twice weekly for 25 weeks (arrow) does not result in tumor growth in the mutant mice,
excluding the possibility that Notch1 loss functions as a tumor initiator. Note the similar
response of Msx2-N1CKO and wild-type controls to the tumor-promoting agent: tumorfree yet hyperplastic epidermis is present in both Msx2-N1CKO and wild-type controls
after 25 weeks of TPA treatment (scale bar: 100µm). (B) Schematic diagram detailing the
treatment paradigm used to study the contribution of Notch1 loss to tumor initiation by
DMBA. Note that in this study 6- to 10-week-old K14CreERT; Notch1flox/flox (K14ERTN1CKO) mice are treated with 4-OHT for five days at the indicated points (red
arrowheads) to induce Notch1 deletion. (C, D) Notch1 deletion after DMBA-mediated
tumor initiation (DOT) induces skin carcinogenesis to a similar level as does Notch1
deletion prior to DMBA treatment (ODT). Both Notch1-deficient cohorts (C) develop
skin tumors earlier and (D) in significantly higher numbers than controls (p <0.05 for all
tumor counts after week 9, student’s t-test). The ODT group has a significantly more
tumors than the DOT group at the last two time points (*: p =0.017, **: p =0.014,
student’s t-test). This points to a potent tumor promoter effect of Notch1 deletion in the
skin. (E, F) Msx2-N1CKO mice treated topically with one dose of DMBA (150µg per
mouse) develop skin tumors in the absence of TPA (E) starting at 10 weeks after DMBA
treatment, and (F) gain a few tumors (all are papillomas) on average per each tumorbearing mouse over time. No skin tumor is formed in DMBA-treated Notch1flox/flox (wild
type) littermates (n=10 for each group; p <0.0001, log-rank test). These data are
confirmed in additional independent experiments.
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Figure 4.4. Wnt and Shh signaling are not activated in direct response to Notch1 loss in
the skin keratinocytes. (A) Immunofluorescence staining of P12 skin with anti-total #catenin antibody demonstrates that #-catenin distribution is not significantly altered in
Msx2-N1CKO, Msx2-Cre/+; Notch1flox/flox; Notch2flox/+; Notch3-/- (Msx2-N1N2hN3CKO)
or Msx2-Cre/+; PS1flox/flox; PS2-/- (Msx2-PSDCKO: lacks all Notch signaling in
keratinocytes) epidermis. Note that rare nuclear #-catenin staining is detected in the
mutant skin (inset: a single positive, supra basal nucleus is shown with the DAPI and #catenin channels separated.). Wild-type hair follicle serves as a positive control showing
frequent nuclear #-catenin staining. #-catenin staining is detected in the red and nuclear
DAPI staining in green channels (scale bar: 50µm). (B) Western blot analysis of
epidermal #-catenin activity at three distinct time points in the life of Msx2-N1CKO
animals shows that #-catenin activation is secondary to epidermal hyperplasia. At P9,
mice with minimal Notch loss (Msx2-N1CKO) and more complete Notch deficiency
(Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox (Msx2-N1N2CKO) and Msx2-PSDCKO) show
no significant change in epidermal #-catenin activity over normal baseline. Note that the
total amount #-catenin is reduced in Msx2-PSDCKO epidermis. 1-year-old Msx2N1CKO mice with hyperplastic epidermis still do not show significant elevation in
epidermal free #-catenin. Tumor-bearing Msx2-N1CKO mice (>P400), however, show
significant increase in epidermal #-catenin activity, especially in tumor cells (Epi:
epidermis, T: tumor; *: p =0.01, **: p =0.008, student’s t-test). Each graph shows the
ratio of free to total #-catenin for any genotype as the percent of that ratio for wild-type
animals, derived from three independent experiments. (C) The protein levels of lymphoid
enhancer binding factor 1 (Lef1), a direct target of #-catenin signaling, is not altered in
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the hyperplastic epidermis of 1-year-old Msx2-N1CKO mice. The graph shows the
relative level of Lef1 protein in Msx2-N1CKO compared to wild-type epidermis, derived
from three independent experiments. (D) Gli2 mRNA levels in P9 Msx2-N1CKO
epidermis is reduced compared to wild-type samples (n=5 for each group, **: p =0.0004,
student’s t-test).
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Figure 4.5. In K14CreERT genetic background, a subset of papillomas (arrowheads) that
are developed in K14CreERT; Notch1flox/flox (K14ERT-N1CKO) skin following treatment
with 4-OHT and DMBA/TPA (DOT and ODT groups, Figure 4.3) progress to invasive
SCC (red circles). A representative K14ERT-N1CKO belonging to DOT group is shown
(P335). Note the hair loss phenotype that confirms Notch1 deletion in the skin of this
mouse.
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Figure 4.6
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Figure 4.6. Notch1 loss in the epidermis causes malignant progression of skin tumors.
(A) Schematic diagram outlining the method used to address the role of Notch1 loss
specifically in tumor progression by deleting Notch1 after DMBA/TPA-induced
papilloma formation in K14CreERT background. (B) Treatment of mice with 4-OHT
starting after the last TPA application (arrow) does not impact the number of tumors
formed in the Notch1-deleted (DTO) or control animals, and the two groups retain
comparable number of tumors over time (n=8 for each group). (C) A significant fraction
(~50%) of tumors in DTO cohort progress to SCC, distinguishable on the back skin of the
mutant mice and on hematoxylin and eosin (H&E)-stained histological section (scale bar:
500µm). In contrast, papillomas on Notch1-expressing control skin show no sign of
malignant progression. Note that loss of Notch1 results in global hair loss phenotype, and
that SCC cells in Notch1-deficient skin invade through the subcutaneous muscle layer
(insets). (D) Malignant skin cancer in DTO mice has metastatic features shown by the
presence of AE1+ epidermal keratinocytes in a draining lymph node of a representative
DTO animal (scale bar: 50µm). (E) Due to their severe skin cancers, DTO mice become
moribund and demise prematurely (p <0.0001, log-rank test).
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Figure 4.7. Notch1 deletion significantly aggravates the skin tumor phenotype caused by
HPV oncogenes. (A) Lifelong monitoring of Msx2-Cre; Notch1flox/flox; K14-HPV16tg/+
(Msx2-N1CKO;K14-HPV; n=12), K14-HPV16tg/+ (K14-HPV; n=10), Msx2-Cre;
Notch1flox/flox (Msx2-N1CKO; n=10) and Notch1flox/flox (wild type; n=10) littermate shows
that spontaneous skin tumors appear much earlier in the life of Msx2-N1CKO;K14-HPV
animals relative to both Msx2-N1CKO and K14-HPV cohorts (p <0.0001, log-rank test).
This heightened susceptibility to skin carcinogenesis means that HPV E6/E7 proteins and
Notch1 loss have synergistic effect on inducing tumor growth. “+” refers to the animals
that died at certain time points during the follow-up period. (B) Macroscopic picture of
the ventral aspect of a Msx2-N1CKO;K14-HPV mouse at P200 shows the presence of
multiple invasive carcinomas (arrows) on the skin of the animal. Note that at this age no
skin tumor is found on Msx2-N1CKO or K14-HPV mice.
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Figure 4.8. Notch1-deletion in epidermal keratinocytes acts as a non-cell autonomous
tumor promoter. (A) The chimeric pattern of Notch1 deletion in Msx2-N1CKO animals
enables us to determine if the tumor-promoting effect of Notch1 loss in the skin is the
consequence of cell autonomous or non-cell autonomous changes. Notch1-expressing
skin patches (white) in Msx2-N1CKO animals serve as an internal control to determine if
initiated cells that express Notch1 are capable of forming skin tumors in a Notch1deficient environment. Considering that in the genetic background we studied none of the
wild-type mice treated with chemical carcinogenesis protocol developed any tumor
(Figure 4.2), tumor growth in Notch1-expressing (white) territory of Msx2-N1CKO skin
would point to a non-cell autonomous tumor-promoting signal from the neighboring
Notch1-deleted territory (blue). (B) X-gal staining of the tumor-bearing skin of a
representative Msx2-N1CKO;Rosa26R mouse treated with DMBA/TPA (Figure 4.2)
shows the presence of significant number of completely white (Cre-negative; arrows)
tumors adjacent to the Notch1-deleted (blue) skin territory. Note the comparable size and
number of white and blue tumors, consistent with a dominant non-cell autonomous effect
downstream of Notch1 loss that results in tumor promotion in wild-type cells. (C) PCR
analysis of DNA isolated from 8 randomly selected Msx2-N1CKO tumors from one
individual confirms that Notch1 locus is intact (i.e. Notch1 is not deleted) in >99% of
tumor-forming cells in a substantial number of tumors (%: deleted allele; M: molecular
marker), demonstrating that these tumors are arisen from Notch1-expressing initiated
cells (see Figure 4.9 for the sensitivity of the method). If Notch1 was a classical tumor
suppressor, such initiated cells should have been suppressed.
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Figure 4.9
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Figure 4.9. PCR protocol used for genotyping tumor DNA is sensitive enough to pick out
a single Notch1-deleted cell out of a hundred wild-type cells. (A) Notch1flox/flox
keratinocytes are used for PCR sensitivity test. A subgroup of these cells is infected with
adenovirus expressing Cre recombines to achieve high degree of Notch1 deletion (i.e.
Notch1!). As ~105 genome equivalents have been used for tumor genotyping in “B”
(Figure 4C), 104 (10%), 103 (1%), 102 (0.1%), or 101(0.01%) genome equivalents of DNA
isolated from Notch1-deleted keratinocytes are mixed with wild-type (untreated
Notch1flox/flox) keratinocytes to reach 105 total genome equivalents in each PCR reaction
of this test. The detection limit of our PCR is lower than 1% (i.e. 103 genome equivalents
of Notch1-deleted DNA is sufficient to be detected within a pool of 105 total genome
equivalents). (B) Given the sensitivity of our PCR method, the absence of Notch1-deleted
(Notch1!) band in several of the tumors (#1, 3, 5, 6 and 8) indicates that more than 99%
of cells that have formed these tumors are wild-type cells. If any cells in the tumors were
Notch1-deficient, they had to constitute less than 1% of tumor cells (i.e. below the
detection limit of in our PCR (A)). Considering that the majority of tumor cells are from
the progeny of a single initiated cell, these results clearly show that a substantial number
of tumors have arisen from Notch1-expressing wild-type cells (adopted from Figure
4.8C).
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Figure 4.10. Impaired epidermal differentiation/barrier formation in Notch pathwaydeficient animals. (A) H&E staining of P0 Msx2-Cre/+; PS1flox/flox; PS2-/- (Msx2PSDCKO) skin shows a severe epidermal differentiation defect and hypoplasia compared
to the wild-type skin (bars). (B) X-gal dye penetration assay on E18.5 embryos confirms
the existence of skin-barrier defect in the areas of Msx2-Cre activity (arrowheads) in
Msx2-PSDCKO animals.
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Figure 4.11. Persistent skin-barrier defects in Notch1-deficient animals leads to their
elevated Serum TSLP levels in adulthood. Serum TSLP levels in adult (6 to 8 months
old) Msx2-N1CKO animals are compared to wild type controls (n=4 for each group; *: p
<0.05, student’s t-test).
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Figure 4.12
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Figure 4.12. Notch1-deficient epidermis creates a wound-like microenvironment in the
skin. (A) H&E staining of Msx2-N1CKO and wild-type (Wt) skin at birth (P0), P9 and 1
year of age demonstrates the progression from relatively hypoplastic epidermis in
newborn Msx2-N1CKO animals to distinct epidermal hyperplasia at 1 year. The dermal
hyperplasia, however, is evident as early as P9. The bars on the left side of each picture
show the average thickness of epidermis (black) and dermis (green) across three 100X
microscope fields (scale bar: 50µm). (B) X-gal staining of 1-year-old Msx2-N1CKO skin
shows similar degree of hyperplasia (brackets) in Notch1-expressing epidermis (red) and
in the Notch1-deleted territory (blue), consistent with the presence of a dominant
proliferative microenvironment in Msx2-N1CKO skin. Immunohistochemical staining
with V1744 (detecting activated Notch1) confirms the presence of elevated Notch1
activity in hyperplastic epidermis adjacent to the Notch1-deficient epidermis of Msx2N1CKO animals (scale bar: 50µm). (C) Leukocyte infiltration into the dermis of Msx2N1CKO is detectable as early as P9 using CD45 pan-leukocyte marker. The bar graphs
show the average number of CD45+ leukocytes in 6 randomly selected 200X microscope
fields (scale bar: 50µm). (D) Flow cytometry (FC) and cell counting methods are used
(Figure 4.14) to calculate the fold increase of each group of immune cells in dermis of 6to 8-month-old Msx2-N1CKO animals relative to their wild-type controls, which is
presented as a bar graph (*: p <0.0001, student’s t-test). (E, F) Treating Msx2N1CKO;DPPI-/- (n=13), Msx2-N1CKO (n=14), DPPI-/- (n=12) and wild-type
(Notch1flox/flox; DPPI+/-; n=12) littermates with DMBA/TPA results in papilloma
formation in both Notch1-deficient cohorts, excluding a dominant tumor-promoting role
for mast cells in Notch1-deficient skin. Although Notch1-deficient mice are significantly
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more prone to DMBA/TPA-induced tumor growth than their Notch1-expressing
counterparts (p <0.0001, log-rank test), there is no major difference between Msx2N1CKO;DPPI-/- and Msx2-N1CKO animals with regard to (E) time to tumor onset (p
=0.31, log-rank test) or (F) average number of tumors per each tumor-bearing mouse (p
=0.12 at week 25 after initiation, student’s t-test). (G) Double staining of skin with "SMA and an endothelial marker (MECA-32) demonstrates the abundance of
myofibroblasts in adult Notch1-deficient skin (asterisk). In addition, it shows the
expansion of microvasculature in Notch1-deficient skin as early as P9 (arrows). The
arrowheads point to arrector pili muscles, which also express "-SMA (scale bar: 50µm).
(H) The number of dermal fibroblasts is significantly increased in Notch1-deficient skin.
Dermal fibroblasts are counted in 6 random 200X microscope fields, and the average
ratio of Msx2-N1CKO to wild-type fibroblast counts at P9 and 1 year of age is presented
as a bar graph (*: p <0.001 compared to wild type, student’s t-test). (I) Dermal fibroblasts
in Notch1-deficient skin overexpress two major keratinocyte proliferative signals, SDF-1
and KGF, which are detected by qRT-PCR on Skin mRNA samples from P9 Msx2N1CKO and wild-type mice (*: p <0.001 compared to wild type, student’s t-test). SDF-1
and KGF transcripts were not detectable in epidermal mRNA samples from these animals
(data not shown). (J) Dermal view of dorsal skin shows expanded vascular network in 1year-old Msx2-N1CKO skin compared to a wild-type littermate (scale bar: 1cm).
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Figure 4.13. Keratin 6 (K6) and keratin 14 (K14) immunofluorescence staining
demonstrates that 1-year-old Msx2-N1CKO epidermis has hyperplasic and dysplastic
features (scale bar: 50µm).
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Figure 4.14
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Figure 4.14. A detailed characterization of immune cell infiltrates in Notch1-deficient
skin demonstrates a prominent CD4+ T cell accumulation in Msx2-N1CKO skin. (A, B)
The breakdown of CD45+ leukocytes into various hematopoietic lineages in 6- to 8month-old Notch1-deficient and wild-type skin using (A) cell count on toluidine bluestained skin sections and (B) flow cytometry (FC) on single cell preparation isolated from
skin (values in red) are shown. Note the significant increase in percentage of CD4+ T
cells (asterisk) in Notch1-deficient skin. These percentages together with absolute
number of dermal CD45+ leukocytes are used to determine the fold increase of each of
the immune cell types in adult Msx2-N1CKO skin relative to wild type (Figure 4.12D).
Representative data are presented in FC panels.
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Figure 4.15. Peripheral blood CD4+ T cell expansion and serum IgE elevation point to a
subacute atopic dermatitis-like allergic inflammation in adult Msx2-N1CKO animals. (A)
FC analysis on blood CD45+ leukocytes from 6- to 8-month-old mice shows a significant
increase in CD4+ T cells in Msx2-N1CKO blood (asterisk) relative to wild-type controls.
Representative data are presented in FC panels. (B) The presence of Th2-dominated skin
inflammation in adult Msx2-N1CKO mice is evident based on their elevated serum IgE
levels (n=4 for each group; *: p <0.05, student’s t-test).
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Figure 4.16
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Figure 4.16. Mast cells accumulate in the dermis of Msx2-N1CKO animals. (A)
Toluidine blue staining shows that dermal mast cells (dark purple) are significantly
increased in Msx2-N1CKO skin at P9 and 1 year of age compared to wild type. The bar
graphs show the average number of mast cells in 10 random 100X microscope fields. (B)
Toluidine blue staining of tumor-bearing Msx2-N1CKO skin (~P600) shows a large
number of mast cells infiltrated into the skin and tumor stroma of Msx2-N1CKO mice
(scale bar: 50µm).

199

Figure 4.17

200

Figure 4.17. The spleens of adult Msx2-N1CKO animals are larger and contain higher
number of Gr-1+CD11b+ myeloid suppressor cells compared to wild types. (A) FC
analysis shows that percentage of CD45+ leukocytes belonging to various immune cell
subtypes (values in red) is comparable in the spleen of adult Notch1-deficient and wildtype mice. Note the moderate increase in percentage of CD4+ T cells and myeloid cells in
Msx2-N1CKO spleen. (B) On average, the size of the spleen in 6- to 8-month-old Msx2N1CKO animals is twice that in wild types. This implies that the absolute number of
CD45+ leukocytes is also significantly higher in the Msx2-N1CKO spleen (*: p <0.01,
student’s t-test). (C) FC analysis on CD45+ leukocytes isolated from spleen, which are
also stained with antibodies to Gr-1 and C11b shows that the population of Gr-1+CD11b+
myeloid suppressor cells are markedly elevated in the spleen of 6- to 8-month-old
Notch1-deficent animals relative to their wild-type controls. Representative data are
presented in FC panels.
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Figure 4.18
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Figure 4.18. Tumor-bearing Msx2-N1CKO (~P600) skin shows significant stromal
changes. Immunostaining the skin with "-SMA demonstrates the abundance of
myofibroblasts and microvasculature in the skin and tumor of Msx2-N1CKO animals
(scale bar: 50µm).
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Figure 4.19
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Figure 4.19. Dermal fibroblasts in Notch1-deficient skin continue to overexpress SDF-1
in adult mice. The levels of SDF-1 transcript are measured at P9 (adopted from Figure
4.12I) and 6 months of age using qRT-PCR on Skin mRNA samples collected from
Msx2-N1CKO and wild-type (Wt) mice.
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Figure 4.20
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Figure 4.20. Loss of Notch2 or Notch3 does not enhance sensitivity to carcinogens. (A)
The epidermal thickness of >P600 Msx2-Cre/+; Notch2flox/flox (Msx2-N2CKO) and
Notch3-/- (N3KO) skin is normal (scale bar: 50µm). (B, C) Mice in the Notch2 and
Notch3 colonies are susceptible to DMBA/TPA-induced tumors due to their genetic
background; however, despite their sensitized background, no statistically significant
enhancement of susceptibility to chemical carcinogenesis is noted in either Notch2- or
Notch3-deficient mice compared to their wild-type littermates (Notch2: p =0.03, Notch3:
p =0.82, log-rank test). Both (B) time to appearance of first tumor and (C) number of
tumors per mouse over 25 weeks of follow-up post initiation were indistinguishable.
After TPA application is stopped (at week 15), significant numbers of tumors shrink and
become undetectable. Note a trend in Notch2-deficient mice towards greater resistance to
carcinogen. Of note, Msx2-N2CKO and N3KO animals do not overexpress TSLP (data
not shown).
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Figure 4.21
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Figure 4.21. Stepwise removal of Notch paralogs in Msx2-N1CKO animals leads to
progressive epidermal hyperplasia and to earlier onset of spontaneous skin
carcinogenesis. (A) Skin histology of compound Notch-deficient mice at P9 demonstrates
progressive epidermal hyperplasia, hyperkeratosis, and dermal hyperplasia as more Notch
alleles are deleted. Note the disorganized epidermal cells with atypia in Notch pathwaydeficient skin (i.e. Msx2-N1N2N3CKO and Msx2-PSDCKO). (B) Although Msx2N1CKO epidermis appears relatively normal at P9, Msx2-Cre/+; PS1flox/flox; PS2-/(Msx2-PSDCKO) skin that lacks all Notch signaling shows severely hyperplastic
epidermis, which overexpresses keratin 14 in suprabasal keratinocytes (marking
epidermal hyperplasia) and expresses keratin 6 (marking epidermal dysplasia). Note that
Msx2-PSDCKO skin is severely hypoplastic at birth (Figure 4.10; (Demehri et al., 2008))
establishing that the Msx2-PSDCKO skin has undergone an acute reactive hyperplasia in
9 days to repair its severe skin-barrier defect. (C) Progressive reduction in Notch signal
dosage impacts both life span (Demehri et al., 2008) and spontaneous tumor onset. The
progressive skin pathology shown in “A” correlates with premature death in compound
Notch-deficient mice which is accompanied by faster tumor onset in genotypes where life
span is sufficiently long. Data are drawn from lifelong monitoring of 10 to 20 mice for
each genotype, and percentages in figure indicate proportion of animals of a given
genotype that developed tumors. Significant differences in average time to tumor onset
between adjacent genotypes are highlighted by brackets. Although the shorting in life
span for most genotypes is due directly to their intrinsic skin phenotype including
exfoliation, bleeding, and infection, Msx2-N1N2CKO, Msx2-N1N2N3CKO and Msx2PSDCKO animals die shortly after birth due to a lethal blood disorder (Demehri et al.,
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2008). Note that Msx2-Cre/+; Notch2flox/flox (Msx2-N2CKO) and Notch3-/- (N3KO) mice
have normal skin and behave like wild type. Abbreviations: Msx2-Cre/+; Notch1flox/flox
(Msx2-N1CKO), Msx2-Cre/+; Notch1flox/flox; Notch2flox/+ (Msx2-N1N2hCKO), Msx2Cre/+; Notch1flox/flox; Notch2flox/+; Notch3+/- (Msx2-N1N2hN3hCKO), Msx2-Cre/+;
Notch1flox/flox; Notch2flox/+; Notch3-/- (Msx2-N1N2hN3CKO), Msx2-Cre/+; Notch1flox/flox;
Notch2flox/flox (Msx2-N1N2CKO), Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox; Notch3-/(Msx2-N1N2N3CKO), Msx2-Cre/+; RBP-jflox/flox (Msx2-RBP-jCKO), and Msx2PSDCKO (scale bar: 50µm).
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Figure 4.22. Mice lacking Notch2 and Notch3 in the skin develop skin-barrier defect,
epidermal hyperplasia and skin tumors. (A) TSLP overexpression (a general biomarker
for postnatal skin-barrier defects (Demehri et al., 2008)) is the common feature of
Notch1-deficient and Notch2/3-deficient epidermis. mRNA for qRT-PCR analysis is
isolated from epidermis of P9 Msx2-N1CKO, Msx2-N2N3CKO and their wild-type
littermates. p21wAF1/Cip1 expression (the direct target of Notch1), which is reduced in
Notch1-deficient epidermis and thought to be essential for tumor formation in Notch1deficient skin (Nicolas et al., 2003), is not altered in Msx2-N2N3CKO epidermis.
However, TSLP mRNA level is highly elevated in both Msx2-N1CKO and Msx2N2N3CKO relative to their wild-type controls (*: p <0.001, **: p <0.0001, student’s ttest). (B) Serum TSLP levels remain elevated in adult (6 to 8 months old) Msx2N2N3CKO animals implying the persistence of defective skin-barrier in these mice (*: p
<0.01, student’s t-test). (C) The presence of a mild allergic inflammation responding to
skin-barrier defects in adult Msx2-N2N3CKO mice is evident based on their elevated
serum IgE levels (n=4 for each group; *: p <0.01, student’s t-test). (D) H&E staining of
Msx2-Cre; Notch2flox/flox; Notch3-/- (Msx2-N2N3CKO) and wild-type skin at P0, P9 and 1
year of age shows a Msx2-N1CKO-like pattern of dermal hyperproliferation starting at
P9 and subsequent epidermal hyperplasia in 1-year-old mutant skin. The bars on the left
side of each picture show the average thickness of epidermis (black) and dermis (green)
across three 100X microscope fields. Keratin 6 (K6) and keratin 14 (K14)
immunofluorescence staining shows distinct epidermal hyperplasia with dysplastic
changes in 1-year-old Msx2-N2N3CKO skin (scale bar: 50µm). (E) Lifelong monitoring
of 4 Msx2-N2N3CKO mice shows that these mice develop spontaneous skin tumors as
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they age, while none of their Notch2flox/flox; Notch3-/- (N3KO) or wild-type controls
develop any skin tumor (p <0.0001, log rank test). (F) A representative Msx2-N2N3CKO
mouse (P418) is shown to demonstrate that the spontaneous tumors in Msx2-N2N3CKO
skin are benign papillomas. Lower panel shows H&E-stained Msx2-N2N3CKO
papilloma that is also examined using K6 and K14 immunostaining (scale bar: 200µm).
(G) Treating Msx2-N2N3CKO and N3KO littermates with DMBA/TPA results in tumor
formation in all Msx2-N2N3CKO mice (n=14). In contrast, only 3 out 16 DMBA/TPAtreated N3KO animals develop tumors (p <0.0001, log-rank test). (H) The average
number of tumors per each tumor-bearing Msx2-N2N3CKO mouse is significantly higher
than that among N3KO controls over the 25-week experimental period (p <0.05 for all
tumor counts after week 8, student’s t-test). (I) This table presents the distribution of total
tumors counted at week 25 after initiation. The majority of skin tumors in DMBA/TPAtreated Msx2-N2N3CKO skin progress to SCC as confirmed by histological examination;
however, none of the papillomas formed in N3KO control mice underwent malignant
progression.
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Figure 4.23
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Figure 4.23. A model describing the feed-forward proliferative loop that culminates in
epidermal hyperplasia and tumor promotion in Msx2-N1CKO skin. (A) At birth, Msx2N1CKO epidermis is mildly hypoplastic (this hypoplasia is more pronounced in mice
lacking total Notch signaling in the keratinocytes). (B) Notch1-deficient keratinocytes
that fail to form a competent barrier release several paracrine signals including TGF-#
into dermis (blue arrow) inducing the stromal activation to repair the breach in barrier.
(C) The components of the activated stroma (i.e. fibroblasts, immune cells and
microvasculature) in turn send strong proliferative signals to the epidermal keratinocytes
(red arrow) and cause epidermal hyperplasia overtime. In this proliferative environment,
cancer stem cells that are generated by initiating carcinogens can readily form tumors.
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Figure 4.24
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Figure 4.24. A representative pedigree demonstrating the composition of litters that
participated in our cancer studies. Note that each litter contains at least one member
belonging to each genotype.
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TABLES

Table 4.1(A)
Weeks Post Initiation
5

6

7

8

9

10

11

12

13

14

15

1(10)

3(10)

7(10)

8(10)

8(10)

8(10)

8(10)

8(10)

9(10)

16

17

18

19

20

21

22

23

24

25

9(9)

9(9)

9(9)

Msx2-N1CKO
# of mice with Tumor: 0(10)

9(10) 10(10) 10(10) 10(10) 10(10) 10(10) 10(10) 10(10)

Tumor #

Mouse ID

Gender

#4

female

0

0

0

1

2

3

3

4

4

5

6

6

6

6

6

6

6

6

6

6

6

#5

male

0

0

1

2

5

12

12

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

#6

male

0

1

10

20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

#7

male

0

0

0

1

1

2

2

3

4

9

12

13

13

13

13

13

13

13

13

13

13

#8

male

0

0

0

0

0

0

0

0

0

0

0

1

1

2

4

4

7

7

7

7

7

#12

female

0

0

0

1

4

4

5

7

9

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

>20

#14

female

0

0

0

0

1

1

1

2

3

4

4

10

10

16

16

16

>20

>20

>20

>20

>20

#15

female

0

0

0

0

0

0

0

0

0

1

2

2

2

8

8

8

8

15

>20

>20

>20

#16

female

0

0

0

2

8

8

10

12

15

>20

>20

>20

>20

>20

>20

>20

>20

>20

-

-

-

#19

female

0

0

1

1

1

1

2

3

3

4

6

9

9

12

12

>20

>20

>20

>20

>20

>20

*Average tumor #:
Standard deviation:

0

1

4

4

7

8

8

10

11

13

14

16

18

20

20

20

20

20

20

20

20

0.0

0.0

5.2

7.1

9.8

9.8

9.7

10.4

10.2

10.3

10.9

12.4

14.6

-

-

-

-

-

-

-

-

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

Wild type
# of mice with Tumor: 0(10)
Mouse ID

Tumor #

Gender

#1

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#2

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#3

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#9

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#10

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#11

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#13

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#17

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#21

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

#24

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

*Average tumor #:

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

*: The number of tumors among tumor-bearing animals are averaged (i.e. "zero" tumor counts are excluded from the average).
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: Dead mouse

4.1(B)
Weeks Post Initiation
5

6

7

8

9

10

11

12

13

14

0(7)

1(7)

2(7)

5(7)

5(7)

6(7)

6(7)

7(7)

7(7)

15

16

17

18

19

20

21

22

23

24

25

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)
25

ODT
# of mice with Tumor: 0(7)

Tumor #

Mouse ID

Gender

1380 (#18)

male

0

0

0

1

3

7

7

13

16

20

20

20

20

25

25

25

25

25

25

25

1383 (#27)

male

0

0

0

0

1

1

2

4

4

4

4

4

4

7

7

7

11

8

9

10

9

1476 (#38)

male

0

0

1

1

1

3

3

3

3

10

10

10

15

17

17

18

18

18

18

18

18

1370 (#20)

female

0

0

0

0

4

7

8

10

10

15

19

19

19

19

19

19

19

19

19

17

19

1372 (#26)

female

0

0

0

0

2

3

4

6

13

20

20

20

20

22

22

24

24

24

24

20

20

1373 (#29)

female

0

0

0

0

0

0

2

3

3

7

7

7

7

11

9

9

10

13

12

14

17

1381 (#21)

male

0

0

0

0

0

0

0

0

2

3

3

3

3

10

12

12

12

12

12

15

15

*Average tumor #:

0

0

1

1

2

4

4

7

7

11

12

12

13

16

16

16

17

17

17

17

18

Standard deviation:

0.0

0.0

0.0

0.0

1.3

2.7

2.6

4.1

5.6

7.2

7.6

7.6

7.7

6.7

6.7

7.1

6.2

6.3

6.2

4.8

4.9

# of mice with Tumor: 0(7)

0(7)

1(7)

2(7)

2(7)

5(7)

6(7)

6(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

7(7)

DOT
Tumor #

Mouse ID

Gender

1376 (#2)

male

0

0

1

2

2

3

8

10

14

15

16

17

18

18

19

20

20

20

15

13

10

1377 (#3)

male

0

0

0

0

0

2

2

3

8

8

13

20

16

16

15

13

15

15

14

14

14

1378 (#5)

male

0

0

0

1

1

2

3

7

7

7

4

5

4

4

7

10

10

13

13

11

13

1475 (#36)

male

0

0

0

0

0

1

1

1

2

3

3

3

4

4

7

7

7

8

8

8

11

1365 (#4)

female

0

0

0

0

0

2

4

5

8

5

6

13

11

11

16

14

14

15

15

14

14

1366 (#6)

female

0

0

0

0

0

0

0

0

3

3

10

10

9

9

11

13

13

14

10

12

10

1367 (#7)

female

0

0

0

0

0

0

2

2

2

4

7

7

7

7

10

10

10

8

8

6

6

*Average tumor #:

0

0

1

2

2

2

3

5

6

6

8

11

10

10

12

12

13

13

12

11

11

Standard deviation:

0.0

0.0

0.0

0.7

0.7

0.7

2.5

3.4

4.3

4.2

4.8

6.3

5.5

5.5

4.6

4.1

4.2

4.2

3.1

3.1

2.9

0(16)

0(16)

0(16)

0(16)

0(16)

2(16)

4(16)

Controls
# of mice with Tumor: 0(16)

8(16) 11(16) 11(16) 14(16) 14(16) 14(16) 14(16) 16(16) 16(16) 16(16) 16(16) 16(16) 16(16)

Tumor #

Mouse ID

Gender

1379 (#13)

male

0

0

0

0

0

0

0

0

0

1

2

2

2

2

2

1

3

3

3

3

3

1368 (#8)

female

0

0

0

0

0

0

0

0

1

2

3

3

2

2

2

4

4

4

4

4

4

1375 (#16)

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

2

2

2

4

3

1382 (#23)

male

0

0

0

0

0

0

0

0

0

1

3

5

5

4

5

5

4

5

5

4

5

1374 (#30)

female

0

0

0

0

0

0

0

1

2

4

5

5

5

6

4

5

5

5

5

5

5

#42

female

0

0

0

0

0

0

1

1

1

4

4

4

4

4

8

8

9

6

5

7

5

#31

male

0

0

0

0

0

0

0

0

0

0

0

2

2

2

2

1

3

3

3

3

3

#35

male

0

0

0

0

0

0

0

0

1

2

3

6

4

3

2

4

4

4

4

4

4

#37

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

2

3

3

4

3

#38

male

0

0

0

0

0

0

0

0

0

1

3

5

5

4

5

5

4

5

5

4

5

#39

male

0

0

0

0

0

0

0

1

5

4

5

5

5

6

4

5

4

4

4

4

3

1371 (#24)

female

0

0

0

0

0

0

1

1

4

4

4

6

4

4

8

8

9

6

5

5

5

#40

female

0

0

0

0

0

0

0

0

1

4

8

8

6

6

5

5

5

5

5

5

4

#41

female

0

0

0

0

0

0

0

0

0

0

0

1

1

1

1

1

1

1

1

1

1

#28

female

0

0

0

0

0

0

0

0

0

0

0

2

2

2

2

2

2

2

2

2

2

#43

male

0

0

0

0

0

0

0

0

6

6

9

9

5

5

6

5

7

5

5

5

5

*Average tumor #:

0

0

0

0

0

0

1

1

3

3

4

5

4

4

4

4

4

4

4

4

4

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.1

1.7

2.3

2.3

1.6

1.7

2.3

2.3

2.4

1.5

1.3

1.4

1.2

*: The number of tumors among tumor-bearing animals are averaged (i.e. "zero" tumor counts are excluded from the average).
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4.1(C)
Weeks Post Initiation
5

6

7

8

9

10

11

12

13

14

0(10)

0(10)

0(10)

0(10)

1(10)

4(10)

4(10)

7(10)

7(10)

15

16

17

18

19

20

21

22

23

24

25

7(10)

8(10)

8(10)

8(10)

9(10)

8(9)

8(9)

9(9)

9(9)

9(9)

9(9)

Msx2-N1CKO
# of mice with Tumor: 0(10)

Tumor #

Mouse ID

Gender

7136

female

0

0

0

0

0

0

0

0

1

1

1

1

1

2

2

3

4

5

6

7

7

7137

male

0

0

0

0

0

1

3

3

3

3

3

3

3

4

4

4

4

5

5

5

5

7141

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

4

4

5

5

5

7

7010

female

0

0

0

0

0

0

1

1

1

2

2

2

3

3

3

-

-

-

-

-

-

7009

male

0

0

0

0

0

0

1

1

2

2

2

2

2

4

4

7

7

7

9

9

10

6950

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

4

6

7

7135

male

0

0

0

0

0

0

0

0

1

2

2

1

2

2

2

2

2

3

3

4

6

7014

male

0

0

0

0

0

0

0

0

0

0

0

1

1

1

1

2

2

2

3

3

8

7006

male

0

0

0

0

0

0

1

2

2

2

3

3

3

3

3

3

3

3

3

6

6

7007

male

0

0

0

0

0

0

0

0

2

2

3

3

4

4

4

4

4

4

5

5

5

*Average tumor #:

0

0

0

0

0

1

2

2

2

2

2

2

2

3

3

4

4

4

5

6

7

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

1.0

1.0

0.8

0.6

0.8

0.9

1.1

1.1

1.1

1.6

1.6

1.7

1.9

1.7

1.6

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

0(10)

Wild type
# of mice with Tumor: 0(10)
Mouse ID

Tumor #

Gender

7134

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7011

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7027

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7003

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6932

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7008

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7018

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7129

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7130

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7131

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

*Average tumor #:

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

*: The number of tumors among tumor-bearing animals are averaged (i.e. "zero" tumor counts are excluded from the average).
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: Dead mouse

4.1(D)

Weeks Post Initiation
5

6

7

8

9

10

11

12

13

14

0(13)

0(13)

0(13)

3(13)

5(13)

5(13)

5(13)

7(13)

7(13)

15

16

7(13)

8(13)

17

18

19

20

21

22

23

24

25

Msx2-N1CKO;DPPI-/# of mice with Tumor: 0(13)

9(13) 10(13) 11(13) 11(13) 12(13) 13(13) 13(13) 13(13) 13(13)

Tumor #

Mouse ID

Gender

7188

female

0

0

0

0

0

0

0

0

0

0

0

1

2

1

1

1

2

3

3

4

4

7182

male

0

0

0

0

0

0

0

0

1

2

4

5

5

8

11

12

12

12

12

11

11

7183

male

0

0

0

0

1

4

5

6

6

8

10

12

10

10

10

8

7

6

5

5

4

7181

female

0

0

0

0

0

0

0

0

3

1

1

3

1

1

1

1

1

2

3

4

5

7171

male

0

0

0

0

0

1

2

2

3

4

4

5

10

11

11

13

13

15

15

15

15

7161

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

1

2

2

7162

female

0

0

0

0

0

0

0

0

0

0

0

0

0

1

2

2

1

1

1

1

1

7156

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

2

3

4

5

7204

male

0

0

0

0

1

1

1

1

2

4

7

11

10

8

8

13

12

12

12

12

12

7205

female

0

0

0

0

0

0

0

0

0

0

0

0

2

2

2

1

2

2

2

2

2

7206

male

0

0

0

0

1

1

1

2

3

2

5

7

8

8

8

9

8

8

8

8

8

7207

male

0

0

0

0

0

1

1

1

1

2

2

3

2

3

3

5

6

6

7

8

8

7208

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2

1

1

1

1

1

1

*Average tumor #:

0

0

0

0

1

2

2

2

3

3

5

6

6

5

5

6

6

5

6

6

6

Standard deviation:

0.0

0.0

0.0

0.0

0.0

1.3

1.7

2.1

1.7

2.4

3.0

3.9

3.9

4.1

4.2

5.1

4.8

4.9

4.8

4.5

4.5

0(14)

0(14)

2(14)

2(14)

3(14)

5(14)

Msx2-N1CKO
# of mice with Tumor: 0(14)

7(14) 11(14) 11(14) 11(14) 11(14) 12(14) 12(14) 13(14) 14(14) 14(14) 14(14) 13(13) 12(12) 12(12)

Tumor #

Mouse ID

Gender

7172

female

0

0

0

0

0

0

0

0

1

1

1

1

3

3

4

5

6

6

6

6

6

7175

male

0

0

0

1

1

4

5

7

11

10

12

18

10

12

13

16

17

19

19

19

19

7176

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

1

1

2

2

2

2

7178

male

0

0

0

1

1

1

3

6

7

8

7

7

7

9

13

14

14

14

14

14

14

7186

male

0

0

0

0

0

3

4

5

6

8

10

11

12

11

10

15

14

14

14

14

14

7180

female

0

0

0

0

0

0

0

1

3

2

4

5

4

6

8

9

8

8

8

8

8

7160

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

2

2

3

4

5

7164

male

0

0

0

0

0

0

0

0

1

3

5

6

8

7

6

8

10

12

-

-

-

7169

female

0

0

0

0

0

0

0

0

0

0

0

0

3

2

1

1

1

1

1

2

2

7165

male

0

0

0

0

0

0

0

1

1

1

1

2

2

3

4

4

5

5

5

5

5

7154

female

0

0

0

0

0

0

1

2

6

7

7

9

10

10

11

15

14

14

14

14

14

7155

14

14

female

0

0

0

0

0

0

0

0

2

2

3

3

8

9

10

11

12

14

14

7209

male

0

0

0

0

0

0

0

0

1

3

5

7

6

8

10

14

14

14

14

-

-

7210

female

0

0

0

0

0

0

1

2

1

3

1

1

4

4

4

6

5

5

6

7

8

*Average tumor #:
Standard deviation:

0

0

0

1

1

3

3

3

4

4

5

6

6

7

7

9

9

9

9

9

9

0.0

0.0

0.0

0.0

0.0

1.5

1.8

2.5

3.4

3.2

3.7

5.0

3.3

3.4

4.2

5.7

5.5

5.8

5.8

5.7

5.6

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

1(12)

1(12)

1(12)

1(12)

1(12)

1(12)

2(12)

2(12)

1(12)

1(12)

1(12)

1(12)

1(12)

DPPI-/# of mice with Tumor: 0(12)

Tumor #

Mouse ID

Gender

7187

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7177

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7214

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7184

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7170

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7157

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7218

male

0

0

0

0

0

0

0

0

1

1

1

1

1

1

1

1

0

0

0

0

0

7223

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

1

1

1

1

1

1

7224

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7225

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7226

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7229

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

*Average tumor #:

0

0

0

0

0

0

0

0

1

1

1

1

1

1

1

1

1

1

1

1

1

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

0(12)

Wild type
# of mice with Tumor: 0(12)
Mouse ID

Tumor #

Gender

7173

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7174

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7179

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7185

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7159

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7166

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7167

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7168

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7158

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7221

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7222

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7220

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

*Average tumor #:

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

*: The number of tumors among tumor-bearing animals are averaged (i.e. "zero" tumor counts are excluded from the average).
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: Dead mouse

4.1(E)
Weeks Post Initiation
5

6

7

8

9

10

11

0(14)

0(14)

0(14)

5(14)

6(14)

8(14)

12

13

14

15

16

17

18

19

20

21

22

23

24

25

Msx2-N2N3CKO
# of mice with Tumor: 0(14)
Mouse ID

8(14) 11(14) 14(14) 14(14) 14(14) 14(14) 14(14) 14(14) 14(14) 13(13) 13(13) 11(11) 11(11) 11(11)

Tumor #

Gender

7268

male

0

0

0

0

0

0

0

0

0

1

1

2

2

3

5

7

8

10

10

7

7

7269

male

0

0

0

0

1

1

2

3

4

3

4

5

3

2

3

3

3

3

3

3

3

7270

male

0

0

0

0

1

1

2

3

4

2

5

7

6

4

6

8

8

8

9

10

9

6404

female

0

0

0

0

0

0

0

0

0

1

1

1

1

2

2

3

3

2

2

2

3

7280

female

0

0

0

0

0

0

0

0

2

2

2

3

3

4

4

5

6

8

6

4

6

7281

male

0

0

0

0

0

0

4

3

3

10

10

10

10

10

11

12

12

12

14

15

16

7282

male

0

0

0

0

1

1

1

2

2

6

5

4

4

4

5

6

-

-

-

-

-

6367

female

0

0

0

0

0

1

1

1

1

2

2

2

2

1

2

3

3

2

3

5

3

6363

male

0

0

0

0

0

0

2

1

1

1

1

2

3

3

3

3

2

1

4

6

4

6387

male

0

0

0

0

0

0

0

0

4

3

6

8

8

8

9

9

8

7

-

-

-

6373

male

0

0

0

0

0

0

0

0

1

1

1

3

3

3

4

5

5

5

5

5

7

6382

female

0

0

0

0

0

0

0

0

0

1

1

1

1

1

2

2

2

2

2

2

2

6383

female

0

0

0

0

1

1

1

1

3

2

3

3

5

7

7

8

8

6

6

6

7

6384

female

0

0

0

0

1

1

1

1

4

2

4

5

5

5

7

8

9

10

-

-

-

*Average tumor #:

0

0

0

0

1

1

2

2

3

3

3

4

4

4

5

6

6

6

6

6

6

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

1.0

1.0

1.3

2.5

2.6

2.7

2.6

2.6

2.7

2.9

3.2

3.6

3.8

3.8

4.0

0(16)

0(16)

0(16)

0(16)

0(16)

0(16)

0(16)

0(16)

0(16)

0(16)

0(16)

1(16)

2(16)

2(16)

3(16)

3(16)

3(16)

3(16)

3(16)

3(16)

N3KO
# of mice with Tumor: 0(16)
Mouse ID
6377

Gender
female

0

0

0

0

0

0

0

0

0

0

Tumor #
0

0

0

0

0

0

0

0

0

0

0

6405

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6399

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6400

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7314

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6366

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1

1

1

1

1

1

6360

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6361

male

0

0

0

0

0

0

0

0

0

0

0

0

1

1

1

1

1

1

1

1

1

6362

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7284

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

7285

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6386

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6385

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6368

female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6371

male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

6372

male

0

0

0

0

0

0

0

0

0

0

0

0

0

2

3

3

3

3

3

4

3

*Average tumor #:

0

0

0

0

0

0

0

0

0

0

0

0

1

2

2

2

2

2

2

2

2

Standard deviation:

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.7

1.4

1.2

1.2

1.2

1.2

1.7

1.4

*: The number of tumors among tumor-bearing animals are averaged (i.e. "zero" tumor counts are excluded from the average).
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: Dead mouse

Table 4.1. The individual animal’s tumor counts are shown to supplement the chemical
carcinogenesis studies described in (A) figure 4.2C&D, (B) figure 4.3C&D, (C) figure
4.3E&F, (D) figure 4.12E&F, and (E) figure 4.22G&H.
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Table 4.2(A)
Dependent Variable

Independent Variable

Time to Tumor Onset

Litter

Msx2-N1CKO vs. Wild type
0.929

Genotype(Litter)

<0.0001

Tumor Count
Week 10

Litter

0.276

Genotype(Litter)

0.054

Litter

0.834

Genotype(Litter)

0.005

Week 15
Week 20

Litter

0.326

Genotype(Litter)

<0.0001

Week 25

Litter

0.054

Genotype(Litter)

<0.0001

4.2(B)
Dependent Variable

Independent Variable

ODT vs. DOT

ODT vs. Controls

DOT vs. Controls

Time to Tumor Onset

Litter

0.308

0.946

0.240

Treatment(Litter)

0.321

0.003

0.004

Tumor Count
Week 10
Week 15
Week 20
Week 25

Litter

0.326

0.090

0.080

Treatment(Litter)

0.068

<0.0001

<0.0001

Litter

0.778

0.611

0.418

Treatment(Litter)

0.554

0.002

0.017

Litter

0.757

0.531

0.968

Treatment(Litter)

0.567

<0.0001

<0.0001

Litter

0.489

0.764

0.383

Treatment(Litter)

0.038

<0.0001

<0.0001

4.2(C)
Dependent Variable

Independent Variable

Time to Tumor Onset

Litter

Msx2-N1CKO vs. Wild type
0.720

Genotype(Litter)

0.0004

Tumor Count
Week 10
Week 15
Week 20
Week 25

Litter

0.452

Genotype(Litter)

0.465

Litter

0.779

Genotype(Litter)

0.081

Litter

0.977

Genotype(Litter)

0.055

Litter

0.474

Genotype(Litter)

<0.0001

4.2(D)
Dependent Variable
Time to Tumor Onset

Independent Variable

Msx2-N1CKO;DPPI-/- Msx2-N1CKO;DPPI-/- Msx2-N1CKO;DPPI-/- Msx2-N1CKO
vs. Msx2-N1CKO
vs. DPPI-/vs. Wild type
vs. DPPI-/-

Msx2-N1CKO
vs. Wild type

DPPI-/vs. Wild type

Litter

0.199

0.809

0.455

0.664

0.432

0.704

Genotype(Litter)

0.636

0.002

<0.0001

<0.0001

<0.0001

0.687

-

Tumor Count
Week 10
Week 15
Week 20
Week 25

Litter

0.546

0.816

0.811

0.596

0.555

Genotype(Litter)

0.904

0.581

0.571

0.452

0.452

-

Litter

0.371

0.246

0.317

0.8

0.608

0.437

Genotype(Litter)

0.458

0.16

0.104

0.035

0.04

0.436

Litter

0.362

0.467

0.525

0.249

0.119

0.808

Genotype(Litter)

0.072

0.125

0.067

<0.0001

<0.0001

0.673

Litter

0.505

0.914

0.991

0.296

0.159

0.88

Genotype(Litter)

0.228

0.036

0.022

<0.0001

<0.0001

0.895
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4.2(E)
Dependent Variable

Independent Variable

Time to Tumor Onset

Litter

Msx2-N2N3CKO vs. N3KO
0.203

Genotype(Litter)

<0.0001

Litter

0.541

Genotype(Litter)

0.053

Tumor Count
Week 10
Week 15
Week 20
Week 25

Litter

0.11

Genotype(Litter)

0.001

Litter

0.177

Genotype(Litter)

<0.0001

Litter

0.436

Genotype(Litter)

<0.0001
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Table 4.2. Nested ANOVA shows no significant strain (litter) contribution to the tumor
parameters (i.e. time to tumor onset and tumor count) measured in (A) figure 4.2C&D,
(B) figure 4.3C&D, (C) figure 4.3E&F, (D) figure 4.12E&F, and (E) figure 4.22G&H.
The comparison of genotypes (or treatment in 4.2B) within each litter (the nested term:
genotype(litter) or treatment(litter)) demonstrates that the reported outcomes are
determined by the genotypes (or treatment in 4.2B) in all experiments. Therefore, the
genotypes or treatment regimen within each litter is the independent variable providing
significant impact on tumor development. Significant (<0.05) p-values are in bold. Only
pair-wise analyses were performed. For detailed description of experimental paradigm
refer to Figures 4.2, 4.3, 4.12, and 4.22.
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Table 4.3(A)
Dependent Variable

Independent Variable

Time to Tumor Onset

Gender

Msx2-N1CKO vs. Wild type
0.912

Genotype(Gender)

<0.0001

Tumor Count
Week 10

Gender

0.172

Genotype(Gender)

0.019

Gender

0.559

Genotype(Gender)

0.003

Week 15
Week 20

Gender

0.868

Genotype(Gender)

<0.0001

Week 25

Gender

0.496

Genotype(Gender)

<0.0001

4.3(B)
Dependent Variable

Independent Variable

ODT vs. DOT

ODT vs. Controls

DOT vs. Controls

Time to Tumor Onset

Gender

0.168

0.973

0.382

Treatment(Gender)

0.533

0.003

0.003

Tumor Count
Week 10
Week 15
Week 20
Week 25

Gender

0.779

0.707

0.008

Treatment(Gender)

0.397

0.003

<0.0001

Gender

0.514

0.173

0.666

Treatment(Gender)

0.387

0.001

0.015

Gender

0.812

0.51

0.801

Treatment(Gender)

0.522

<0.0001

<0.0001

Gender

0.986

0.537

0.198

Treatment(Gender)

0.043

<0.0001

<0.0001

4.3(C)
Dependent Variable

Independent Variable

Time to Tumor Onset

Gender

Msx2-N1CKO vs. Wild type
0.102

Genotype(Gender)

<0.0001

Gender

0.435

Genotype(Gender)

0.467

Tumor Count
Week 10
Week 15
Week 20
Week 25

Gender

0.062

Genotype(Gender)

<0.0001

Gender

0.307

Genotype(Gender)

<0.0001

Gender

0.763

Genotype(Gender)

<0.0001

4.3(D)
Dependent Variable
Time to Tumor Onset

Independent Variable

Msx2-N1CKO;DPPI-/- Msx2-N1CKO;DPPI-/- Msx2-N1CKO;DPPI-/- Msx2-N1CKO
vs. Msx2-N1CKO
vs. DPPI-/vs. Wild type
vs. DPPI-/-

Msx2-N1CKO
vs. Wild type

DPPI-/vs. Wild type

Gender

<0.0001

0.002

<0.0001

0.095

0.051

0.662

Genotype(Gender)

0.071

<0.0001

<0.0001

<0.0001

<0.0001

0.371

-

Tumor Count
Week 10
Week 15
Week 20
Week 25

Gender

0.003

0.021

0.022

0.056

0.057

Genotype(Gender)

-

0.009

0.007

0.037

0.03

-

Gender

<0.0001

<0.0001

<0.0001

0.017

0.021

0.333

Genotype(Gender)

0.293

<0.0001

<0.0001

0.0002

<0.0001

0.36

Gender

<0.0001

<0.0001

<0.0001

0.052

0.067

0.132

Genotype(Gender)

0.042

<0.0001

<0.0001

<0.0001

<0.0001

0.092

Gender

0.001

0.0004

0.001

0.069

0.078

0.333

Genotype(Gender)

0.066

<0.0001

<0.0001

<0.0001

<0.0001

0.36
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4.3(E)
Dependent Variable

Independent Variable

Time to Tumor Onset

Gender

Msx2-N2N3CKO vs. N3KO
0.709

Genotype(Gender)

<0.0001

Gender

0.653

Genotype(Gender)

0.013

Tumor Count
Week 10
Week 15
Week 20
Week 25

Gender

0.145

Genotype(Gender)

<0.0001

Gender

0.224

Genotype(Gender)

<0.0001

Gender

0.078

Genotype(Gender)

<0.0001

228

Table 4.3. Nested ANOVA shows that the significant impact of genotypes (or treatment
in 4.3B) on the outcomes of chemical carcinogenesis studies (i.e. time to tumor onset and
tumor count) is not due to between-gender differences. Each table relates to the cancer
study described in (A) figure 4.2C&D, (B) figure 4.3C&D, (C) figure 4.3E&F, (D) figure
4.12E&F, and (E) figure 4.22G&H. The comparison of genotypes (or treatment in 4.3B)
within each gender reveals that in the absence of gender factor, significant differences
persist; hence, the reported outcomes are determined by the genotypes (or treatment in
4.3B) in all experiments. Only pair-wise analyses were performed. Significant (<0.05) pvalues are in bold. For detailed description of experimental paradigm refer to Figures 4.2,
4.3, 4.12, and 4.22.
Interestingly, in the DPPI experiment (D), between-gender differences have
significant impact on all outcomes when comparing Msx2-N1CKO;DPPI-/- to Msx2N1CKO (boxed in 4.3D). This reflects the fact that males had more tumors and their
tumors developed sooner than in females independent of genotype. Importantly, the
exclusion of gender contribution (genotype(gender)) by nested ANOVA has uncovered a
trend toward rescuing the tumor phenotype in Msx2-N1CKO animals when inactivating
mast cells (values in red, time to tumor onset and tumor count on week 20).
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Table 4.4

% Developing papilloma

# Needed in Each Group

Control Mice

Test Mice

Power = .70

Power = .80

10

99

4.2

4.5

10

90

5.2

5.8

10

80

6.7

7.7

10

70

8.7

10.2

10

60

11.6

13.9

10

50

16.4

19.8

10

40

25.3

31.0

10

30

46.5

58.0

10

20

138.7

176.0
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Table 4.4. Determining the number of animals needed for cancer studies using power
analysis. Assuming that survival will be the same and that the assay endpoint will be
reached when 10% of our control mice will develop at least one papilloma, this table
shows the number of mice needed in each group to obtain a significant difference (onetailed) between the experimental and control groups using Fisher’s Exact Test. Fisher’s
test is an alternative to the chi-square test (which relies on a large sample approximation)
that is appropriate when a small number of events are expected in one or more cells of a 2
X 2 contingency table (the calculations here are made using Cassagrande et al.’s method
(Cassagrande et al., 1978), assuming an equal number of mice in each group, and an
alpha of 0.05. Results of these calculations are shown separately for power levels of 70%
and 80%. Treated mice are presented as the percentage of mice that develop tumors. If at
least 90% of DMBA/TPA treated test group develop tumors, 6 mice are required in order
to detect a difference between the test and control groups, assuming a power of 80%.
Therefore the use of ~10 mice in each group should generate ample power to detect a
statistically significant difference between the groups.
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CHAPTER V

Notch-deficient skin induces a lethal systemic Blymphoproliferative disorder by secreting TSLP, a sentinel
for epidermal integrity.

Publication & Copyright
Results and text presented in this chapter have been previously published:
Demehri S, Liu Z, Lee J, Lin M, Crosby S, Roberts CJ, Grigsby PW, Miner JH, Farr AG, Kopan
R. Notch-deficient skin creates an environment induces a lethal systemic B-lymphoproliferative
disorder by secreting TSLP, a sentinel for epidermal integrity. PloS Biology, 2008 May
27;6(5):e123. Reproduced with permission of the Public Library of Science.
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SUMMARY
Epidermal keratinocytes form a highly organized stratified epithelium and sustain a
competent barrier function together with dermal and hematopoietic cells. The Notch
signaling pathway is a critical regulator of epidermal integrity. Here, we show that
keratinocyte-specific deletion of total Notch signaling triggered a severe systemic Blymphoproliferative disorder (B-LPD) causing death. RBP-j is the DNA-binding partner
of Notch but both RBP-j-dependent and independent Notch signaling were necessary for
proper epidermal differentiation and lipid deposition. Loss of both pathways caused a
persistent defect in skin differentiation/barrier formation. In response, high levels of
thymic stromal lymphopoietin (TSLP) were released into systemic circulation by Notchdeficient keratinocytes that failed to differentiate, starting in utero. Exposure to high
TSLP levels during neonatal hematopoiesis resulted in drastic expansion of peripheral
pre- and immature B-lymphocytes causing B-LPD associated with major organ
infiltration and subsequent death, a previously unappreciated systemic effect of TSLP.
These observations demonstrate that local skin perturbations can drive a lethal systemic
disease and have important implications for a wide range of humoral and autoimmune
diseases with skin manifestations.
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INTRODUCTION
The vertebrate skin is an organ in which keratinocytes, underlying mesenchymal
cells, and circulating hematopoietic cells engage in reciprocal communication as they
monitor organ integrity (Morasso and Tomic-Canic, 2005). Therefore, skin is an ideal
system in which to study how complex, multi-compartmental networks function.
Epidermal keratinocytes are organized in several distinct layers with the innermost
(basal) layer containing the stem cells and transiently amplifying cells (Clayton et al.,
2007). The next layer contains spinous cells that, under normal conditions, begin a
terminal differentiation program giving rise to granular and cornified layers (Fuchs and
Raghavan, 2002; Jamora and Fuchs, 2002). However, after injury, spinous cells
proliferate to contribute to the restoration of an intact integument and produce cytokines
that trigger an inflammatory response (Morasso and Tomic-Canic, 2005). Defects in
execution of this terminal differentiation program can lead to what is collectively known
as “skin-barrier defects” (Segre, 2006).
Notch activation contributes to spinous cell differentiation: Loss of “canonical”
Notch signaling, induced by deletion of RBPSUH gene (coding for RBP-j, the DNA
binding partner of Notch), causes severe epidermal barrier and differentiation defects
highlighted by reduced spinous, granular and cornified layer cells (Blanpain et al., 2006).
On the other hand, overexpression of activated Notch1 exclusively in basal cells under
the K14 promoter triggers their premature differentiation into spinous cells, concomitant
with loss of proliferative capacity (Blanpain et al., 2006). The pattern of Notch1
activation in epidermal keratinocytes is consistent with its proposed role in suppressing
basal cell proliferation and promoting spinous cell differentiation via cell autonomous
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modulation of targets (Blanpain et al., 2006; Devgan et al., 2005; Mammucari et al.,
2005; Nguyen et al., 2006; Okuyama et al., 2004; Rangarajan et al., 2001). However,
overexpression of activated Notch1 in the differentiated spinous cells (where it is
normally present) triggers basal cell hyperproliferation and formation of acanthotic
epidermis with thickened granular layer (Uyttendaele et al., 2004), indicating that the
Notch signaling pathway has a complex role by not only promoting differentiation and
exit from the basal layer but also by contributing in a non-cell autonomous fashion to
skin homeostasis (Lin and Kopan, 2003; Uyttendaele et al., 2004). How Notch performs
its functions within spinous cells is a matter of some controversy and multiple
autonomous mechanisms have been proposed, including both canonical and noncanonical pathways (Blanpain et al., 2006; Devgan et al., 2005; Mammucari et al., 2005;
Nguyen et al., 2006; Okuyama et al., 2004; Rangarajan et al., 2001).
To study the role of Notch signaling in skin homeostasis and barrier formation,
we employed the Msx2-Cre line to delete components of the Notch signaling pathway in
skin keratinocytes (Pan et al., 2004). A burst of Msx2-Cre expression on embryonic day
9.5 (E9.5) creates chimeric skin with dorsal and ventral patches (“clones”) lacking floxed
alleles, confining the consequences of gene loss only to a fraction of the surface area (for
detailed analysis of Msx2-Cre expression in skin, see ref. (Lee et al., 2007; Pan et al.,
2004)). This allows animals lacking total Notch signaling to survive through birth (Figure
5.1A). With this system, we have previously shown that Notch loss also involves non-cell
autonomous alteration in Tgf-# and IGF signaling (Lee et al., 2007). Removal of both
Notch1 and Notch2 proteins, or both presenilin-1 (PS1) and presenilin-2 (PS2) proteins
(the catalytic subunits of !&secretase) within epidermal clones is sufficient to cause early

235

postnatal lethality (Pan et al., 2004).

In the current study, we investigated the

mechanistic basis for this early demise.
The progressive loss of Notch alleles in skin keratinocytes generated a dosedependent increase in thymic stromal lymphopoietin (TSLP) expression by suprabasal
keratinocytes in direct response to defective skin differentiation/barrier formation in
utero. TSLP is a recently discovered, epidermally-derived cytokine implicated in
pathogenesis of atopic dermatitis and asthma (Huston and Liu, 2006). Like IL-7, TSLP
can support B cell development, however, the in vivo effects of high TSLP levels on Blymphopoiesis are not fully understood (Leonard, 2002). Perinatal increase in TSLP
levels produced a dose-dependent expansion of pre- and immature B cells in the
periphery causing a B-lymphoproliferative disorder (B-LPD), a previously unappreciated
effect of TSLP. In its extreme form, B-LPD complications including B cell infiltration
into vital organs culminated in death. Therefore, this study provides the first
physiological confirmation that skin perturbation can cause a lethal systemic disease.
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RESULTS
Mice lacking !-secretase or all Notch proteins in the skin develop severe B-LPD
after birth.
Removal of total Notch signaling from the skin using Msx2-Cre led to death at
weaning (Figure 5.1B; see ref. (Pan et al., 2004)). To identify the cause of death in Msx2Cre/+; N1flox/flox; N2flox/flox (N1N2CKO) and Msx2-Cre/+; PS1flox/flox; PS2-/- (PSDCKO)
mice, a comprehensive necropsy was performed on the moribund animals. Surprisingly,
we found that mice from both genotypes had extremely high white blood cell (WBC)
counts (>150,000 cells/$l) at around the time of death (Figure 5.1C). Importantly,
analysis of an extensive Notch allelic series revealed that the severity of the leukocytosis
during the first few weeks of life was inversely correlated with Notch dosage (Figure
5.1C).
To characterize the cells causing leukocytosis, we analyzed various hematopoietic
parameters in Notch-deficient mice. Peripheral blood analysis showed that the
leukocytosis

in

both

N1N2CKO

and

PSDCKO

animals

was

of

lymphoblastic/lymphocytic nature; hence the mice displayed a severe case of
lymphoproliferative disorder (LPD; Figure 5.2A). This LPD was accompanied by failure
of bone marrow (BM) to participate in normal hematopoiesis evidenced by reduced red
blood cells and platelets (normocytic anemia and thrombocytopenia; Figure 5.2A). Since
the blood phenotypes of N1N2CKO and PSDCKO mice were similar, we use the term
“mutant” to describe the common LPD features of both genotypes and “wild type” for all
genetic combinations that either lack Cre or carry Msx2-Cre and a wild-type allele of
PS1. Macroscopic examination showed that mutant mice were smaller than their wild-
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type littermates, had enlarged spleen and lymph nodes but smaller than normal thymus,
suggesting that the expanding lymphocytes are of B cell origin (Figure 5.2B and Table
5.1). Flow cytometry (FC) analysis on blood from mutant animals confirmed that the
expanding population contributing to LPD was of the B cell lineage (B-LPD; Figure
5.2C). These observations suggested that extreme B-LPD could be the cause of death in
PSDCKO and N1N2CKO animals.

RBP-j-independent (but !-secretase-dependent) Notch signaling in the skin
contributes to longevity.
Unexpectedly, Msx2-Cre/+; RBP-jflox/flox (RBP-jCKO) mice lived significantly
longer (95 days on average) and showed lower WBC counts (~70,000 cells/$l) compared
to mice lacking Notch receptors or !-secretase (Figure 5.1B & C). Although we could not
exclude the possibility that Cre-mediated deletion of RBPSUH is marginally less efficient
than that of PS-1 or Notch1 and Notch2, examination of RBP-j protein in RBP-jCKO
animals confirmed its loss in keratinocytes (Figure 5.3). If RBP-j could actively repress
some target genes in the absence of Notch signaling, and this repression would be lost
upon RBP-j deletion, the milder RBP-j phenotype could be explained by de-repression of
some targets that ameliorated the phenotype (Koelzer and Klein, 2006). Alternatively, the
Notch pathway may have bifurcated; RBP-j-independent (yet !-secretase-dependent)
targets of Notch in skin (Arias et al., 2002; Rangarajan et al., 2001) may contribute to the
severity of the phenotypes reported here. To distinguish between these possibilities, mice
that lack both !-secretase and RBP-j in the skin were generated (Msx2-Cre/+; PS1flox/flox;
PS2-/-; RBP-jflox/flox; PSDRBP-jCKO). In this genetic experiment, de-repressed targets
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should suppress the PSDCKO phenotype (i.e., the PSDRBP-jCKO would display the
RBP-jCKO phenotype (Koelzer and Klein, 2006)). On the other hand, if RBP-jindependent targets of Notch contribute to the life span and leukocytosis, the !-secretase
mutation should be epistatic to RBP-j (i.e., the animal will have the PSDCKO
phenotype). A combination of both would be expected to produce an intermediate
phenotype.
The PSDRBP-jCKO mice lost RBP-j yet had the same life expectancy as
PSDCKO mice (Figure 5.1B) and had WBC counts comparable to PSDCKO (Figure
5.1C), a result inconsistent with target de-repression. To confirm that these outcomes
were Notch-dependent but RBP-j-independent, we also created the triple mutant Msx2Cre/+; N1flox/flox; N2flox/flox; RBP-jflox/flox (N1N2RBP-jCKO). As with PSDRBP-jCKO
animals, the life span of N1N2RBP-jCKO animals was not prolonged by removal of
RBP-j (Figure 5.1B and C), indicating that a Notch-dependent activity contributes to the
phenotype. This suggested that canonical Notch signaling could not be the sole
determinant of the phenotypes described and instead support the alternative assertion that
RBP-j-independent effects of Notch in the skin may contribute to leukocytosis
(Rangarajan et al., 2001; Talora et al., 2002). This result provides the first genetic
evidence in a vertebrate to support the existence of a bifurcation in Notch signaling
down-stream of !-secretase.

Drastic but transient expansion of B-lymphocytes results in severe systemic
complications in Notch-deficient animals
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To understand B-LPD progression better, WBC count from mutant animals was
measured over their life span (Figure 5.2D). WBC counts increased exponentially over
the first two weeks starting at around P4 but plateaued during the third week of life,
within the same time window when most mutant animals expired. However, to our
surprise, the longest surviving mice showed a trend toward normalization of their WBC
counts (Figure 5.2D). A reduction in peripheral B cell number (and thus normalization of
WBC count) was more evident in animals with partial loss of Notch signaling and in the
longer living RBP-jCKO mice (data not shown). Accompanying the surge in peripheral
WBC count, B220+ B cells expanded the spleen (splenomegaly) and infiltrated several
vital organs including lung and liver (Figure 5.2E, F and 5.4A). To characterize the
identity of the expanding cells in B-LPD further, two additional markers, CD43 and IgM,
were applied to segregate pro-, pre- and immature B cell populations by FC (Figure
5.5A). FC analysis showed that pre-B cells (B220+CD43-IgM-) constituted the majority
of the expanding population in both BM and periphery (Figure 5.5B, red ovals).
Immature B cells also expanded, as would be expected if differentiation of pre- to
immature B cells persisted in the mutant animals (Figure 5.5B). The ability of pre-B cells
to differentiate and the high WBC counts reached at an early age are consistent with a
polyclonal origin of this B-LPD (Costinean et al., 2006). Large expansion of immature B
cells was associated with elevated IgM levels, which precipitated at low temperature, a
condition known as Cryoglobulinemia (Figure 5.4B). Overall, despite the short duration
of B-LPD in Notch-deficient mice, we hypothesized that extremely high WBC count,
leukostasis, cryoglobulinemia, anemia and infiltration of B cells into vital organs
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conspired with the skin phenotype to produce cachexic mice that fail to thrive during the
early stages of postnatal development.

Blocking B-LPD prevents early lethality in the mutant mice
To determine whether B-LPD was an important contributor to early death, we
performed an allogeneic BMT experiment with mutant animals as the recipients. Lethally
irradiated mutant mice transplanted with BM derived from their wild-type littermates
around postnatal day 10 (P10) lived significantly longer than their untransplanted
counterparts (Figure 5.6A). However, the transplanted mutants still died within few
weeks after transplantation, this time because of severe skin phenotypes including
exfoliation, bleeding, inflammation and infection (Figure 5.4C). When treated with
systemic antibiotics, the life span of transplanted N1N2CKO animals was further
extended and became comparable to that of RBP-jCKO mice (Figure 5.6A and B).
However, antibiotic treatment of PSDCKO mice did not further extend their life span due
to the greater severity of skin disease in these animals (Figure 5.4C). The WBC counts
and FC analyses showed no reoccurrence of B-LPD in the transplanted mutants (Figure
5.6B and C). However, a significant expansion of granulocytes/monocytes was observed
in the peripheral blood of transplanted mutant animals during the final days of life with
WBC counts reaching ~20,000 cells/$l (Figure 5.6B, C and 5.7). Similar granulocytosis
accompanied by elevated peripheral T-lymphocyte percentage was observed in RBPjCKO mice of the same age (Figure 5.7).
The observations detailed above suggested that if B-LPD was controlled, life
expectancy of the mutant animals could be increased significantly. Indeed, either
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sublethal dose of total body irradiation (~450-cGy) or focal irradiation of the mutant
animals, extended their life span. In both cases, life expansion correlated with a delay in
B-LPD surge (Figure 5.8). Taken together, these experiments strongly demonstrated that
B-LPD, acquired by animals with Notch or !-secretase deficient skin, was a critical
mediator of early lethality. However, the short life expectancy of transplanted mutants
and RBP-jCKO was related to their skin disease, infection and to granulocytes/monocytes
expansion, which again occurred in Notch-dose dependent manner and in all adult
animals lacking canonical Notch signaling (data not shown, Dumortier et al, personal
communication).

B-LPD is a non-autonomous consequence of losing Notch or !-secretase in skin
keratinocytes.
Considering the importance of Notch signaling at various stages of lymphopoiesis
(Maillard et al., 2003; Pear and Radtke, 2003) and the potential for ectopic expression of
Msx2-Cre in an hematopoietic organ, we asked whether deletion of Notch in BM or any
hematopoietic organ might have caused B-LPD. To map the sites of Msx2-Cre activity
thoroughly, we applied the following approaches.
First, using a PCR protocol designed to detect the deleted allele of PS1 (PS1!), we
confirmed that neither hematopoietic cells nor any hematopoiesis-related organ
experienced Cre-mediated deletion of PS1 in PSDCKO mice (Figure 5.6D). Of note, we
collected peripheral blood from the mutant animals at peak WBC counts, which was thus
composed mostly (>90%) of expanding B cells, but still found no evidence of PS1
deletion. To rule out the possibility that loss of Notch signaling in a small subset of BM
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stromal cells could drive B cell expansion in the mutant animals, we re-analyzed Prx1Cre; PS1flox/flox; PS2-/- mice in which Cre is active in BM stroma, the osteoblasts (Hilton
et al., 2008; Pan et al., 2005) and the osteoblasts (Bai et al., 2007). WBC analysis in all
these mice showed no sign of B cell expansion (data not shown), indicating that another
organ provided the trigger for B-LPD. Next, we analyzed two reporter lines, Msx2-Cre;
ZEG/+ and Msx2-Cre; Rosa26R/+. Only the skin was marked by these reporters (data
not shown), with no detectable reporter staining in any hematopoietic lineage or organ.
Together, these findings led us to hypothesize that B-LPD was driven non-autonomously
in wild-type B cells as a consequence of reduced Notch signaling in the skin.
To test this hypothesis, we applied the allogeneic BMT paradigm to ask whether
hematopoietic stem cells isolated from the mutant animals could propagate B-LPD in
normal recipients. BM derived from mutant or wild-type littermates was equally
competent in its ability to engraft in lethally irradiated wild-type littermate hosts and
reconstitute a complete hematopoietic system that sustained a normal WBC count in the
recipient animals over several months of follow-up (Figure 5.6E). PCR analysis
confirmed the complete repopulation of the recipients’ hematopoietic system by donors’
derived BM (Figure 5.9B). In addition, BM transplanted from mutant or wild-type
animals into sublethally irradiated NOD/SCID mice were indistinguishable in their ability
to rescue the recipients (Figure 5.10). Collectively, these findings confirmed the nonautonomous nature of B-LPD and implicated the skin as the primary organ responsible
for the disease in Notch/!-secretase-deficient animals.
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High levels of TSLP strongly correlate with the intensity and timing of B-LPD in
Notch-deficient animals.
Having identified skin keratinocytes as the only cells in which Cre-mediated
deletion of Notch signaling was occurring, we hypothesized the existence of (an)
epidermally derived cytokine(s) capable of driving B cell expansion that accumulated to
high systemic levels in inverse correlation with Notch dose. To search for such factor(s),
we performed microarray analysis of mutant and wild-type total skin RNA samples
collected at P9. Given the dose-response observed with life expectancy and B-LPD, we
performed modified trend analysis asking for transcripts that were modestly elevated in
Notch1-deficient (N1CKO) skin but substantially elevated in N1N2CKO or PSDCKO
skin. A small subset of altered transcripts, highly enriched for chemokines and
chemoattractants, displayed the desired trend (Figure 5.11A, 5.12 and Table 5.2). Among
them, TSLP was the second most abundant transcript and the only epidermal-derived
cytokine capable of driving fetal B cell proliferation in mouse (Leonard, 2002;
Vosshenrich et al., 2003).
qRT-PCR on epidermal mRNA samples confirmed a ~20 fold increase of TSLP
mRNA in mutants (Figure 5.11A and Table 5.2), and immunohistochemical analysis on
skin sections identified suprabasal keratinocytes as the source of TSLP (Figure 5.12B and
5.13). ELISA measurements detected TSLP levels >5000 fold above the normal levels in
sera from mutant mice (~50ng/ml vs. <10pg/ml) that were already detectable at birth
(data not shown). A comprehensive serum analysis failed to detect differences in any
other cytokine or autoimmune signature that could provide an alternative mechanism for
B-LPD in the mutant mice (Table 5.3), including IL-7, the main cytokine implicated in B
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cell development. IL-6, the only other cytokine implicated in B-lymphopoiesis, which
showed moderate yet significant up-regulation in the skin microarray trend analysis, was
elevated <2 fold in serum (Figure 5.11C). Examination of the sera from entire allelic
series of Notch-deficient mice by ELISA confirmed and extended our trend analysis:
TSLP levels showed a strong inverse correlation with the dose of Notch signaling and life
expectancy (Figure 5.11D), and a direct correlation with WBC counts of the mutant
animals (Figure 5.1B, C, D, 5.14).

Increasing TSLP levels is sufficient to cause B-LPD in mice but only during the first
weeks of life.
Collectively, RNA and protein analyses created a consistent picture pointing to
TSLP as the likely candidate satisfying most of the criteria for the B-LPD-inducing
agent: sensitivity to reduction in Notch dose, systemic availability and the ability to
promote B cell development (Leonard, 2002; Vosshenrich et al., 2003). However, such a
proliferative role for TSLP has not been previously demonstrated. To satisfy the Koch’s
postulate for disease causation, we injected recombinant mouse TSLP into wild-type
mice. Daily injection of the animals with TSLP starting at birth and continuing for 7 days
led to a dose-dependent elevation of WBC count (Figure 5.15A). The FC analysis on
peripheral blood from the mice injected with TSLP identified the expanding cell
population as B220+ B-lymphocytes, not seen in mice receiving carrier alone (Figure
5.15B). Further analysis of peripheral blood from wild-type mice receiving 1$g TSLP
identified the expanding B cell population as pre- and immature B cells (Figure 5.15C).
Injecting wild-type animals with 1µg of TSLP daily resulted in steady-state serum TSLP
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levels of ~250pg/ml, comparable to that in N1CKO animals (Figure 5.15A, D and 5.14).
Likewise, WBC counts in these animals were also indistinguishable from those seen in
N1CKO mice at P8 (Figure 5.15A, C and 5.14). Thus, elevated TSLP levels were
sufficient to cause mild B-LPD in an otherwise normal newborn mouse. Significantly and
in agreement with published reports, no surge in WBC count was detected when the
treatment regimen was initiated at P14 or later (Figure 5.15A; (Al-Shami et al., 2004;
(Al-Shami et al., 2004; Astrakhan et al., 2007)). To demonstrate a correlation between
exogenous levels of TSLP and high WBC counts, we analyzed K14-TSLPtg transgenic
mice (Chappaz et al., 2007). This analysis revealed high serum TSLP levels of ~3ng/ml
in K14-TSLPtg newborns and, as predicted by our hypothesis, neonatal B-LPD similar to
that observed in RBP-j-deficient animals (Figure 5.15D-G and 5.14). Importantly, B-LPD
in K14-TSLPtg newborns developed in the absence of any overt skin morphology (data
not shown), indicating elevated TSLP is not impeding epidermal differentiation.
Consistent with the findings above, K14-TSLPtg animals also developed B-LPD only
during the neonatal period, which disappeared later in life despite elevated serum TSLP
levels (Figure 5.15D and E). This experiment confirmed that TSLP overexpression after
the neonatal period did not sustain B-LPD in mice.
To ask if B-LPD represented the confluence of high TSLP with a responding,
fetal pre-B cell population, we performed fetal liver transplantation (FLT) into lethally
irradiated mutant animals. Surprisingly, FLT reconstituted normal adult hematopoiesis in
the recipients, suggesting that fetal pre-B cells in an adult niche microenvironment lost
their ability to respond to high levels of TSLP (Figure 5.16). To ask if continuous
exposure to high TSLP levels sustained a responding pre-B cell population, we
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performed a third allogeneic BMT experiment in which BM from the mutant animals was
transplanted into their lethally irradiated mutant littermates (which continued to produce
high TSLP levels, data not shown). Again, the donor-derived BM reconstituted normal
adult hematopoiesis in the recipients, curing their B-LPD, consistent with the limited
temporal window in which B-LPD can develop (Figure 5.6A). These results confirmed
that B-LPD developed as a result of exposure to high TSLP levels in the perinatal period.

TSLP signaling is required for B-LPD development in Notch-deficient animals
Although we determined that a high serum TSLP level alone was sufficient to
cause neonatal B-LPD, the large array of cytokines and chemokines overproduced by
Notch-deficient keratinocytes might have contributed to B cell expansion in these
animals. To address this possibility, we blocked TSLP signaling in Notch-deficient
animals through the deletion of TSLP receptor. The removal of IL7r" arm of the receptor
in RBP-jCKO and N1N2CKO animals (Msx2-Cre/+; RBP-jflox/flox; IL7r"-/- (RBPjCKO;IL7r"-/-)

and

Msx2-Cre/+;

Notch1flox/flox;

Notch2flox/flox;

IL7r"-/-

(N1N2CKO;IL7r"-/-), respectively), resulted in compelete normalization of WBC counts
in RBP-jCKO;IL7r"-/- and N1N2CKO;IL7r"-/- (Figure 5.17A and C). The FC analysis
on peripheral blood of these animals confirmed the absence of B-lymphocyte expansion
in the mutant animals that lacked functional TSLP receptor (Figure 5.17B). TSLP
receptor shares its IL7r" subunit with IL7 receptor (Liu et al., 2007). Therefore, to rule
out that the rescue phenotype was the secondary consequece of a cripeled B cell
development because of lack of IL7 signal reception on fetal B cells, we generated
PSDCKO animals that lacked TSLPR arm of TSLP receptor Msx2-Cre/+; PS1flox/flox;
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PS2flox/flox; TSLPR-/- (PSDCKO;TSLPR-/-). As expected, B-LPD was completely cured in
PSDCKO;TSLPR-/- newborns as well, confirming that TSLP is the cause of B-LPD, in
Notch-deficient animals (Figure 5.17D). Importantly, the rescue of B-LPD in
N1N2CKO;IL7r"-/- and PSDCKO;TSLPR-/- animals led to their extended life span
similar to animals that were treated with BMT (Figure 5.17E and F).

TSLP overproduction is a general response to structural abnormalities in Notchdeficient skin before birth.
Loss of Notch signaling in skin keratinocytes leads to elevated epidermal TSLP
production and high serum TSLP levels, reaching a maximum only when all Notch
proteins or !-secretase are removed (Figure 5.11). TSLP overexpression may thus be a
general response of epidermal keratinocytes to differentiation (and skin-barrier) defect
(Segre, 2006). Notch-deficient epidermis was defective in epidermal differentiation,
leading to incomplete formation of upper spinous and granular layers, as reported in
RBP-j-deficient animals (Figure 5.18A; (Blanpain et al., 2006)). This was accompanied
by global down-regulation of skin lipid biosynthetic enzymes and reduced epidermal
lipid content (Figure 5.18B, C and Table 5.4). Consequently, a defect in skin-barrier
function was detectable directly by using the dye exclusion assay; this procedure stains
areas with defective barrier and indeed, only the stereotypical pattern of Cre-expression
was stained in the mutant animals, consistent with a barrier defect in !-secretase-deficient
keratinocytes (Figure 5.18D; (Blanpain et al., 2006)).
To further ascertain if TSLP overexpression is a consequence of Notch loss or a
consequence of defective differentiation/barrier formation, we isolated keratinocytes
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from mutant and wild-type pups and measured TSLP in the culture medium of cells
grown on plastic. Both mutant and wild-type keratinocytes fail to form a fully
differentiated epidermis under these conditions and both secreted similar and significant
levels of TSLP, as would be expected if TSLP overproduction was a general consequence
of abnormal keratinocytes differentiation and not a specific consequence for loss of
Notch signaling (Figure 5.18E). Since NF$B signaling, a potent inducer of
differentiation, can activate TSLP (Kaufman and Fuchs, 2000; Lee and Ziegler, 2007),
we asked if this pathway was responsible for TSLP expression in cultured keratinocytes.
Addition of an inhibitor of NF$B signaling, BAY 11-7082 (Pierce et al., 1997),
abrogated TSLP production in a dose dependent manner in both wild-type and !secretase-deficient keratinocytes (Figure 5.18E). To solidify the conclusion that TSLP
overproduction is a readout of failed differentiation and not a specific repressed target of
Notch signaling, we analyzed wrfr-/- mice that lack fatty acid transport protein (FATP)4
and die at birth because of severe epidermal differentiation and skin-barrier defects
(Moulson et al., 2003). As in Notch-deficient mice, B-LPD was not yet detectable in
wrfr-/- mice at birth. These mice, however, did show a substantial surge in skin TSLP
transcript levels around the time of stratification and barrier formation (E15.5-17.5),
which led to elevated serum TSLP levels at birth (Figure 5.18F). Since FATP4
expression is not altered in Notch-deficient skin (data not shown), and Notch pathway
targets are not altered in wrfr-/- skin (Figure 5.18F), this observation provided an
independent confirmation that up-regulation of TSLP expression is a common readout of
differentiation/barrier formation defects and not a repressed target of Notch signaling.
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DISCUSSION
Skin-specific deletion of Notch signaling leads to a lethal B-LPD.
This report details the mechanism by which a local perturbation to the skin
induced a lethal systemic disease. We demonstrate that progressive loss of Notch
signaling in the embryonic ectoderm caused a dose-dependent impairment of epidermal
differentiation and reduced lipid biogenesis, stimulating keratinocytes to secrete excess
TSLP into the systemic circulation. The pathophysiological consequence of persistent
differentiation/barrier defects and the subsequent accumulation of TSLP had a potent
proliferative effect on fetal/newborn B-lymphopoiesis, causing an exceptional expansion
of pre- and immature B cell populations in newborn animals (i.e. neonatal B-LPD; Figure
5.19). A severe B-LPD with its systemic complications including infiltration of B cells
into various vital organs, anemia and cryoglobulinemia explained the early death of the
animals lacking total (canonical and non-canonical) Notch signaling in the skin. Indeed,
we were able to extend the life span of the mutant newborn animals simply by
suppressing their B-LPD through either BMT, TSLP receptor deletion, sublethal or focal
irradiation administered before the onset of full-blown B-LPD in the second week of life.
The ameliorating effects of these treatments also reflect the fact that pre-B cells emerging
in the adult BM niche are refractory to high TSLP levels (see below).

Novel function of TSLP explains the main features of B-LPD in Notch-deficient
newborns.
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A growing body of work has provided extensive evidence that TSLP
overexpression in skin or lung epithelia can cause local allergic inflammation and
subsequent development of atopic dermatitis and asthma, respectively (Holgate, 2007;
Huston and Liu, 2006; Liu, 2006). However, the systemic consequences of TSLP
overexpression were not clear (Astrakhan et al., 2007; Osborn et al., 2004). In this report
we describe for the first time the mice in which defects in skin differentiation drive
endogenous TSLP expression, beginning before birth. We find that TSLP levels are
directly correlated with the degree of disruption in differentiation. This enabled us to
recognize novel consequence for TSLP elevation unique to fetal/newborn hematopoiesis
and to ascribe TSLP production to failure in skin differentiation rather than its cause, as
high levels of TSLP did not alter skin differentiation in newborn K14-TSLPtg mice.
It has been recognized that TSLP has a differential effect on fetal versus adult Blymphopoiesis (Vosshenrich et al., 2003; Vosshenrich et al., 2004), despite the presence
of fully functional TSLP receptor on both fetal and adult B cells (Carvalho et al., 2001;
Vosshenrich et al., 2003). In addition, in vitro results show that liver-derived fetal pre-B
cell line NAG8/7, but not BM derived adult pre-B cell line IxN/2B, proliferate in
response to TSLP (Isaksen et al., 2002). Consistent with these findings, we demonstrate
that endogenously overexpressed or exogenously supplied TSLP, delivered during the
perinatal period, lead to B-LPD and appearance of substantial number of pre-B cells
(B220+CD43-IgM-) in the periphery, in a dose-dependent manner (Figure 5.14).
Transition from fetal/newborn to adult hematopoiesis occurs during the second week of
life in the mouse BM (Kikuchi and Kondo, 2006). We find that persistently high levels of
TSLP do not produce B-LPD after this transition, explaining why B-LPD has not been
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detected in previous studies (Astrakhan et al., 2007; Osborn et al., 2004). The narrow
window in which TSLP can drive pre-B cell expansion explains why B-LPD in Notchdeficient and K14-TSLPtg animals is (1) confined to the first few weeks of life, (2)
disappears in animals that experience a less sever disease, and (3) does not recur in the
mutant mice after BMT, since adult-type pre-B cells that are reconstituted from the donor
BM, do not proliferate in response to high TSLP levels (Vosshenrich et al., 2004). In
addition, the fact that B-LPD does not recur in the mutant mice after FLT is consistent
with the hypothesis that the niche is instrumental in regulating the response of pre-B cells
to TSLP. This is reminiscent of the critical role the hematopoietic stem cell (HSC) niche
plays in defining the fetal versus adult characteristics of HSCs (Martinez-Agosto et al.,
2007).

Intrinsic skin phenotype and infection cause death in adult mice lacking canonical
Notch signaling.
N1N2CKO or PSDCKO mutant animals transplanted with either wild-type or
mutant BM do not enjoy a normal life span, dying before three months of age. Mice
lacking some Notch alleles or lacking RBP-j do not develop lethal B-LPD, but instead die
prematurely from compromised skin integrity, exfoliation, inflammation and systemic
infection (data not shown). Although antibiotic treatment delays the death of the mutant
animals by controlling their infection, we find a persistent granulocytosis even in
antibiotic-treated mice suggesting that systemic infection and the resulting inflammatory
response are severe and incurable. Infection is the most likely cause of granulocytosis in
the mutant animals; however, it is intriguing to speculate that persistently high levels of
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TSLP also contribute to this blood disease ((Osborn et al., 2004) and Dumortier et al,
personal communication).
TSLP overexpression in Notch-deficient skin is a common keratinocyte response to
skin-barrier formation defect.
Notably, we observe a tight correlation between systemic TSLP levels, WBC
counts, and degree of Notch loss in the neonatal skin. All Notch paralogs contribute to
skin homeostasis and stepwise reduction of Notch dosage leads to progressive skin
perturbation resembling atopic dermatitis (data not shown). However, we find no
evidence arguing for a specific molecular connection between Notch loss and TSLP.
Instead, the tight reverse correlation between the serum TSLP levels and Notch dosage in
the skin highlights the fact that TSLP levels reflect, with a great precision, the magnitude
of the differentiation defects. Thus, TSLP may be a direct readout of defects in
differentiation, a systemic signal that many insults, including Notch loss, activate. To
confirm this, we demonstrate that wild-type and mutant keratinocytes release significant,
but similar, levels of TSLP when placed in culture in absence of any exogenous stimulus
(e.g. TNF"). In addition, wrfr-/- embryos show a substantial increase in epidermal TSLP
transcripts in utero around the time of barrier formation. Therefore, TSLP is a
keratinocytes “quality control” response to defective differentiation/barrier formation and
not a secondary product of functional barrier failure after birth. One model for how the
TSLP “sensor” works may be through the compensatory activation of NF$B. However,
precisely how Notch loss in vivo leads to NF$B activation remains an important
unanswered question that falls beyond the scope of this paper.
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A striking finding is that RBP-jCKO mice show lower TSLP levels, a sublethal BLPD, and improved epidermal morphology when compared to mice lacking total Notch
signaling (Figure 5.20). To differentiate between de-repression of canonical targets and
loss of non-canonical target expression, we performed genetic analysis demonstrating
unequivocally that RBP-j-independent Notch activity is of significance in skin
homeostasis. This points to the importance of RBP-j-independent effects of Notch,
including non-cell autonomous effects on ligand (Delta and Jagged) presenting cells, and
that only when all these arms of Notch signaling are lost, extreme TSLP levels are
reached, causing lethal B-LPD (Figure 5.19). Identification of the relevant non-canonical
targets also falls beyond the scope of this manuscript.
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CONCLUSION
In this report, we identified canonical and non-canonical Notch signaling as
essential regulators of epidermal differentiation/barrier formation, TSLP as a faithful
reporter of keratinocyte differentiation/barrier defects, and B-LPD as the pathological
consequence of chronic, perinatal TSLP elevation. Our analysis was done in a
physiologically relevant setting: chronic skin-barrier formation defect caused by localized
reduction in Notch signaling in a temporal and dose-dependent manner. How
keratinocytes directly sense the degree of differentiation/barrier defect and translate such
a stimulus into TSLP output remains an important, unsolved question. Nonetheless, the
demonstration that defective skin differentiation can drive a lethal systemic B-LPD in
mice through TSLP overexpression and the observation that human B cells also respond
to TSLP (Astrakhan et al., 2007) bring up a therapeutically important possibility that
chronic high levels of TSLP may be an initiating factor in loss of B cell tolerance and/or
B-lymphocytosis, a leukemia-like disease in humans. More important, this raises the
possibility that skin has a central role in driving a wide variety of inflammatory and
humoral diseases in which skin complications are also present.
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EXPERIMENTAL PROCEDURES
Generation of mice
Compound strains of mice were engineered as described (Pan et al., 2004). All animals
were maintained in mixed genetic backgrounds; however, littermates were compared
whenever possible. All mice were kept in the animal facility under Washington
University animal care regulations. In studies related to longevity, mice were monitored
regularly for sign of cachexia and failure to thrive; care was taken to reduce competition
for affected pups by removal of wild-type littermates unnecessary for the study. Severely
affected individuals were left with their dams for their entire life span. Morphological
detail of the cutaneous phenotypes will be published elsewhere. The following cohort of
animals was analyzed: Msx2-Cre/+; N1flox/flox (N1CKO), Msx2-Cre/+; N1flox/flox; N2flox/+
(N1N2hCKO), Msx2-Cre/+; N1flox/flox; N2flox/+; N3-/- (N1N2hN3CKO), N1N2CKO,
PSDCKO,

RBP-jCKO,

PSDRBP-jCKO,

N1N2RBP-jCKO,

RBP-jCKO;IL7r"-/-,

N1N2CKO;IL7r"-/-, PSDCKO;TSLPR-/-, Prx1-Cre/+; PS1flox/flox; PS2-/-, Msx2-Cre/+;
Rosa26R/+, Msx2-Cre/+; ZEG/+, CD4-Cre/+; ZEG/+, K14-TSLPtg. Wild-type cohorts
in this study included Cre-negative littermates, Msx2-Cre/+; PS1flox/+; PS2-/-, Msx2Cre/+; RBP-jflox/+, and Msx2-Cre/+; Notch1flox/+.

Histology and Imunohistochemistry
For Hematoxylin-and-eosin staining, tissue samples were fixed in 4% paraformaldehyde
in PBS, dehydrated in ethanol, and paraffin-embedded. Tissues blocks were sectioned at
5µm; Lac-Z staining on E15.5 embryo was performed as previously described (Pan et al.,
2004). Immunostaining on paraffin-embedded tissue samples was performed with the
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following biotinylated antibodies: Anti-B220 (clone RA3-6B2, BD Pharmingen, San
Diego, CA), anti-F4/80 (Abcam, Cambridge, UK), anti-CD3e (clone 145-2C11, BD
Pharmingen), and anti-TSLP (R&D Systems). HRP-conjugated streptavidin and DAB
substrate kit (Pierce, Rockford, IL) were used to visualize the signal. For RBP-j staining,
anti-RBP-j antibody (clone T6709, Institute of Immunology Co., Tokyo, Japan) was used
together with biotinylated anti-rat secondary antibody. Sections were counterstained with
Hematoxylin.

Serology
Serum TSLP, IL-6 and IL-7 levels were measured according to manufacturer’s
instructions in the Quantikine mouse TSLP, IL-6 and IL-7 ELISA kits (R&D Systems,
Minneapolis, MN). For comprehensive serum antigen and autoimmune signature
measurements, serum samples were collected, frozen and shipped on dry ice to Rules
Based Medicine Laboratory (Austin, TX).

Antibodies and Flow cytometry
Single cell suspensions from peripheral blood, BM and spleen were prepared for FC
analysis as described(Zhang and Ren, 1998). The following antibodies were used: antiB220 (RA3-6B2) conjugated to fluorescein (FITC), phycoerythrin (PE), or peridinin
chlorophyll-a protein-cyanin 5.5 (PerCP-Cy5.5), anti-CD45 (30-F11) conjugated to
PerCP-Cy5.5, anti-Ly-6G (1A8), anti-TER-119, anti-Thy-1 (5E10), anti-CD3e (500A2),
and anti-CD43 (S7) conjugated to PE, anti-IgM (R6-60.2) conjugated to FITC and PE (all
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from BD Pharmingen). Stained cells were studied using BD FACScan Flowcytometer
(Cytek Development), and the data were analyzed using FlowJo software (Ashland, OR).

Bone marrow transplantation (BMT)
For allogeneic BMT, the immunocompetent recipient mice were lethally irradiated with
950-cGy at ~P10 and transplanted with freshly harvested, unfractionated BM cells from
their littermates as previously described (Zhang and Ren, 1998). However, NOD/SCID
mice received BMT after sublethal dose of irradiation (300-cGy). In each case, 2x106
cells in 100µl PBS+2%FBS were injected into retro-orbital sinus of the irradiated
recipient animal. A cohort of transplanted N1N2CKO mice were orally treated with 50ul
of 200mg/ml of Cephalexin (Ranbaxy Pharmaceuticaks Inc., New Delhi, India) twice
daily.

Disease monitoring
To study disease progression and monitor disease occurrence/recurrence, all mutant and
irradiated/transplanted mice were monitored closely over their life spans for signs of
weakness, weight loss, and morbidity. Blood samples were collected from the mandibular
vein. Hematological analysis [Hemavet 950 analyzer (Drew Scientific Inc., Oxford, CT)]
comprised complete blood count (CBC) including white blood cells (WBC), platelets, red
blood cells, white cell differential counts, and hemoglobin measurements (Lim et al.,
2005). White cell differential counts were confirmed on blood smears. In addition, blood
samples were collected for FC analysis. Moribund mice were sacrificed and peripheral
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blood, BM, lymph nodes, thymus, lung, liver and spleen were collected for a
comprehensive pathological analysis as described previously (Qyang et al., 2004).

TSLP injection
Wild-type mice were injected intravascularly with carrier alone (50µl PBS) or with
carrier containing 0.5, 1, or 1.5µg of recombinant mouse TSLP (R&D Systems) daily for
7 days starting on P0, P7, or P14. Mice were sacrificed 12hr after the last injection and
tissues were collected for analysis. An ELISA assay of serum measured the systemic
TSLP level. CBC and FC analyses on BM, blood, and spleen were performed to check
for any sign of B-LPD.

Barrier function assay
To test barrier function defect, dye penetration assay was performed as previously
outlined(Hardman et al., 1998). Briefly, intact E18.5 embryos were stained in X-gal (pH
4.5) for 12hr at 37°C. After X-gal staining and three rounds of PBS wash, the embryos
were photographed with a digital camera.

Keratinocyte culture
Primary keratinocytes were isolated from the dorsal midline skin of newborn mutant and
wild-type littermates. The cells were maintained in 60-mm2 dishes with medium of low
calcium concentration as previously described (Missero et al., 1996). Keratinocytes were
plated at 40% confluence and allowed to double. Confluent plates (80%) were treated
with 2.5, 5 or 10µM 'F$( in

(BAY 11-7082) or carrier alone (DMSO).
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24hr later, cells were re-fed with inhibitor/DMSO containing fresh medium with or
without 2mM CaCl2 to induce differentiation. After 24hr, cells and their media were
harvested for analysis.

Immunoblotting
Keratinocyte lysates in SDS were immunoblotted to check for PS1 (H-70, Santa Cruz
Biotechnology, Santa Cruz, California) and "-tubulin (B-5-2, Sigma-Aldrich, Saint
Louis, MO) as described (Lee et al., 2007).

Nile Red stain
frozen skin sections, 7µm, were stained with 0.15 mg/ml Nile Red in 75% glycerol for
2min and counterstained with DAPI (Gareus et al., 2007).

PCR and qRT-PCR
Conventional PCR for PS1 alleles was done on genomic DNA of most tissues. For blood,
fresh or frozen blood samples were used directly as template with KlenTaq10 (DNA
Polymerase Technology, St. Louis, MO) supplemented with 1.3M final concentration of
betaine. qRT-PCR was performed as described (Lee et al., 2007). The primer sequences
are provided in the text below.

Microarray
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Detailed description of microarray analyses on skin or epidermal mRNA samples from
P9 Notch-deficient animals, and skin mRNA samples from wrfr-/- embryos are provided
in the text below.

Statistical analysis
The bar graphs present mean + standard deviation of each measured parameter. Student’s
t-test is applied as the test of significance unless otherwise specified.

Sublethal and focal irradiation
In the sublethal irradiation experiments, mutant and wild-type newborns (~P10) received
a sublethal dose of total body irradiation (450-cGy) (Zhang and Ren, 1998). The thymus
or liver of the newborn animals was focally irradiated by delivering 950-cGy of

-

irradiation to a ~20mm2 area of the skin over the respective organ by using a microRT®
radiation device (Stojadinovic et al., 2006). Irradiation was specifically targeted to
thymus or liver. The organ-targeted irradiation did not destroy the host hematopoiesis;
therefore, no post-irradiation BMT was required.

Fetal liver transplantation (FLT)
N1N2CKO, RBP-jCKO and their wild-type littermates (age: P8-P12) were lethally
irradiated with 950-cGy, and injected intravenously with 2x106 fetal liver cells from
E13.5 CD1 wild-type embryos in 100ml PBS+2%FBS.

PCR and qRT-PCR primer sequences
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Primers used

to

amplify

the wild-type and

floxed

ACGTGGCAGGGGCCTCAACTCCTCCAGAGTCAGG-3’

PS1

allele were: 5’and

5’-

TTTTGGTCTCTTTCTGCCCCCTCTCCATTTTCTC-3’; the former primer was used in
conjunction with primer 5’-CTGGCCTTGTCAAGGTTTCCCTCCATCTTGGTTG-3’ to
amplify the Cre-mediated deleted PS1 allele (PS1!#. The primers used to amplify TSLP
were: 5’-CCAGGCTACCCTGAAACTGA-3’ and 5’-TCTGGAGATTGCATGAAGGA3’; the primers used for IL-7 are: 5’-ATCCTTGTTCTGCTGCCTGT-3’ and 5’TGGTTCATTATTCGGGCAAT-3’.

RNA isolation and microarray analyses
For total skin microarray analyses, total dorsal skin RNA was collected from five P9
mice of each genotype (N1CKO, N1N2CKO, PSDCKO and their wild-type littermates)
using QIAGEN RNeasy Mini Kit (QIAGEN Sciences, Valencia, CA). cRNA was
prepared for the hybridization conducted at Rosetta Inpharmatics (Seattle, WA). Both
Resolver microarray suite (MAS) and dChip software <http://www.dchip.org> were used
for analysis and comparisons. 1176 genes (approximately 5% of the genes on the array)
were altered more than 1.5-fold at p <0.0001 in all three the mutant groups we analyzed.
For reverse trend analysis, fold change values were converted to Log10 values, imported
into excel an algorithm scored the data for systematic increase in fold value as Notch
functions diminish. Only 73 genes fit the search criteria.
To monitor transcriptional changes within the epidermis, epidermal microarray
analysis was performed on mRNA samples from dorsal epidermal keratinocytes of three
PSDCKO mice and their wild-type littermates at P9. Keratinocytes were isolated by
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scraping them off frozen skin on dry ice. RNAs purified by using QIAGEN RNeasy Mini
Kit (QIAGEN Sciences) were qualitatively assessed by RNA BioAnalyzer2100 (Agilent,
Palo Alto, CA) and quantified spectrophotometrically in NanoDrop ND-1000 (NanoDrop
Technologies, Wilmington, DE). For each genotype, labeled aRNA derived from 100ng
of total RNA was hybridized to an array of the Illumina Mouse6 expression beadchip
according to Illumina’s protocol. Three samples of each genotype were hybridized to
three arrays at the Microarray Facility at Washington University Genome Sequencing
Center <http://genome.wustl.edu/services/microarray.cgi>. After the arrays were
scanned, image data was de-encrypted using Illumina BeadStudio. Non-normalized
intensity values were imported into Partek Genomics Suite (St. Louis, MO). Data was
first quantile normalized then log2 normalized. ANOVA analysis was used to determine
significant differences between groups, removing the small contribution of litter-to-litter
and chip-to-chip variation. Lipid metabolic enzyme heat map was generated based on a
list of enzymes involved in lipid synthesis pathway (de Guzman Strong et al., 2006),
using SpotfireTM software.
To analyze wrfr-/- RNA, total RNAs were isolated from dorsal skin of wrfr-/- and
wrfr+/- embryos at E15.5 using a tissue homogenizer (Powergen 125) and the RNeasy
Fibrous Tissue Mini kit following the manufacturer’s instructions (Qiagen, Chatsworth,
CA). Tail tips were saved for genotyping by PCR. The purified RNAs were qualitatively
assessed by RNA LabChip (Agilent) and quantified spectrophotometrically in NanoDrop
ND-1000 (NanoDrop Technologies). To make analytical duplicates, equal amounts of
two RNA samples of the same genotype were pooled and split into two tubes. The
preparation of biotin-labeled, antisense cRNA targets and microarray hybridization were
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performed in the Gene Chip Facility in campus (Alvin J. Siteman Cancer Center,
Washington University) using the standard protocols supplied by the manufacturer
(Affymetrix, Santa Clara, CA). Double-stranded cDNAs were generated from 5$g of
total RNA with T7-T24 primers (Genset, Paris, France), Superscript II reverse
transcriptase, E. coli ligase, and E. coli polymerase I (Invitrogen, Carlsbad, CA). Biotinlabeled, antisense cRNA targets were generated from the synthesized cDNAs using the
Enzo BioArray High Yield RNA Transcript Labeling kit (Enzo Biochemical, New York,
NY). Ten micrograms of each biotinylated cRNA preparation were fragmented and
hybridized to the mouse genome array MOE430A2 for 16hr in Hybridization Oven 640.
The data were processed using Affymetrix Microarray Suite (MAS 5.0, Affymetrix Inc.,
Santa Clara, CA) and exported as text files containing both qualitative and quantitative
analyses for each probe set. The cell intensity files were normalized based on total
intensity

using

affy

package

(RMA

method)

from

BioConductor

(http://www.bioconductor.org, Biostatistics Unit of Dana Farber Cancer Institute,
Harvard Medical School/ Harvard School of Public Health) and exported as text files for
numerical analyses. Wrfr embryos with or without gross skin abnormalities (experimental
samples as the numerator) were compared to their heterozygous littermates (control
samples as the denominator). Data from analytical duplicates were analyzed statistically
by multtest package (Resampling-based multiple hypothesis testing, BioConductor) and
those with adjusted p-value less than 0.05 were selected. To treat up- and down-regulated
genes in a similar fashion, the fold changes were indicated in logarithm base 2. To filter
false positives, data with increased fold changes and with absent calls in the experimental
samples or those with decreased fold changes and with absent calls in the control samples
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were eliminated. A cut-off value of 0.59 in logarithm base 2, i.e., 1.5-fold change, was
used to identify genes that show most significant variation in expression. To biologically
annotate genes that show differential expression, GenMAPP was applied to grouping
genes along Gene-Ontology categories or biological pathways (http://www.genmapp.org,
Gladstone Institutes, University of California at San Francisco).
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FIGURES
Figure 5.1

275

Figure 5.1. Notch dosage in the skin, the animals’ life span, and WBC count are tightly
correlated. (A) Chimeric pattern of Msx2-Cre activity is shown on the left by X-gal
staining of an E15.5 Msx2-Cre/+; Rosa26R/+ embryo (also see ref. (Lee et al., 2007; Pan
et al., 2004)). On the right, the dorsal patch of hair loss in P9 Msx2-Cre/+; PS1flox/flox;
PS2-/- (PSDCKO) mice (border is highlighted by red broken line) matches the area of Cre
activity. Progressive (B) shortening of life span and (C) increase in peak WBC count
measured during the second week of life are caused by stepwise removal of Notch
proteins, RBP-j, Presenilins, or certain combinations of those. Abbreviations: wild type
(Wt), Msx2-Cre/+; N1flox/flox (N1CKO), Msx2-Cre/+; N1flox/flox; N2flox/+ (N1N2hCKO),
Msx2-Cre/+; N1flox/flox; N2flox/+; N3-/- (N1N2hN3CKO), Msx2-Cre/+; N1flox/flox; N2flox/flox
(N1N2CKO),

PSDCKO,

Msx2-Cre/+;

RBP-jflox/flox

(RBP-jCKO),

Msx2-Cre/+;

PS1flox/flox; PS2-/-; RBP-jflox/flox; (PSDRBP-jCKO), and Msx2-Cre/+; N1flox/flox; N2flox/flox;
RBP-jflox/flox (N1N2RBP-jCKO). Note that N1N2CKO, PSDCKO, PSDRBP-jCKO, and
N1N2RBP-jCKO animals live only a few weeks and experience a severe leukocytosis.
Data are collected from lifelong monitoring of 10 to 20 animals from each genotype.
Significant difference (p <0.05) between adjacent genotypes is highlighted by an asterisk.
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Figure 5.2
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Figure 5.2. Mice lacking total Notch signaling in the skin develop severe B-LPD. (A)
Table shows the peripheral blood analysis of the mutant mice during the second week of
life when WBC counts are at their maximum (n = 6, for each group). The values are
presented as mean + standard deviation (a, p <0.001 and b, p <0.05 (compared to wildtype control)). (B) Macroscopic examination of a P14 mutant (N1N2CKO) compared to
its wild-type littermate reveals the mutant’s smaller body size, yet significantly larger
spleen and lymph nodes. (C) Peripheral blood smear (Giemsa-stained; 250X
magnification) and FC analysis show the appearance of lymphoblasts (inset) and the
expansion of B220+ B cells in the mutant blood, respectively. (D) Monitoring the mutant
animals’ WBC counts over their life span (n = 10 for each genotype) demonstrates a
surge during the first two weeks and plateau during the third week of life, when most
mutants die (asterisk). Note the trend of WBC counts toward normalization in a few mice
that live a few days longer. Severe B-LPD leads to infiltration of liver, lung and spleen of
the mutant animals with B220+ B cells shown on (E) H&E-stained tissue sections and (F)
antibody-stained liver sections (200X magnification).
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Figure 5.3
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Figure 5.3. RBP-jCKO keratinocytes lack RBP-j protein. "-RBP-j antibody staining of
the P0 dorsal skin from wild-type and RBP-jCKO mice confirms the absence of RBP-j
protein in RBP-jCKO keratinocytes at birth (200X magnification). Arrowheads refer to,
black: basal layer of the epidermis, green: hair follicle and red: dermal fibroblasts.
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Figure 5.4
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Figure 5.4. Phenotypes of Notch-deficient mice before and after BMT. (A) B220+ Blymphocytes infiltrate vital organs of P14 mutant animal (200X magnification). Note that
B-lymphocytes have filled the bone marrow, interfering with normal hematopoiesis and
contributing to the anemia and thrombocytopenia in mutant animals. (B) Substantial
cryoglobulin formation is detected in the mutant serum after incubating the sera at 4°C
for 48hr. (C) Dorsal and ventral views of BMT-rescued animals show that PSDCKO
mice have a faster progressing skin disease than N1N2CKO mice. Due in part to this skin
phenotype, BMT-rescued PSDCKO mice have a shorter life span than N1N2CKO mice,
reaching the terminal stage at P40.
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Figure 5.5
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Figure 5.5. Expanding pre- and immature B cells cause B-LPD in the mutant animals.
(A) Schematic representation of how surface markers applied (B220, CD43 and IgM)
identify pro-, pre- and immature B cells. (B) FC analyses of BM and spleen cells
demonstrate a clear expansion of pre- (red circle) and immature (blue circle) B cells in
both central and peripheral compartments of the mutant animals. More than three mice
from each genotype (PSDCKO, N1N2CKO and wild-type littermates) are analyzed.
Representative plots are shown.
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Figure 5.6
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Figure 5.6. BMT cures the lethal B-LPD in the mutant animals and confirms the local
deletion of Notch pathway in the skin as the sole driver of B-LPD. (A) Both PSDCKO
and N1N2CKO mice, lethally irradiated and transplanted with BM from their wild-type
(n = 4) or mutant (n = 3) littermates (at ~P10), live significantly longer than their
untransplanted mutant counterparts (n = 20; p <0.001, log rank test). In N1N2CKO
group, three mice that are transplanted with wild-type BM, also receive daily antibiotic
treatment after BMT, leading to their significantly longer life span compared to other
transplanted mutants (p <0.001, log rank test). B-LPD does not recur in the transplanted
mutant animals shown by (B) their persistently low WBC count during their post BMT
life (data are drawn from 4 animals in each genetic group) and (C) on average lower
B220+ B cell percentage in their blood as compared to the wild-type recipients, measured
25 days after transplantation (4 PSDCKO and 4 wild-type littermates are compared).
Note that at this stage the transplanted PSDCKO animals develop granulocytosis with
significantly higher granulocyte/monocyte percentage (*, p <0.05). (D) Msx2-Cremediated PS1 gene deletion (PS1!) is only detectable in the skin of the PSDCKO
animals. The data are representative of three independent tests. DNA samples are
prepared from PSDCKO animals with WBC count >100,000 cells/µl. BM samples are
unfractionated and include BM stroma. (E) Wild-type mice (~P10) receiving BMT from
their mutant (n = 12, both N1N2CKO and PSDCKO are included) or wild-type (n = 12)
littermates reconstitute normal hematopoiesis and have normal life span without
developing B-LPD.
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Figure 5.7
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Figure 5.7. FC analysis on peripheral blood samples from N1N2CKO and RBP-jCKO
mice. Comparing the profiles obtained at P12 with those seen at P78 demonstrates the
transition from B-LPD (P12) to granulocytosis (P78) relative to wild-type controls. Blymphocytes, T-lymphocytes and granulocytes/monocytes percentages are shown in
blood. Note that to allow N1N2CKO animal to reach P78, this individual has undergone
BMT at P10 and has been receiving daily antibiotic treatment.
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Figure 5.8
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Figure 5.8. Delay in B-LPD surge increased life span of the mutant mice. (A) Either
sublethal dose of total body irradiation (~450-cGy) or focal irradiation of liver or thymus
significantly extended life span of N1N2CKO and PSDCKO mice (n = 3 per genotype
for each treatment group; p <0.01, log rank test). Note that N1N2CKO mice live longer
than PSDCKO mice, most likely due to milder skin phenotype. (B) Monitoring WBC
count shows that B-LPD, although delayed, surge in N1N2CKO and PSDCKO mice
receiving sublethal or focal irradiation.
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Figure 5.9
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Figure 5.9. Documenting the success of BMT by genotyping. DNA from peripheral
blood of recipient animals analyzed for the presence of PS1 alleles 25 days after BMT
confirms repopulation of the recipients’ hematopoietic system by donor-derived BM cells
both in rescue (A) and disease propagation (B) experiments. Since there is no Cre activity
in the hematopoietic system, the difference between homozygous (one band) or
heterozygous (two bands) is detected. Controls for the various genotypes are shown in B.
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Figure 5.10
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Figure 5.10. NOD/SCID mice that receive BM from the mutant animals do not develop
B-LPD. (A) NOD/SCID mice receiving BM from mutant or wild-type newborn donors
are indistinguishable over 2 months of follow-up. (B) The percentage of B220+ B-cell in
mice receiving BM from mutant or wild-type donors is not significantly different. (C)
Genotyping for PS1 alleles in peripheral blood from NOD/SCID mice 25 days after BMT
shows that most of their WBCs are derived from the donor BM.
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Figure 5.11
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Figure 5.11. TSLP is highly expressed in the skin lacking total Notch signaling, leading
to its high systemic levels. Such elevated serum levels inversely correlate with Notch
dosage in the skin. (A) Modified trend analysis performed on microarray data from P9
mutant and wild-type total-skin RNA samples identifies TSLP as the most up-regulated
cytokine gene in the mutants. The epidermal overexpression of TSLP in the mutant mice
is confirmed by qRT-PCR. (B) TSLP is mainly produced by suprabasal keratinocytes in
the mutant epidermis (200X magnification). (C) Unlike IL-6 and IL-7, TSLP serum
protein levels measured on ELISA are highly elevated in the mutant animals. (D) Serum
analyses during the second week of life show that TSLP levels increase as more alleles of
Notch are removed from the skin. Data are extracted from comparing three mutant (of
each genotype) and three wild-type littermates (*, p <0.05, **, p <0.01, ***, p <0.0001).
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Figure 5.12
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Figure 5.12. Trend analysis of microarray data. Cytokines/chemokines that are up- or
down-regulated in P9 mutant vs. wild-type skin mRNA samples are enriched by this
analysis. Note absence of TNF".
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Figure 5.13
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Figure 5.13. TSLP Immunostaining of P5 dorsal skin. PSDCKO mice produce TSLP in
supra-basal keratinocytes whereas wild-type mice do not (dash lines demarcate the
basement membrane; 200X magnification). For immunoflorescence, Cy-3-conjugated
streptavidin is used to detect biotinylated "-TSLP, and sections are counterstained with
DAPI nuclear stain.

300

Figure 5.14
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Figure 5.14. Tight correlation between serum TSLP levels and WBC counts in the
newborn mice. Comparing (A) the serum TSLP levels and (B) WBC counts of all animal
cohorts examined in this study (compiled from the data shown in figure 5.1, 5.11 and
5.15) reveals a tight correlation between the systemic TSLP elevation and WBC count
increase in newborn mice. The measurements are obtained from mutant mice in the
second week of life and from TSLP treated wild-type animals at P8 (n = 3, for each
group; significant difference between adjacent genotypes is highlighted: *, p <0.05, **, p
<0.01).
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Figure 5.15
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Figure 5.15. TSLP is sufficient to drive B-LPD in newborn animals. (A) Wild-type mice
injected intravascularly with carrier alone (PBS), 0.5µg, 1µg or 1.5µg recombinant
mouse TSLP daily for 7 days show dose-dependent increase in serum TSLP levels and
WBC counts (measured 12hr after the last dosing) only if the treatment starts at P0. The
impact of elevated serum TSLP on WBC count is diminished or absent when the
treatment starts on P7 or P14, respectively (n = 3, for each condition; *, p <0.05 and **, p
<0.01). (B and C) FC analysis on peripheral blood from mice receiving 1µg TSLP daily
for 7 days starting at P0, confirms that the increase in WBC count is because of the
expansion of pre- (red circles) and immature B cells in the periphery, identical to N1CKO
newborns that have similar serum TSLP levels and WBC counts (n = 3, for each group;
*, p <0.05). (D) K14-TSLPtg mice phenocopy the neonatal BLPD in RBP-jCKO animals;
they have highly elevated serum TSLP levels at several time points during the first two
weeks of life (averaged as pup). Adult animals (>P21) also have elevated TSLP in their
serum, but to a lesser degree than in the pups. (E, F) In addition, K14-TSLPtg mice have
high WBC counts due to B-LPD during the first few weeks of life (*, p <0.05). (G) FC
analysis identifies the expanding population of cells causing B-LPD as pre- (red circle)
and immature B cells. TSLP measurements and FC analyses are performed on three K14TSLPtg mice and three wild-type littermates. WBC counts are obtained from six mice in
each group.
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Figure 5.16. Fetal liver transplantation (FLT) cures B-LPD in Notch-deficient animals.
(A) Monitoring the WBC counts of the transplanted mice shows no B-LPD recurrence in
the mutant animals post FLT (n = 3, for each group). (B) DNA from peripheral blood of
transplanted N1N2CKO animals, analyzed for the presence of Notch1 alleles 25 days
after FLT, confirms the repopulation of the recipients’ hematopoietic system by donorderived fetal liver cells. (C) FC analysis on peripheral blood from transplanted
N1N2CKO, RBP-jCKO and wild-type mice collected 25 days after FLT shows no sign of
B cell expansion in the mutant animals. (D) As with BMT, curing the lethal B-LPD in
N1N2CKO animals by FLT (n = 3) leads to a relative extension in life span compared to
untransplanted N1N2CKO mice (n = 20; p <0.001, log rank test).
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Figure 5.17
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Figure 5.17. TSLP is required for B-LPD occurrence in Notch-deficient animals. TSLP
binds to a heterodimeric receptor that shares one of its subunits (IL-7r") with IL-7
receptor. Inhibiting TSLP effects by removing either TSLPR (TSLPR-/-) or IL-7r" (IL7r"/-

) subunit of TSLP receptor leads to disappearance of B-LPD in the mutant mice. (A)

WBC counts of RBP-j-deficient animals lacking IL-7r" (Msx2-Cre/+; RBP-jflox/flox; IL7r"-/- or RBP-jCKO;IL7r"-/-) are within the normal range at P14. Data are complied
from 4 animals in each group. (B) FC analysis on peripheral blood shows no signs of BLPD in RBP-jCKO;IL7r"-/- mice compared to their Msx2-Cre/+; RBP-jflox/flox; IL-7R"+/(RBP-jCKO) littermates at P14. The representative FC results are shown with B220+ B
cell percentage (red) in the upper right corner of each dot plot. IL-7r"-/-%&% and wild type
littermates are also analyzed as controls. Note that WBC counts and B cell percentage of
RBP-jCKO;IL7r"-/- and IL-7r"-/-%&% mice are lower than wild-type (IL-7r"+/-&%) littermates.
This may be due to a simultaneous inhibition of IL-7 reception and reduction in baseline
B and T cells especially in adulthood. (C) WBC counts of N1N2CKO animals lacking
IL-7r" (Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox; IL-7r"-/- or N1N2CKO;IL7r"-/-) are
normal at P14 (n = 4 for each group). (D) Similar normalization of WBC counts is seen
with PSDCKO animals that have lost TSLPR arm of TSLP receptor (Msx2-Cre/+;
PS1flox/flox; PS2flox/flox; TSLPR-/- or PS1PS2CKO;TSLPR-/-, n = 4 for each group). (E, F)
B-LPD prevention leads to increased life span among (E) N1N2CKO;IL7r"-/- and (F)
PS1PS2CKO;TSLPR-/- animals compared to their N1N2CKO and PSDCKO littermates,
respectively (p <0.001, log rank test).
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Figure 5.18
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Figure 5.18. Skin-barrier defect explains how loss of Notch signaling in the skin leads to
elevated TSLP production. (A) P0 PSDCKO dorsal skin shows a severe epidermal
differentiation defect (loss of spinous and granular layers) compared to Wt littermate
(200X magnification). (B) Heat map of microarray data on P9 epidermal RNA shows
down-regulation (green) of genes involved in epidermal lipid biogenesis in the mutants
versus their wild-type littermates. Note that TSLP probes are included as a control. (C)
The Nile Red florescent staining of the polar (red) and non-polar (green) lipids in the
epidermis of a P5 PSDCKO mouse demonstrates a deficient lipid coat in !-secretase
deficient (mutant) versus unaffected areas (wild type) of the epidermis(Gareus et al.,
2007). Note the prominent green florescent staining of the sebaceous gland in the wildtype section (arrow), which is absent in the skin lacking Notch signaling(Pan et al.,
2004). (D) Dye penetration assay shows a defect in skin barrier of the mutant animal at
E18.5. (E) Keratinocytes cultured from the mutant (PSDCKO) or wild-type littermates in
presence or absence of calcium, release similar yet significant amount of TSLP into their
medium. However, keratinocytes TSLP production decreases by inhibiting NF$B
signaling (BAY 11-7082: 2.5, 5, 10µM; *: p <0.01) in a dose-dependent manner (data are
accumulated from 3 independent experiments; TSLP levels are presented relative to that
of wild-type cells in absence of calcium and inhibitor). The immunoblot panel confirms
that the mutant keratinocyte are deficient in PS1 protein. (F) wrfr-/- embryos show a
surge in the skin TSLP expression around the time of skin barrier formation, detected by
microarray. Note that known Notch targets, Hes and Hey proteins, are not altered in wrfr/- mice. TSLP up-regulation translates into its highly elevated serum levels in wrfr-/mice at birth (n = 3; p <0.0001).
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Figure 5.19
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Figure 5.19. Model of the role of Notch signaling pathway in setting up competent skin
barrier and preventing B-LPD in newborn animals. RBP-j-dependent and independent
Notch signaling is required for proper epidermal differentiation and lipid biogenesis in
the skin to form a competent barrier. The RBP-j-independent signals may be non-cell
autonomous. Embryonic loss of Notch signaling leads to aberrant epidermal
differentiation/lipid biogenesis and, therefore, the defective barrier formation. In
response, TSLP is released by keratinocytes that fail to differentiate, triggering a systemic
B-LPD in newborns that results in neonatal lethality at the highest level.
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Figure 5.20
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Figure 5.20. PSDCKO mice have a more severe skin phenotype than RBP-jCKO
counterparts. Cross-sections of the P0 dorsal skin from PSDCKO, RBP-jCKO and wildtype mice show a progressive loss of epidermal differentiation (200X magnification).
PSDCKO skin is most severely affected, with loss of all epidermal layers other than basal
and squamous. A less severe defect is seen in RBP-jCKO skin, correlating with the lower
TSLP levels and improved survival of RBP-jCKO compared to PSDCKO animals.
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TABLES

Table 5.1

Genotype

Weight
(g)

Spleen mass
(g)

Liver mass
(g)

Lymph Nodes

PSDCKO

6.8 + 2.0

0.22 + 0.03

a

0.53 + 0.05

Enlarged

N1N2CKO

6.6 + 2.2

0.20 + 0.03

a

0.56 + 0.04

Enlarged

Wt

10.6 + 0.6

0.08 + 0.02

0.63 + 0.09

Normal

315

Table 5.1. Enlargement of the hematopoietic-related organs in the mutant animals.
Measuring the weight of the animals and their organs at P14 reveals that mutant mice are
smaller than their wild-type littermates, yet have bigger spleen and lymph nodes (n = 3,
for each group). The values are presented as mean + standard deviation (a, p <0.001
(compared to wild-type control)).
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Table 5.2
Gene Symbol
2310034C09Rik
Cxcl2
Tslp
Krt2-6b
Mmp9
Mmp8
Il6
Il6
1190003K14Rik
Ccl3
Adam8
Hsd11b1
Hsd11b1
Hsd11b1
Cxcl1
Clec4e
Reg3g
Gzmb
Olfm4
Prok2
Pla1a
Ms4a6c
Mrc1
Prg4
Krt1-16
Gpr65
Akr1b8
Fpr-rs2
1810033B17Rik
Tcra
Bcl3
LOC545051
Ccl6
Sod3
2410039E07Rik
Lcp2
Tcfec
Ctla2a
Il23a
Mmp12
Serpina3n
Ltb
Slc2a1
Klk1
Bcl2a1d
8430417A20Rik
Il18r1
Trp73
Fcgr2b
Il7r
Msr1
Fabp9
4833411O04Rik
Srms
Cldn8
Slc17a1
Elf5
Slc40a1
Glrb
Ces3
Ogn
Ogn
2310015J09Rik
Tnfrsf13c
Slc6a19
Crym
2310032F03Rik
Bmp8a
Mt4
Tchhl1
4733401L19Rik
Acsm3
Fbp1

Gene Title
RIKEN cDNA 2310034C09 gene
chemokine (C-X-C motif) ligand 2
thymic stromal lymphopoietin
keratin complex 2, basic, gene 6g
matrix metalloproteinase 9
matrix metalloproteinase 8
interleukin 6
interleukin 6
CD177 antigen
chemokine (C-C motif) ligand 3
a disintegrin and metalloprotease domain 8
11 beta-hydroxysteroid dehydrogenase-1
11 beta-hydroxysteroid dehydrogenase-1
11 beta-hydroxysteroid dehydrogenase-1
chemokine (C-X-C motif) ligand 1
C-type lectin domain family 4, member e
regenerating islet-derived 3 gamma
granzyme B
olfactomedin 4
prokineticin 2
phospholipase A1 member A
membrane-spanning 4-domains, subfamily A, member 6C
mannose receptor, C type 1
proteoglycan 4
keratin complex 1, acidic, gene 16
G-protein coupled receptor 25
aldo-keto reductase family 1, member B8
Mus musculus N-formylpeptide receptor-like 2 gene
RIKEN cDNA 1810033B17 gene
2 days neonate thymus thymic cells cDNA, RIKEN full-length enriched library
B-cell leukemia/lymphoma 3
similar to T-cell receptor alpha chain C region
chemokine (C-C motif) ligand 6
superoxide dismutase 3, extracellular
RIKEN cDNA 2410039E07 gene
lymphocyte cytosolic protein 2
transcription factor EC
trophoblast specific protein beta
interleukin 23, alpha subunit p19
matrix metalloproteinase 12
serine (or cysteine) proteinase inhibitor, clade A, member 3N
lymphotoxin B
solute carrier family 2 (facilitated glucose transporter), member 1
kallikrein 9
B-cell leukemia/lymphoma 2 related protein A1a
RIKEN cDNA 8430417A20 gene
interleukin 18 receptor 1
Mus musculus p73 gene, exons 5 through 14 and partial cds.
Mouse beta Fc receptor type II (FCRII) gene, complete cds.
interleukin 7 receptor
macrophage scavenger receptor 1
fatty acid binding protein 9, testis
RIKEN cDNA 2600010E01 gene
src-related kinase lacking C-terminal regulatory tyrosine and N-terminal
myristylation sites
claudin 8
solute carrier family 17 (sodium phosphate), member 1
E74-like factor 5
solute carrier family 40 (iron-regulated transporter), member 1
glycine receptor, beta subunit
carboxylesterase 3
osteoglycin
osteoglycin
RIKEN cDNA 2310015J09 gene
tumor necrosis factor receptor superfamily, member 13c
solute carrier family 6 (neurotransmitter transporter), member 19
crystallin, mu
RIKEN cDNA 2310032F03 gene
3-oxoacid CoA transferase 2A
metallothionein 4
trichohyalin-like 1
RIKEN cDNA 4733401L19 gene
acyl-CoA synthetase medium-chain family member 3
fructose bisphosphatase 1
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Log(Ratio)
N1CKO/Wt

Log(Ratio)
N1N2CKO/Wt

Log(Ratio)
PSDCKO/Wt

0.38
0.335
0.46
0.424
0.461
0.26
0.391
0.346
0.317
0.281
0.484
0.315
0.205
0.193
0.477
0.439
0.416
0.405
0.31
0.228
0.182
0.443
0.469
0.405
0.363
0.458
0.484
0.301
0.434
0.482
0.475
0.458
0.332
0.394
0.252
0.385
0.185
0.327
0.415
0.251
0.376
0.432
0.469
0.194
0.421
0.416
0.358
0.35
0.328
0.351
0.423
-0.359
-0.35

1.688
1.076
1.64
1.557
1.261
1.523
1.43
1.43
1.398
0.998
1.142
1.099
1.099
1.099
1.122
1.123
1.358
0.972
1.384
1.418
0.85
1.055
1.133
0.939
0.898
0.962
0.889
0.992
1.145
0.751
0.788
0.782
0.72
0.79
0.923
0.971
0.873
0.723
0.752
0.976
0.685
0.847
0.753
0.951
0.852
0.528
0.743
0.586
0.982
0.718
0.898
-0.648
-0.672

1.92
1.782
1.662
1.516
1.306
1.29
1.255
1.255
1.254
1.226
1.17
1.075
1.075
1.075
1.064
1.061
1.06
1.055
1.019
1.014
1.003
0.999
0.955
0.955
0.955
0.953
0.94
0.912
0.895
0.893
0.891
0.88
0.879
0.878
0.877
0.864
0.863
0.861
0.86
0.847
0.842
0.841
0.838
0.824
0.823
0.823
0.821
0.821
0.819
0.815
0.81
-0.805
-0.807

-0.202

-0.831

-0.808

-0.347
-0.41
-0.215
-0.343
-0.387
-0.235
-0.189
-0.214
-0.492
-0.353
-0.479
-0.338
-0.41
-0.449
-0.366
-0.498
-0.446
-0.473
-0.343

-0.695
-0.566
-0.627
-0.801
-0.753
-0.52
-0.552
-0.552
-1.156
-0.989
-0.833
-1.043
-0.992
-1.172
-1.118
-1.09
-1.101
-1.396
-1.237

-0.808
-0.823
-0.848
-0.851
-0.865
-0.924
-0.952
-0.952
-1.008
-1.018
-1.05
-1.052
-1.061
-1.068
-1.101
-1.131
-1.19
-1.37
-1.434

Table 5.2. Data for the skin microarray trend analysis shown in Figure 5.10. Values are
shown as log of fold change. Down regulated genes are labeled with a minus sign.
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Table 5.3
A

B
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Table 5.3. Serum analysis of the mutant animals. Comprehensive (A) antigen and (B)
autoimmune analysis on sera collected from P14 mutant (N1N2CKO; n = 3) and wildtype (n = 3) animals does not identify any other factor besides TSLP that could
potentially explain B-LPD in the mutant animals. The antigens with significantly higher
levels in mutant serum are marked (values in red). Note that least detectable dose (LDD)
for each factor is calculated as 3 standard deviation above the average value obtained
measuring 20 blank samples. Therefore, values below LDD are below accurate detection
range. Rules Based Medicine Laboratory (RBM) cutoff values for autoimmune analysis
signify upper limit of normal ratios for each factor measured.
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Table 5.4

p -value

Probe ID

Symbol

Definition

6290093
4150397
2060064
3170427
5340746
2360309
2630372
101510348
2690050
2680441
4760138
105360215
3930707
730193
6450195
1780273
1410309
5220333
6590059
6860050
2450019
70458
2370358
1990500
5550717
106200484
4810181
520164
3360484
730408

Alox12
Asah3
Alox12e
Adh1
Elovl6
Liph
Aloxe3
Alox12
Liph
Scd1
Elovl1
Lipl3
Sgpp1
Ptgs1
Ptgs1
Ptgs1
Smpd1
Elovl4
Lipl2
Elovl3
Elovl1
Lipl2
Tslpr
Tslp
Smpd1
Elovl3
Sult2b1
Smpd3
Sult2b1
Tslp

arachidonate 12-lipoxygenase (Alox12).
N-acylsphingosine amidohydrolase (alkaline ceramidase) 3 (Asah3).
arachidonate lipoxygenase, epidermal (Alox12e).
alcohol dehydrogenase 1 (class I) (Adh1).
ELOVL family member 6, elongation of long chain fatty acids (yeast) (Elovl6).
lipase, member H (Liph).
arachidonate lipoxygenase 3 (Aloxe3).
arachidonate 12-lipoxygenase (Alox12).
lipase, member H (Liph).
stearoyl-Coenzyme A desaturase 1 (Scd1)
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1 (Elovl1).
lipase-like, ab-hydrolase domain containing 3
sphingosine-1-phosphate phosphatase 1 (Sgpp1).
prostaglandin-endoperoxide synthase 1 (Ptgs1).
prostaglandin-endoperoxide synthase 1 (Ptgs1).
prostaglandin-endoperoxide synthase 1 (Ptgs1).
sphingomyelin phosphodiesterase 1, acid lysosomal (Smpd1).
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 4 (Elovl4).
lipase-like, ab-hydrolase domain containing 2
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 (Elovl3).
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 1 (Elovl1).
lipase-like, ab-hydrolase domain containing 2
thymic stromal-derived lymphopoietin, receptor (Tslpr).
thymic stromal lymphopoietin (Tslp).
sphingomyelin phosphodiesterase 1, acid lysosomal (Smpd1).
elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 3 (Elovl3).
sulfotransferase family, cytosolic, 2B, member 1 (Sult2b1).
sphingomyelin phosphodiesterase 3, neutral (Smpd3).
sulfotransferase family, cytosolic, 2B, member 1 (Sult2b1).
thymic stromal lymphopoietin (Tslp).

(PSDCKO/Wt)
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0.000001
0.000001
0.000176
0.001750
0.001571
0.001263
0.001286
0.000002
0.009203
0.017313
0.005893
0.000253
0.000093
0.003103
0.001999
0.021620
0.111435
0.625118
0.814034
0.827319
0.899655
0.629916
0.831755
0.980370
0.841169
0.191433
0.713639
0.491531
0.124677
0.000116

GFoldChange

Log(ratio)

(PSDCKO/Wt) (PSDCKO/Wt)
-19.03
-6.96
-5.75
-3.37
-2.93
-2.55
-2.32
-2.21
-2.19
-2.19
-2.03
-1.91
-1.85
-1.63
-1.46
-1.43
-1.39
-1.07
-1.06
-1.05
-1.03
-1.03
-1.01
1.00
1.04
1.06
1.07
1.16
1.50
19.79

-1.279
-0.843
-0.760
-0.528
-0.467
-0.407
-0.365
-0.345
-0.341
-0.340
-0.308
-0.280
-0.267
-0.213
-0.164
-0.155
-0.142
-0.028
-0.027
-0.022
-0.012
-0.012
-0.004
0.001
0.017
0.025
0.028
0.063
0.177
1.296

Table 5.4. Changes in selected group of lipid metabolic enzymes from PSDCKO and
wild-type epidermal microarray. For comparison, TSLP probes are also included. The
color highlights samples with p <0.005.
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CHAPTER VI

Skin-derived TSLP triggers progression from epidermalbarrier defects to asthma
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SUMMARY
Asthma is a common allergic lung disease frequently affecting individuals with a prior
history of eczema/atopic dermatitis (AD); however, the mechanism underlying the
progression from AD to asthma (the so-called ”atopic march”) is unclear. Here we
demonstrate that, like humans with AD, mice with skin-barrier defects develop AD-like
skin inflammation and are susceptible to allergic asthma. Furthermore, we show that
thymic stromal lymphopoietin (TSLP), overexpressed by skin keratinocytes, is the
systemic driver of this bronchial hyper-responsiveness. As an AD-like model, we used
mice with keratinocyte-specific deletion of RBP-j that sustained high systemic levels of
TSLP. Antigen-induced allergic challenge to the lung airways of RBP-j-deficient animals
resulted in a severe asthmatic phenotype not seen in similarly treated wild-type
littermates. Elimination of TSLP signaling in these animals blocked the atopic march,
demonstrating that high serum TSLP levels were required to sensitize the lung to allergic
inflammation. Furthermore, we analyzed outbred K14-TSLPtg mice that maintained high
systemic levels of TSLP without developing any skin pathology. Importantly, epidermalderived TSLP was sufficient to trigger the atopic march, sensitizing the lung airways to
inhaled allergens in the absence of epicutaneous sensitization. Based on these findings,
we propose that in addition to early treatment of the primary skin-barrier defects,
selective inhibition of systemic TSLP may be the key to blocking the development of
asthma in AD patients.
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INTRODUCTION
Allergic asthma is a chronic lung disease characterized by T-helper2 (Th2)mediated inflammation and airway obstruction in response to allergen exposure (Meyer
et al., 2008). Asthma is an increasingly common disorder affecting more than 300 million
individuals around the world (Masoli et al., 2004). Atopic dermatitis (AD) is another
prevalent allergic disease, and 17% of U.S. children suffer from this disorder (Spergel
and Paller, 2003). Compared to its 4-8% prevalence in the general population, asthma
develops in up to 70% of patients with history of severe AD, a phenomenon referred to as
atopic march (Spergel and Paller, 2003). It may be possible to prevent asthma in these atrisk individuals by early diagnosis of AD and blockage of the atopic march. To achieve
this, it is critical that we understand the mechanism triggering the development of asthma
in AD patients.
Survey of the literature has identified several possible mechanisms underlying the
clinical link between AD and asthma. These include: (a) a systemic immune system
disorder leading to excessive Th2 response at epithelial surfaces exposed to allergens
(Umetsu et al., 2002), (b) a barrier defect shared by both skin and lung epithelia which
leads to overstimulation of the immune cells by invading allergens (Morar et al., 2006),
or (c) systemic consequences of a skin-specific barrier defect causing immune cells to
mount an allergic inflammation at any allergen-exposed epithelial surface (Segre, 2006).
Epidemiological data supporting the third hypothesis include the observation that AD
tends to be the first manifestation of the atopic march (Spergel and Paller, 2003). Another
supportive observation relates to Filaggrin, a skin cornified envelope protein that is
absent from the lung epithelia (Palmer et al., 2006; Ying et al., 2006). Although
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controversial (Rogers et al., 2007), AD patients with filaggrin loss-of-function mutations
seem to exhibit increased incidence of asthma (Marenholz et al., 2006; Palmer et al.,
2007; Weidinger et al., 2008). This is consistent with the third hypothesis that loss of an
epidermal-specific barrier protein can trigger systemic atopy in humans. Mechanistically,
it is suspected that epicutaneous sensitization with allergens underlies the development of
airway hyperreactivity in mice (Spergel et al., 1998) and in humans with filaggrin
mutations (Marenholz et al., 2006; Palmer et al., 2007). However, it is unclear if intrinsic
skin-barrier defects can trigger asthma in the absence of any epicutaneous sensitization. If
epicutaneous exposure is not required, it will imply that systemic factor(s) produced by
AD skin may be involved in sensitizing the bronchial epithelia. Such factors will be
important as therapeutic targets in preventing asthma.
To address this question, we have studied mice lacking Notch signaling in the
skin. Skin keratinocytes are organized in highly interconnected basal, spinous, granular
and cornified layers forming an elaborate barrier protecting the organism from the outside
environment. One of the major molecular regulators of this structure is Notch signaling
(Blanpain et al., 2006; Demehri et al., 2008; Rangarajan et al., 2001). Notch is a
transmembrane receptor interacting with ligands expressed on the surface of neighboring
keratinocytes (Blanpain et al., 2006; Lubman et al., 2004). Upon activation, sequential
proteolysis of Notch releases its intracellular domain, which then translocates into the
nucleus, binds to RBP-j (the DNA-binding partner of Notch), and activates downstream
targets (Lubman et al., 2004). Keratinocyte-specific deletion of Notch signaling pathway
components impairs epidermal differentiation, resulting in skin-barrier defects (Blanpain
et al., 2006; Demehri et al., 2008). We have recently demonstrated that Notch signaling
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loss in the skin also triggers a severe neonatal B-lymphoproliferative disorder (B-LPD;
(Demehri et al., 2008)). This systemic disease is directly caused by elevated levels of
thymic stromal lymphopoietin (TSLP) released into the circulation by Notch-deficient
keratinocytes failing to differentiate (Demehri et al., 2008). TSLP, a general biomarker
for skin-barrier defects (Demehri et al., 2008), is an interleukin-7 (IL-7)-like cytokine
produced by epithelial cells and is implicated in the pathogenesis of both AD and asthma
(Al-Shami et al., 2005; Huston and Liu, 2006; Leonard, 2002; Liu, 2006; Zhou et al.,
2005). TSLP expression is sustained as long as barrier defects persist (Demehri et al.,
2008). Thus, the potentially high systemic availability of skin-derived TSLP and its
central role in promoting asthma brings up the possibility that TSLP may be the factor
predisposing AD patients to Asthma.
Identifying a clear mechanism for the atopic march in the complex network of
genetic, immunological and environmental factors that contribute to AD has been a
challenge to the field and has resulted in much debate as to the right therapeutic approach
to prevent asthma (Segre, 2006). To determine the mechanisms underlying the
progression from AD to asthma, we first generated the animals that lacked Notch
signaling in a portion of their skin surface by embryonic removal of RBP-j from
keratinocytes using Msx2-Cre transgene (Msx2-Cre/+; RBP-jflox/flox or RBP-jCKO).
Msx2-Cre is ectopically expressed at E9.5 in clusters of ectodermal cells, resulting in a
chimeric pattern of RBP-j deletion in the skin (Pan et al., 2004). The presence of
unaffected skin surfaces allowed RBP-jCKO animals to live for ~100 days on average
with a few surviving up to one year (Figure 6.1; (Blanpain et al., 2006; Demehri et al.,
2008)), presenting a model in which to determine if a defective skin-barrier could cause
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AD-like symptoms and render susceptibility to asthma in absence of epicutaneous
sensitization. We found that defective skin-barrier function in adult RBP-j-deficient
animals caused the development of an AD-like allergic inflammation and a subsequent
susceptibility to asthma. To determine if TSLP is required for this susceptibility, we
deleted the TSLP receptor in RBP-jCKO mice and showed that this genetic manipulation
blocked the development of asthma in animals with persistent AD-like pathology and
inflammation. To ask if TSLP overexpression by skin keratinocytes is sufficient, we used
outbred transgenic mice overexpressing TSLP in epidermal keratinocytes and show that
epidermal-derived was sufficient to confer a severe asthmatic phenotype even in the
absence of any skin defect. These findings establish that high systemic availability of
TSLP (Demehri et al., 2008) can sensitize the lung to allergens and provide a novel
molecular mechanism for the atopic march. Serum TSLP is thus an important potential
therapeutic target in preventing asthma in AD patients.
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RESULTS
RBP-jCKO mice develop an AD-like skin phenotype
Ablation of Notch signaling in skin keratinocytes by removing RBP-j severely
impairs the differentiation of basal layer keratinocytes and maintenance of upper spinous
and granular cell layers (Blanpain et al., 2006; Demehri et al., 2008). Such a defect in
epidermal stratification leads to an aberrant skin-barrier function signified by
transepidermal water loss and penetration of dye through the defective barrier in RBP-jdeficient mice at birth (Blanpain et al., 2006; Demehri et al., 2008). After birth, the
persistence of barrier defect in RBP-j-deficient skin is evident by the presence of reactive
epidermal hyperplasia, TSLP overexpression and upregulation of antimicrobial peptides
(Figure 6.2 and Table 6.1 (Aberg et al., 2008; Blanpain et al., 2006; Demehri et al., 2008;
Kuramoto et al., 2002)). Defective skin-barrier function has been suggested to be a
hallmark of atopic dermatitis (AD) (Palmer et al., 2006; Segre, 2006). In agreement with
this notion, the impaired skin-barrier function in RBP-jCKO mice initiated an
inflammatory cascade culminating in development of an AD-like skin phenotype. The
hyperplastic epidermis, acanthosis, hyperkeratosis, parakeratosis, and mast cell
infiltration were evident in RBP-jCKO skin as early as one week after birth, followed by
dramatic dermal mast cell accumulation, serum IgE elevation, and systemic Th2 cell
expansion in adult RBP-j-deficient animals (Figure 6.3A, B and C). Therefore, adult
RBP-jCKO mice resemble humans with AD to a degree that allows us to examine the
systemic consequences of an allergic inflammation in the skin.
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AD-like skin disease predisposes RBP-jCKO animals to allergic asthma
The lungs of 10-week-old mice with RBP-j-deficient skins were normal and did
not show any sign of allergic inflammation under standard housing conditions; however,
the longest living mutant animals (52 weeks) did develop spontaneous lung inflammation
(Figure 6.3D). To determine if this phenotype was a true indicator of increased
susceptibility to an asthmatic phenotype, we utilized an ovalbumin (OVA)-induced
model of allergic inflammation with 5- to 7-week-old RBP-jCKO mice. This protocol
faithfully mimics the development of asthma in humans (Zhou et al., 2005). OVA-treated
RBP-jCKO animals developed a more severe lung inflammation compared to OVAtreated wild-type littermates (Figure 6.4). Although the wild-type animals tolerated the
intranasal OVA challenge well, 2 out of 10 OVA-treated RBP-jCKO mice died during
this procedure following a period of severe labored breathing. In the surviving mutants,
the number of bronchoalveolar lavage (BAL) leukocytes and the percentage of BAL
eosinophils were significantly higher compared to the wild-type littermates (Figure 6.4A
and B). The absolute number of eosinophils was ~7-fold higher in the mutant mice. In
addition, IgE was only detectable in the BAL fluid of RBP-j-deficient animals (Figure
6.4C). Histology of the lungs from OVA-challenged RBP-jCKO and wild-type controls
clearly confirmed the existence of severe airway inflammation in RBP-jCKO mice,
including significant leukocyte infiltration around the airways and blood vessels,
extensive goblet cell hyperplasia in the large airways and distinct appearance of goblet
cells in medium-sized airways (Figure 6.4D). Considering that RBP-j is not deleted in the
lung (Figure 6.5 and 6.6), these data clearly show that the skin-barrier defect can serve as
a primary risk factor for development of asthma in a normal lung.
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TSLP signaling is required for the atopic march in RBP-j-deficient animals
It is possible that atopic skin lesions are the essential component downstream of
skin-barrier defects that initiate systemic atopy in RBP-jCKO mice (Spergel and Paller,
2003). If this hypothesis was true, Th2 cells generated at the site of inflamed skin would
migrate to other sites, including lung mucosa, and release high levels of Th2-derived
cytokines, which would sensitize the lung airways to allergic inflammation. This model,
however, is challenged by findings which demonstrate that Th2 cells generated in mouse
models of AD specifically home to skin (Yoo et al., 2005). In addition, it is unclear
whether the presence of AD lesions is required for initiation of the atopic march (Palmer
et al., 2007). Skin-barrier defects lead to systemic TSLP elevation (Demehri et al., 2008),
which remained elevated in the serum of RBP-jCKO animals throughout life (Figure 6.2).
Based on these observations and that localized TSLP overexpression in lung epithelium is
capable of inducing asthma (Al-Shami et al., 2005; Huston and Liu, 2006; Zhou et al.,
2005), we have articulated an alternative hypothesis: it is possible that TSLP could be a
systemic signal that sensitizes the animals to allergen exposure in the lung. In that case,
high systemic levels of epidermal-derived TSLP should render RBP-jCKO animals
susceptible to the asthmatic phenotype upon exposure to allergen.
To test this hypothesis we deleted IL7R" subunit of TSLP receptor in RBP-jCKO
animals (Msx2-Cre/+; RBP-jflox/flox; IL7r"-/- or RBP-jCKO;IL7r"-/- (Park et al., 2000)).
This strategy was chosen because the TSLPR subunit of the TSLP receptor is linked to
RBP-j locus. The inhibition of TSLP reception reduced the severity of local AD-like
inflammation in the skin of RBP-jCKO animals as judged by the reduction of dermal
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mast cells in RBP-jCKO;IL7r"-/- mice relative to their RBP-jCKO littermates (He et al.,
2008). However, a significant elevation in mast cell number was still detectable in RBPjCKO;IL7r"-/- skin compared to wild type (Figure 6.7A and B). In addition, epidermal
hyperplasia and TSLP overexpression that mark the presence of postnatal skin-barrier
defects persisted in aged RBP-jCKO;IL7r"-/- mice (Figure 6.7A and 6.8). Importantly,
deletion of IL7R" did not affect the intensity of systemic Th2 response to allergic skin
inflammation and serum IgE levels remained elevated in RBP-jCKO;IL7r"-/- mice
(Figure 6.7C and D). This could be due to other cytokines/chemokines made by defective
skin barrier in RBP-jCKO;IL7r"-/- animals (Demehri et al., 2008), which together with
exposure to allergens/pathogens through the compromised skin, sustain a robust systemic
Th2 response even in the absence of TSLP reception (He et al., 2008). Therefore, RBPjCKO;IL7r"-/- animals provide a suitable system in which to determine if skin-barrier
defects and AD-like skin inflammation including a systemic Th2 response with its
consequences (e.g. elevated IgE) could confer susceptibility to asthma in the absence of
TSLP signaling.
We challenged the lung airways of age- and gender-matched RBP-jCKO;IL7r"-/, RBP-jCKO;IL7r"+/- (RBP-jCKO), IL7r"-/-, and wild-type littermates with OVA. To
prevent RBP-jCKO lethality, all the animals in this experiment received intranasal OVA
challenge only twice. Despite this reduced exposure, RBP-jCKO animals developed a
severe asthmatic response, which was absent in RBP-jCKO;IL7r"-/- mice (Figure 6.7EH). Histological analysis could not detect goblet cell hyperplasia or significant
inflammation around the airways and vasculature in RBP-jCKO;IL7r"-/- lungs (Figure
6.7E). Total white blood cell count and eosinophilia in BAL fluid from OVA-treated
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RBP-jCKO;IL7r"-/- mice was indistinguishable from IL7r"-/- littermates (Figure 6.7F
and G). In addition, IgE was undetectable in BAL fluid from OVA-treated RBPjCKO;IL7r -/- mice (Figure 6.7H). These findings show that without a TSLP signal, no
progression from allergic skin inflammation to asthma is observed indicating that atopic
march requires TSLP signals.

Airway hyper-responsiveness in RBP-jCKO mice is blocked by inhibiting TSLP
signaling
Airway hyper-responsiveness is a hallmark of allergic asthma (Zhou et al., 2005).
To determine if skin-derived TSLP could cause airway hyper-responsiveness in RBPjCKO mice, we used the OVA-induced model of allergic inflammation and challenged
the lung airways of age- and gender-matched RBP-jCKO;IL7r"-/-, RBP-jCKO, IL7r"-/-,
and wild-type littermates twice with OVA. Thereafter, we measured the total lung
resistance of OVA-treated mice at basal state (vehicle alone) or in response to increasing
doses of nebulized methacholine. As expected, OVA-treated RBP-jCKO mice mounted a
severe airway resistance compared to their wild-type littermates when exposed to low
doses of methacholine, and could not tolerate the higher doses of methacholine (Figure
6.9). RBP-jCKO;IL7r"-/-, however, did not develop any significant airway resistance
even when exposed to high doses of methacholine (Figure 6.9). These results confirm
that skin-barrier defects predispose animals to asthmatic phenotypes and that TSLP is
required for this predisposition.
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TSLP overexpression by the skin is sufficient to trigger the atopic march
Although we demonstrate that TSLP signaling is necessary for the development
of asthma in RBP-j-deficient animals with chronic allergic skin inflammation, it remains
unclear whether or not other factors associated with AD-like skin lesions contribute to
this atopic march. TSLP overexpression in mouse skin leads to an AD-like pathology on
an inbred background (Yoo et al., 2005). However, we discovered that on an outbred
background, the same K14-TSLPtg mice (Demehri et al., 2008) maintained high serum
TSLP levels under normal conditions (~450 pg/ml) without any skin or lung
inflammation (Figure 6.10 and 6.11; (Whitehead et al., 2003)). Normal skin morphology
and the lack of mast cell hyperplasia evident in K14-TSLPtg mice demonstrated that in
this outbred background and in the absence of skin-barrier defects, TSLP overproduction
was insufficient to attract mast cells to the skin (Figure 6.10B). In addition, serum IgE
levels and Th2 cell numbers in the peripheral lymph nodes of K14-TSLPtg mice were
indistinguishable from the wild type, confirming the absence of allergic skin
inflammation in K14-TSLPtg animals that were not exposed to any external stimulus (e.g.
allergen exposure; Figure 6.10C and D). Therefore, outbred K14-TSLPtg mice constituted
a suitable model in which to examine whether epidermal TSLP overexpression alone
would increase susceptibility to asthma upon allergen exposure.
Next, we sensitized and challenged the lung airways of 5- to 7-week old K14TSLPtg mice and their age- and gender-matched wild-type littermates three times with
allergen. As seen in OVA-treated RBP-jCKO animals exposed to three doses of
intranasal OVA, K14-TSLPtg mice developed a severe asthmatic response and significant
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lethality, which were not seen in the control group (Figure 6.12). Two out of 8 OVAtreated transgenic mice died during the intranasal challenge. Histological examination of
lungs from surviving K14-TSLPtg animals revealed pronounced airway remodeling with
goblet cell hyperplasia and inflammation around the lung airways and vasculature (Figure
6.12A), which were negative for TSLP expression (Figure 6.6 and 6.13). Total leukocyte
count was >5-fold higher in BAL fluid from K14-TSLPtg mice compared to similarly
treated wild-type animals (Figure 6.12B), which was mainly due to a severe BAL fluid
eosinophilia in the transgenic animals (Figure 6.12C). In addition, IgE reached detectable
levels only in BAL fluid from OVA-treated K14-TSLPtg mice (Figure 6.12D), which also
experienced significantly higher serum IgE levels (Figure 6.12E, 1.6µg/ml versus
0.18µg/ml in OVA-treated wild-type serum, p <0.05). Thus, K14-TSLPtg mice developed
an intense Th2 response upon allergen exposure. In airway reactivity test, OVA-treated
K14-TSLPtg mice showed a severe airway hyper-responsiveness to low doses of
nebulized methacholine, which was not seen among similarly treated wild-type
littermates (Figure 6.12F).
Even though outbred K14-TSLPtg animals developed a severe asthmatic
phenotype, their skin retained its normal appearance after OVA treatment, confirming
that the lung inflammation did not depend on a concurrent skin lesion (Figure 6.14).
Although low levels of TSLP are expressed in the trachea, the K14-TSLP transgene is not
expressed in the lung of K14-TSLPtg animals (Figure 6.6 and 6.13). Therefore, these
observations are most consistent with a model in which systemic TSLP is sufficient to
predispose mice to allergic lung inflammation.
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DISCUSSION
This report uncovers the mechanism that mediates the progression of a local
allergic skin disease to a disseminated allergic inflammation downstream of skin-barrier
defects in mice. We show that creating an intrinsic skin-barrier defect (by removing
Notch signaling specifically from some skin keratinocytes) results in the sensitization of
the lung airways to allergens. Similar to the clinical cases, barrier-defective mice require
a secondary insult by allergens to expose their predisposition to asthma. Importantly, we
show that epicutaneous sensitization with a common allergen (Spergel and Paller, 2003)
is not required to achieve this pronounced lung hyper-responsiveness. Therefore, RBPjCKO animals demonstrate that skin-barrier impairment provides a signal that promotes
development of a distant atopy in the lung, most likely by a systemic, diffusible cytokine.
We identified this signal to be TSLP, a central player in the early stages of allergic
inflammation (Al-Shami et al., 2005; Liu, 2006; Zhou et al., 2005) and a barrier-defectsensitive product of skin keratinocytes that is released prior to development of an ADlike skin lesion (Demehri et al., 2008). In contrast to TSLP overexpression by lung
epithelia, which does not result in systemic accumulation of this cytokine (Zhou et al.,
2005), we have shown that overexpression of TSLP in the skin results in high systemic
availability (Demehri et al., 2008). Therefore, skin is capable of acting as a signaling
organ, driving susceptibility to allergic inflammation in another barrier organ (i.e. lung)
by releasing TSLP.
Importantly, we were able to demonstrate that TSLP was necessary to predispose
RBP-j-deficient animals to the asthmatic phenotype. Concomitant removal of IL7R"
subunit of the TSLP receptor in RBP-jCKO mice prevented the atopic march despite
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persistent AD-like pathology and elevated serum IgE levels. Complementing this
experiment is the demonstration that overexpression of TSLP by skin keratinocytes leads
to high serum levels of TSLP that are sufficient to sensitize the lung airways to allergic
inflammation in the absence of any skin pathology. If the low levels of TSLP in the
trachea of K14-TSLPtg mice contribute to the phenotype, they do so by adding to the
already high levels of skin-derived serum TSLP. Because TSLP can activate dendritic
cells (Liu et al., 2007), T cells (Rochman et al., 2007; Rochman and Leonard, 2008), and
myeloid cells (Reche et al., 2001), we speculate that its high systemic levels directly
prime these immune cells at distant sites (e.g. the lung) to mount an intense allergic
inflammation in response to a second stimulatory signal (e.g. allergens in the lung
airways); however, the specific contribution of these immune cells to the atopic march
downstream of TSLP-mediated activation remains a subject for future investigation. Of
note, elevated TSLP expression is also reported in psoriatic skin (Guttman-Yassky et al.,
2007); however, there is no evidence linking psoriasis to predisposition to asthma. This
phenomenon could be explained by the dominance of Th1 response in patients with
psoriasis and the unresponsiveness of their immune cells to TSLP (Guttman-Yassky et
al., 2007).
The findings outlined in this report have a potentially important implication for
human health. They provide a plausible explanation why a large number of AD patients
develop asthma and other allergic disorders later in life (Galli et al., 2007; Pourpak et al.,
2008). Because TSLP overproduction is triggered by skin-barrier defects and faithfully
mirrors the severity of these defects (Demehri et al., 2008), our data emphasizes that an
early and aggressive treatment of the underlying skin-barrier defects in AD-prone
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patients (Marenholz et al., 2006; Palmer et al., 2007) may be more beneficial in
preventing asthma than treating the outbreaks of AD lesions (Segre, 2006). Although
serum TSLP levels in AD patients are yet to be determined, its high expression levels in
human AD lesions (Soumelis et al., 2002) suggests that this diffusible cytokine could also
reach systemic levels sufficient to trigger atopic march in AD patients. If indeed serum
TSLP levels are elevated in AD patients, our findings suggest that an aggressive
management of TSLP levels in these patients will lower the incidence of asthma later in
their life.
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EXPERIMENTAL PROCEDURE
Mice
Msx2-Cre/+; RBP-jflox/flox (RBP-jCKO), Msx2-Cre/+; RBP-jflox/flox; IL7r"-/- (RBPjCKO;IL7r"-/-), and K14-TSLPtg mice were generated as previously described (Demehri
et al., 2008). All animals were kept in mixed C57BL/6 and CD1 outbred genetic
background, which are resistant to Th2-mediated inflammation (Whitehead et al., 2003).
Age- and gender-matched mutant and wild-type littermates were used in each analysis.
All mice were maintained in the animal facility under Washington University animal care
regulations.

OVA treatment
The allergic sensitization and lung airways challenge with OVA was carried as
previously outlined (Zhou et al., 2005). Briefly, wild-type and mutant mice at 5-7 weeks
of age were sensitized on day 0 and 14 by 250µl intraperitoneal injection of antigen
solution containing 50µg OVA (Sigma, St. Louis, MO) dissolved in 1.3mg aluminum
hydroxide gel (Sigma) and PBS. On day 21, 22 and 23, mice were intranasally challenged
with 150µg OVA dissolved in 40µl of PBS. Mice cohorts designated as “Controls”
included the mutant and wild-type animals that underwent the same regimen without
OVA antigen. On day 24, all the animals were sacrificed for the analysis. To avoid
mortality among RBP-jCKO animals, all the age- and gender-matched littermates used in
the rescue experiments presented in Figure 6.7 and 6.9 were challenged only twice with
OVA. Note that RBP-jCKO;IL7r"-/- mice could tolerate the repeated OVA intranasal
challenge, but RBP-jCKO mice developed severe response even after 2 exposures. The
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OVA experiments were conducted on male and female animals; however, within-gender
analyses were performed to avoid any gender effect on phenotypes observed.

Airway reactivity test
The airway responsiveness to aerosolized methacholine was determined in OVA-treated
animals by measuring total lung resistance and dynamic compliance as previously
outlined (Martin et al., 1988). Briefly, mice were treated with OVA as described above
(two intranasal OVA challenge for all mice in rescue experiments (Figure 6.9) and three
intranasal OVA challenge for all mice in sufficiency experiments (K14-TSLPtg and wild
type; Figure 6.12)). The animals were then anesthetized for airway reactivity test on day
24 post OVA sensitization. They were ventilated through a tracheotomy and monitored
for intrapleural pressure using an oroesophageal tube. PBS (vehicle) or Methacholine
(Sigma) in PBS were delivered at 3min intervals using an in-line nebulizer. The
respiratory flow signals were collected between deliveries using pneumotach (SenSym
SCXL004, Buxco Electronics, Sharon, CT) For detailed description of the devise, refer to
(Patel et al., 2006).

Histology
Dorsal skin samples were harvested from the mice and fixed in 4% paraformaldehyde at
4°c overnight. Lungs were inflated through the trachea to 25 cm water pressure with 4%
paraformaldehyde prior to excision from the chest and fixation. These lungs were
paraformaldehyde-fixed for 24hr at 4°c and embedded in paraffin. The paraffinembedded tissues were sectioned at 5-6µm and stained with hematoxylin and eosin
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(H&E), toluidine blue, or periodic acid-Schiff (PAS). For RBP-j immunohistochemical
staining, anti-RBP-j antibody (clone T6709, Institute of Immunology Co., Tokyo, Japan)
and biotinylated anti-rat secondary antibody were used. HRP-conjugated streptavidin and
DAB substrate kit (Pierce, Rockford, IL) were used to visualize the signal. Hematoxylin
was used to counterstain the sections. For TSLP immunostaining, paraffin-embedded
tissue samples and biotinylated anti-TSLP antibody (R&D Systems, Minneapolis, MN)
were used. Sections were counterstained with DAPI nuclear stain.

BAL analyses
BAL fluid was collected by infusing the lungs of the anesthetized mouse with 1ml PBS
through tracheal insertion of a Surflo catheter (Terumo Medical Corp., Elkton, MD).
Leukocyte count in BAL fluid was determined using Hemavet 950 analyzer (Drew
Scientific Inc., Oxford, CT). BAL fluid was spun down and the supernatant was stored
for cytokine/immunoglobulin analysis. The cell pellet was resuspended in PBS and used
for differential cell count after Giemsa staining on the slide.

ELISA
Serum TSLP levels were determined using Quantikine mouse TSLP kit according to
manufacturer’s instructions (R&D Systems, Minneapolis, MN). Serum and BAL fluid
IgE levels were measured using Mouse IgE ELISA kit (Immunology Consultants
Laboratory Inc., Newberg, OR).

Flow cytometry
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Intracellular cytokine staining was conducted to estimate Th2 cell census as previously
described (Yoo et al., 2005). Single cell suspensions were prepared from spleen and
lymph node samples and cultured in presence of PMA (50ng/ml), ionomycin (1µg/ml)
and monensin (10µg/ml) for 4hr. Cells were then stained with phycoerythrin (PE)-cy7
conjugated anti-CD4 antibody (552775, BD Bioscience PharmingenTM, San Diego, CA).
After fixation in 2% paraformaldehyde and permeabilization with 0.5% saponin, cells
were stained with PE conjugated anti-IL4 (554389) and APC conjugated anti-IFN-!
(554412) antibodies from BD Bioscience PharmingenTM (Ong et al., 2008).

PCR
Conventional PCR for RBP-j allele was performed on genomic DNA isolated from skin
and lung of adult RBP-jCKO mice using KlenTaq10 (DNA Polymerase Technology, St.
Louis, MO) supplemented with 1.3M final concentration of betaine (amplification
cycles=32). The following primers were used to distinguish between deleted (RBP-j!) and
(RBP-jflox)

floxed

alleles

of

RBP-j.

TGTTTGCCACCAGAATCTGTTTGTTATTTGC-3’

Deleted

allele:

and

5’5’-

ATTTGCTTGAGGCTTGATGTTCTGTATTGC-3’.
Floxed

allele:

5’-TGTTTGCCACCAGAATCTGTTTGTTATTTGC-3’

and

5’-

AGGTACCTGGTACTAACTGTCTGGGACCG-3’.

qRT-PCR
mRNA isolated from P4 epidermis and lung of RBP-jCKO and wild-type littermates was
used to perform qRT-PCR analysis as previously described (Lee et al., 2007). The
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primers

used

to

amplify

thymic

stromal

lymphopoietin

(TSLP)

were:

5’-

CCAGGCTACCCTGAAACTGA-3’ and 5’-TCTGGAGATTGCATGAAGGA-3’.

Statistical analysis
The quantitative measurements were assessed using Student’s t-test as the test of
significance and presented as mean + standard deviation in bar graph format. Our studies
were conducted in outbred cohorts of animals; therefore, we used nested ANOVA to
exclude any effect of between-family differences and make certain the significant
differences observed were solely attributable to the gene removed (RBP-jCKO and RBPjCKO;IL7r"-/-) or overexpressed (K14-TSLPtg).
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FIGURES
Figure 6.1
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Figure 6.1. RBP-jCKO animals die prematurely (p <0.001 compared to wild-type life
span, log-rank test) due to their severe skin phenotype. However, a few mutant mice that
survive up to one year (red circles) develop spontaneous lung inflammation.
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Figure 6.2

353

Figure 6.2. Serum TSLP levels of RBP-jCKO is highly elevated. TSLP overproduction is
evident in RBP-jCKO serum at 1 week (1wk) after birth, which reaches extreme levels in
the adult animals (n = 4 for each group; *: p <0.01, comparing the mutants to the wildtype littermates).
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Figure 6.3
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Figure 6.3. RBP-jCKO mice lacking RBP-j (and thus, Notch signaling) in skin
keratinocytes develop a progressive, AD-like disease culminating in aged animals with
lung inflammation. (A) H&E and Toluidine blue staining of the skin documents severe
AD-like changes in RBP-j-deficient mice, including epidermal hyperkeratosis,
parakeratosis, acanthosis, skin inflammation and increased number of dermal mast cells
(insets) detectable as early as 1 week after birth (1wk), which worsen as RBP-jCKO
animals age (6wks and 10wks). Note that the keratin cysts formed in the dermis of RBPjCKO mice is due to the destruction of RBP-j-deficient hair follicles (Yamamoto et al.,
2003). (B) The progression of skin inflammation is reflected in RBP-jCKO serum IgE
levels, which are dramatically elevated by 10 weeks of age (10wks; n = 4 for each group;
*: p <0.01). (C) Intracellular cytokine staining of CD4+ T cells isolated from lymph nodes
(mixture of inguinal and axillary) or spleen shows a robust interleukin (IL)-4-positive and
interferon (IFN)-!-negative Th2 cell presence in 10-week-old RBP-jCKO animals,
indicating the development of a full-blown AD-like allergic inflammation. Percentage of
cells in each quadrant is included (representative data are presented). (D) H&E and
periodic acid-Schiff (PAS) staining of the lung do not show any sign of inflammation in
10-week-old RBP-jCKO animals; however, at 52 weeks (1year), the mutant mice develop
lung inflammation. The pathology of RBP-jCKO lung includes immune cell infiltration
around the airways and blood vessels (arrowheads), goblet cell hyperplasia in the airways
(arrow; insets), and airway remodeling (representative pictures are presented. scale bar:
50µm).
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Figure 6.4
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Figure 6.4. 5- to 7-week-old RBP-jCKO mice develop a severe allergic lung
inflammation in an OVA-induced murine model of asthma. (A and B) There are more
leukocytes (A) and a higher percentage of eosinophils (B) present in BAL fluid collected
from OVA-treated RBP-jCKO mice compared to their wild-type littermates (Msx2Cre/+; RBP-jflox/+, RBP-jflox/flox, RBP-jflox/+), indicating a severe airway inflammation in
these mutant animals (M, macrophages; E, eosinophils; L, lymphocytes; N, neutrophils).
(C) IgE reaches detectable levels only in BAL fluid from RBP-j-deficient mice, further
indicating the high intensity of OVA-induced allergic inflammation in RBP-jCKO lung.
(D) Comparing lung histology of RBP-jCKO with wild-type littermates sensitized and
challenged with OVA shows a significantly more intense lung inflammation in RBPjCKO mice. H&E and PAS staining shows greater immune cell infiltration around the
airways and blood vessels (arrowheads), increased airway remodeling, goblet cell
hyperplasia (insets), and mucus overproduction in the mutant lung (representative
pictures are presented. scale bar: 50µm). “Controls” refers to RBP-jCKO and wild-type
animals treated with PBS instead of OVA (n = 4 for each group; *: p <0.05, comparing
the adjacent groups). These data are confirmed in additional independent experiments.
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Figure 6.5

359

Figure 6.5. Lung epithelium is normal in RBP-jCKO animals. (A) PCR analysis of DNA
isolated from adult RBP-jCKO (Msx2-Cre/+; RBP-jflox/flox) and wild-type (RBP-jflox/flox)
skin and lung demonstrates that RBP-j locus is intact (i.e. RBP-j is not deleted) in the
lung (%: deleted allele; M: molecular marker; S: skin; L: lung). (B) Immunohistochemical
analysis for RBP-j protein confirms that RBP-j is present in the lung airway epithelium.
Skin sections stained under the same condition are presented as controls (scale bar:
50µm).
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Figure 6.6
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Figure 6.6. Lung epithelium does not overexpress TSLP in adult K14-TSLPtg, RBPjCKO, or RBP-jCKO;IL7r"-/- animals. Immunofluorescence staining for TSLP protein
(red) confirms that TSLP is only overexpressed in the epidermal keratinocytes of the
mutant mice. All sections are stained under the same condition. Dotted lines outline the
basement membrane and asterisks highlight the epidermal keratin cysts present in RBPjCKO skin (scale bar: 50µm).
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Figure 6.7
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Figure 6.7. TSLP signaling blockade rescues asthmatic phenotype of RBP-jCKO mice.
(A) H&E and Toluidine blue staining of the skin shows the persistence of epidermal
hyperplasia, hyperkeratosis, parakeratosis, and acanthosis in 10-week-old RBPjCKO;IL7r"-/- skin. However, the local skin inflammation and number of dermal mast
cells (insets) are markedly reduced in RBP-jCKO;IL7r"-/- skin (representative pictures
are presented. scale bar: 50µm (He et al., 2008)). (B) The quantitative analysis of mast
cell infiltration in the dermis of RBP-jCKO;IL7r"-/- (R;I) demonstrates that there is still
more mast cell accumulation in RBP-jCKO;IL7r"-/- compared to wild-type (Wt) and
IL7r"-/- (I) skin. The bar graphs show the average number of mast cells in 10 random
100X microscope fields (*: p <0.001). (C) Serum IgE levels of 10-week-old RBPjCKO;IL7r"-/- mice are highly elevated and are comparable to those of RBP-jCKO
(Msx2-Cre/+; RBP-jflox/flox; IL7r"+/-, R) littermates (*: p <0.01). (D) Intracellular
cytokine staining shows a significant population of IL-4-producing Th2 cells in
inguinal/axillary lymph nodes and spleen of 10-week-old RBP-jCKO;IL7r"-/- animals
(representative data are presented). (E) Comparing lung histology of 5- to 7-week-old
RBP-jCKO;IL7r"-/-, RBP-jCKO, IL7r"-/-, and wild-type littermates sensitized and
challenged with OVA shows a complete reversal of the intense RBP-jCKO lung
inflammation in RBP-jCKO;IL7r"-/- mice. H&E and PAS staining shows the muted
inflammatory response around the airways and blood vessels (arrowheads), and lack of
airway remodeling or goblet cell hyperplasia (insets) in RBP-jCKO;IL7r"-/- lung
(representative pictures are presented. scale bar: 50µm). (F and G) The average number
of leukocytes (F) and percentage of eosinophils (G) in BAL fluid from OVA-treated
RBP-jCKO;IL7r"-/- lung is lower than that of wild-type lung treated similarly, indicating
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that deletion of IL7R" rescues the allergic lung inflammation in RBP-jCKO mice (M,
macrophages; E, eosinophils; L, lymphocytes; N, neutrophils). (H) IgE remains below
detection levels in BAL fluid from OVA-treated RBP-jCKO;IL7r"-/- mice, further
confirming that the intense OVA-induced allergic inflammation in RBP-jCKO lung is
absent in RBP-jCKO;IL7r"-/- lung. To avoid death among RBP-jCKO cohort, all the
animals in this study are challenged intranasally with OVA twice. Although the asthmatic
response among RBP-jCKO;IL7r"-/-, IL7r"-/-, and wild-type groups is minimal, a
severe response is seen in RBP-jCKO mice. “Controls” refers to RBP-jCKO;IL7r"-/-,
RBP-jCKO, IL7r"-/-, and wild-type animals treated with PBS instead of OVA (n = 4 for
each group; *: p <0.01, compared to wild-type cohort). These data are confirmed in
additional independent experiments.
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Figure 6.8
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Figure 6.8. Serum TSLP levels of 10-week-old RBP-jCKO;IL7r"-/- mice is highly
elevated, indicating that skin-barrier defects caused by the loss of RBP-j in epidermal
keratinocytes persist in the absence of IL7R" (n = 5 for each group; *: p <0.01). Note that
serum TSLP levels in RBP-jCKO;IL7r"-/- mice is consistently and significantly higher
than RBP-jCKO animals. We are currently investigating the underlying reason for this
surge.
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Figure 6.9
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Figure 6.9. Severe airway hyper-responsiveness among OVA-treated RBP-jCKO mice is
dependent on TSLP signaling. Age- and gender-matched RBP-jCKO;IL7r"-/-, RBPjCKO, IL7r"-/-, and wild-type littermates are sensitized and challenged with OVA as in
Figure 6.7. Airway reactivity at the basal state (vehicle alone; V) and in response to
increasing doses of methacholine (2.5, 5, 10, 20, 40 and 80 mg/ml) is monitored in OVAtreated animals using total lung resistance (RL; n = 4 for each group). OVA-treated RBPjCKO animals mount a severe airway hyper-responsiveness at 5mg/ml of methacholine
and do not tolerate methacholine doses >10mg/ml, developing fatal labored breathing.
OVA-treated RBP-jCKO;IL7r"-/-, IL7r"-/-, and wild-type mice on the other hand show
moderate response only to the highest dose of methacholine (*: p <0.01). Data are
presented as average + standard deviation of percent increase in total lung resistance
compared to basal state (vehicle alone; V) in each group. These measurements are
confirmed in another independent set of experiments.
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Figure 6.10

370

Figure 6.10. K14-TSLPtg mice exhibit no sign of skin or lung allergic inflammation under
normal conditions. (A) Skin-derived TSLP overexpression leads to high systemic TSLP
levels in the serum of K14-TSLPtg mice (n = 10 for each group; *: p <0.01). (B, C and D)
Under normal conditions, skin TSLP overproduction on an outbred C57BL/6-CD1
background does not elicit any allergic inflammation in K14-TSLPtg mice. Note the
normal skin histology (B), normal serum IgE levels (n = 10 in each group) (C), and
normal number of peripheral IL-4-producing Th2 cells (D) in K14-TSLPtg mice at
postnatal day 120 (P120). (E) H&E and PAS stained lung sections of K14-TSLPtg animals
confirm that no inflammation or airway remodeling occurred at P120 (scale bar: 50µm).
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Figure 6.11
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Figure 6.11. The ear and skin of K14-TSLPtg mice appear normal at P120. This
emphasizes that in an outbred genetic background (C57BL/6 and CD1 mix) these
transgenic animals do not develop any skin inflammation under normal conditions.
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Figure 6.12
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Figure 6.12. OVA treatment reveals that K14-TSLPtg mice are prone to asthmatic
phenotype. (A) Histological analysis demonstrates severe inflammatory cell infiltrates
(arrowheads), airway remodeling, and goblet cell hyperplasia (arrow; insets) in the lung
airways of 5- to 7-week-old K14-TSLPtg animals that are sensitized and challenged with
OVA but not in similarly treated wild-type littermates (scale bar: 50µm). (B, C and D)
BAL fluid analysis shows more leukocytes (B), a higher percentage of eosinophils (C),
and specific appearance of IgE in lung airways of OVA-treated K14-TSLPtg mice (D),
confirming the higher intensity of the asthmatic phenotype conferred by the TSLP
overexpression in the morphologically normal skin (M, macrophages; E, eosinophils; L,
lymphocytes; N, neutrophils). (E) The severe allergic inflammation in OVA-treated K14TSLPtg lungs leads to drastic elevation of serum IgE in the animals. “Controls” refers to
K14-TSLPtg and wild-type mice treated with PBS alone (n = 4 for each group; *: p <0.05,
comparing the adjacent groups). (F) Total lung resistance (RL) measurements show that
OVA-treated K14-TSLPtg lung airways are hyper-responsive to increasing doses of
nebulized methacholine as compared to OVA-treated wild types (V: vehicle only basal
measurement; n = 4 for each group; *: p <0.05). These findings are confirmed in
additional independent experiments.
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Figure 6.13
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Figure 6.13. Since K14 is expressed in basal cells located in the lung trachea, we
analyzed mRNA levels by qRT-PCR on samples isolated from epidermis, trachea and
lung of K14-TSLPtg and wild-type mice. The analysis demonstrates that there is no TSLP
overexpression detectable in K14-TSLPtg lung airways or parenchyma. The K14-TSLP
transgene is active in basal cells within the trachea, but the overall levels are 200 fold
lower than those made by epidermal keratinocytes (***: p <0.0000001 and *: p <0.01
compared to wild type).
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Figure 6.14
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Figure 6.14. The skin of OVA-treated K14-TSLPtg mice remains normal. H&E and
toluidine blue staining of K14-TSLPtg and wild-type skin show no significant sign of
cutaneous inflammation in the transgenic mice (scale bar: 50µm).
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TABLES

Table 6.1

Fold Increase
(RBP-jCKO/Wt)

Gene Symbol

Gene Title

S100a8

Mus musculus S100 calcium binding protein A8 (calgranulin A)

16.454

S100a9

Mus musculus S100 calcium binding protein A9 (calgranulin B)

12.240

Defb3

Mus musculus defensin beta 3 (Defb3)

2.928
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Table 6.1. Major antimicrobial peptides are overexpressed in postnatal epidermis of
RBP-jCKO animals, indicating the persistence of skin-barrier defect in these mice after
birth (Aberg et al., 2008). Data is extracted from a microarray study on P9 epidermis of
RBP-jCKO and wild-type littermates as previously described (Demehri et al., 2008). The
fold increase in antimicrobial peptide mRNA in RBP-j-deficient epidermis relative to
wild type is presented.
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Future Directions
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CHAPTER VII

Carcinogenesis in Notch signaling-deficient skin
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RATIONALE
Gradual reduction of Notch signaling in epidermal keratinocytes is associated
with corresponding decline in skin-barrier function, creation of a wound-like
environment and increased susceptibility to carcinogenesis (Chapter IV and Figure 4.21).
This trend is not extended into mice lacking total Notch signaling in their skin (i.e.,
Msx2-Cre/+; Notch1flox/flox; Notch2flox/flox (Msx2-N1N2CKO) and Msx2-Cre/+; PS1flox/flox;
PS2-/- (Msx2-PSDCKO)) perhaps because these animals die shortly after birth, not
allowing enough time for skin tumor development. RBP-j-deficient animals (Msx2Cre/+; RBP-jflox/flox or Msx2-RBP-jCKO), however, live 100 days on average, which is
comparable to animals lacking partial Notch signaling in their skin (Msx2-Cre/+;
Notch1flox/flox; Notch2flox/+; Notch3-/- (Msx2-N1N2hN3CKO). Surprisingly, while 20% of
Msx2-N1N2hN3CKO mice developed skin tumors, none (0/40) of the Msx2-RBP-jCKO
mice that have been examined developed any spontaneous tumor (Figure 4.21).
RBP-j is the DNA-binding partner of Notch (Lubman et al., 2004), and RBP-j
deletion results in loss of canonical Notch signaling in keratinocytes. Accordingly, mice
with chimeric pattern of RBP-j deletion develop a severe skin-barrier defect that leads to
atopic dermatitis (AD)-like disease in adult life (Chapter VI). Given this magnitude of
Notch signaling reduction and skin-barrier impairment, it is unclear why Msx2-RBPjCKO mice do not develop spontaneous skin tumors at an age when mice with partial loss
of Notch signaling in the skin do (Figure 4.21). This chapter outlines experiments aimed
to determine the underlying mechanism preventing skin carcinogenesis in RBP-jdeficient animals.
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PRELIMINARY STUDIES
RBP-j-deficient mice are resistant to skin carcinogenesis
To determine if Msx2-RBP-jCKO mice were susceptible to skin carcinogenesis,
we incraesed the liklihood of tumor formation by subjecting Msx2-RBP-jCKO and wildtype (Msx2-Cre/+; RBP-jflox/+ and RBP-jflox/flox) littermates to the multistage chemical skin
carcinogenesis model (Figure 4.2C; (Yuspa et al., 1994)). These animals were maintained
in a susceptible genetic background (mixed FVB and C57BL/6 outbred genetic
background) to further facilitate tumor development in a short treatment period. 3-weekold Msx2-RBP-jCKO and wild-type littermates were treated with a single initiating dose
of DMBA, followed by a twice-weekly dose of TPA for 14 weeks (Nicolas et al., 2003).
Suprisingly, no tumor was detected in DMBA/TPA-treated Msx2-RBP-jCKO animals,
whereas the majority of wild-type littermates developed more than 20 papillomas/mouse
after 15 weeks of follow-up (n = 7 for each group, p <0.0001, Figure 7.1). These results
are in stark contrast to the enhanced susptability of Msx2-N1CKO mice to DMBA
(Chapter IV) and demonstrate that RBP-j-deficient skin is in fact resistant to
carcinogenesis.

RBP-j-deleted epidermal clones are replaced by wild-type keratinocytes overtime
The resistance of Msx2-RBP-jCKO mice to carcinogens may reflect the low
proliferative capacity of RBP-j-deficient keratinocytes (Blanpain et al., 2006). The
chimeric pattern of RBP-j deletion in Msx2-RBP-jCKO animals (Pan et al., 2004)
allowed us to examine this possibility indirectly by observing the size of the area covered
with RBP-j-deficient cells on dorsal skin of the mutant mice over their life span. The
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results of this analysis demonstrated that RBP-j-deficient epidermal clones disappeared as
animal aged (Figure 7.2), perhaps reflecting a proliferative disadvantage. Although the
death of Msx2-N1N2CKO and PSDCKO mice at weaning excluded the possibility of
monitoring their epidermal clone sizes overtime, similar shrinkage in Notch1/2-deleted
clones were detected in adult Msx2-N1N2CKO animals rescued by bone marrow
transplantation (data not shown; Chapter V). In addition, Notch/RBP-j-deficient skin
showed reduction in MAPK/ERK signaling, a major growth/proliferation signaling
pathways in keratinocytes, as early as postnatal day 9 (P9; Figure 7.2).
These results could be interpreted to conclude that Notch/RBP-j-deficient
keratinocytes are intrinsically less proliferative in vivo; however, the prominent
epidermal hyperplasia and cellular proliferation in postnatal skin of Notch/RBP-jdeficient animals do not support this hypothesis (Figure 4.21A and B; (Blanpain et al.,
2006; Pan et al., 2004)). Alternatively, the reduction in MAPK/ERK signaling and
disappearance of Notch/RBP-j-deficient epidermal clones in the chimeric skin of Msx2RBP-jCKO animals could point to a non-cell autonomous mechanism that eliminates the
Notch/RBP-j-deficient

barrier-defective

epidermis,

replacing

it

with

wild-type

neighboring cells.

H-ras infected Notch/RBP-j-deficient keratinocytes are highly tumorigenic in nude
mice
To test if Notch/RBP-j-deficient keratinocytes have any intrinsic defect that
prevents them from forming tumors in response to carcinogens, we applied the tumor
induction method in nude mice (Nicolas et al., 2003). First, we isolated keratinocytes
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from newborn RBP-jflox/flox and RBP-jflox/+ littermates. Cells were infected with activated
H-ras-expressing retrovirus and Cre-expressing adenovirus in culture. 1.5 x 106 H-rasinfected RBP-j-/- or RBP-j+/- cells were then injected subcutaneously into nude mice and
tumor development was monitored overtime. Importantly, RBP-j-/- keratinocytes formed
large tumors while no significant tumor mass was formed by wild-type (RBP-j+/-)
keratinocytes after 30 days of follow-up (Figure 7.3). Similar results were obtained using
Notch-deficient keratinocytes (data not shown).
The tumor formation by Notch/RBP-j-deficient cells determines that there is no
cell autonomous defect in these cells, leaving the apparent resistance of Msx2-RBPjCKO animals to skin carcinogenesis a mystery. The main difference in the environment
of these cells is the presence of inflammation in Msx2-RBP-jCKO and its absence in
nude mice.

RBP-j-deleted skin contains an acute inflammation
The inflammation seen in Msx2-RBP-jCKO animals could provide a non-cell
autonomous protection by rejecting RBP-j-deficient epidermal cells, which prevents
carcinogenesis in these animals. As previously discussed (Chapter VI), the severe skinbarrier defects in Msx2-RBP-jCKO mice lead to the development of a full-blown ADlike allergic inflammation in the animals. This level of skin-barrier and inflammation is
not detected in Msx2-N1N2hN3CKO (Chapter V). The detailed analysis of Msx2-RBPjCKO skin demonstrated a significant accumulation of CD45+ leukocytes including mast
cells beneath the RBP-j-deficient epidermal clones (Figure 7.4). This high level of dermal
inflammation could potentially explain the muted response of Msx2-RBP-jCKO skin to
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chemical carcinogenesis and the apparent rejection of RBP-j-deficient tissue overtime
(Coussens and Werb, 2002).

Blocking TSLP reception in Msx2-RBP-jCKO animals results in a dramatic
expansion of RBP-j-deleted epidermal clones
To address the role of inflammation in limiting Msx2-RBP-jCKO skin
carcinogenesis potential, we examined Msx2-RBP-jCKO mice that lacked IL7r" arm of
the TSLP receptor (Msx2-Cre/+; RBP-jflox/flox; IL7r"-/- or Msx2-RBP-jCKO;IL7r"-/-,
Chapter VI). TSLP is an epidermal-derived cytokine that has been implicated in initiation
of allergic inflammation in mice and humans (Leonard, 2002; Liu, 2006; Yoo et al.,
2005). Deletion of IL7r" subunit of TSLP receptor in Msx2-RBP-jCKO mice leads to
reduced local inflammation in the skin of Msx2-RBP-jCKO;IL7r"-/- (Chapter VI and
Figure 6.7; (He et al., 2008)).
The lifelong monitoring of Msx2-RBP-jCKO;IL7r"-/- animals revealed a clear
reversal of Msx2-RBP-jCKO phenotype: the size of RBP-j-deficient epidermal clones
dramatically expanded in Msx2-RBP-jCKO;IL7r"-/- mice overtime (Figure 7.5). Msx2N1N2CKO animals that were rescued by eliminating TSLP signaling (Msx2N1N2CKO;IL7r"-/-, Chapter V) also showed expansion of their Notch1/2-deleted skin
territories (data not shown). To confirm that this effect is specific to TSLP and is not an
indirect consequence of reduced lymphocyte number caused by IL7r" deletion (Peschon
et al., 1994), we deleted TSLPR arm of the TSLP receptor in Msx2-PSDCKO animals
(Msx2-PSDCKO;TSLPR-/-), which ensured their survival after weaning (Chapter V and
Figure 5.17). As expected, the !-secretase-deficient epidermal clones expanded in these
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animals (Figure 7.5). Therefore, high levels of TSLP are required to initiate the process
that leads to elimination of Notch/RBP-j-deficient keratinocytes, which are intrinsically
proliferative. Due to the specific effect of TSLP on immune cells, this process is probably
mediated by skin inflammation downstream of TSLP signaling.

In the absence of TSLP signaling, Msx2-RBP-jCKO animals develop spontaneous
skin cancers
Interestingly, several cancerous lesions (SCCs) were detectable on the skin crosssections of Msx2-RBP-jCKO;IL7r"-/- animals at 10 to 15 weeks of age (Figure 7.6).
Therefore, TSLP mediates the resistance to carcinogenesis and the elimination of RBPdeficient cells in mice lacking canonical Notch signaling in their skin, and the underlying
cancer-prone phenotype in these animals can be uncovered by removing the effects of
TSLP.
In summary, Msx2-RBP-jCKO do not develop spontaneous tumors, are more
resistant to chemically induced carcinogenesis relative to their wild-type littermates, and
their resistance to carcinogenesis correlates with the observation that RBP-j-deleted
epidermal clones in these animals are gradually replaced by neighboring wild-type cells.
Activated H-ras-expressing Notch/RBP-j-deficient cells, however, can form tumors in
nude mice, establishing that Notch signaling is not necessary for carcinogenesis, rather,
its loss leads to a higher tumorigenic potential in keratinocytes placed in an
immunodeficient microenvironment. The RBP-j-deficient barrier-defective skin contains
large numbers of immune cells honing in on RBP-j-deleted epidermis, suggesting that
skin

inflammation

is

eradicating

RBP-j-deficient
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cells

and

preventing

skin

carcinogenesis. Importantly, when we blunt the AD-like inflammation by blocking the
response to TSLP, reduction of local skin inflammation in Notch/RBP-j-deficient animals
results in an aggressive expansion of RBP-j-deleted epidermal clones and spontaneous
skin carcinogenesis. Taken together, these findings suggest that local skin inflammation
downstream of TSLP that is overproduced by barrier-defective skin plays a protective
role against skin carcinogenesis by eradicating the Notch/RBP-j-deficient epidermal cells.
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RESEARCH DESIGN
Although TSLP signaling is found essential in eliminating the Notch/RBP-jdeficient epidermal clones and preventing carcinogenesis, the downstream effecter cell(s)
that respond(s) to keratinocyte-derived TSLP is not clear. To identify the cells involved
in this immunosurveillance, we will take the following approaches:

I) We will investigate if hematopoietic stem cell (HSC)-derived immune cells are
required and sufficient to deliver the TSLP effects.
To perform these studies, we will utilize bone marrow transplantation (BMT). We
will reconstitute the hematopoiesis of lethally irradiated Msx2-RBP-jCKO;IL7r"/- or Msx2-RBP-jCKO mice with bone marrow (BM) isolated from wild-type or
IL7r"-/- mice, respectively.
Anticipated outcomes and conclusions: If the RBP-j-deficient epidermal clones
disappear overtime in Msx2-RBP-jCKO;IL7r"-/- mice transplanted with wildtype BM and no spontaneous tumor is formed in the recipients (i.e., a phenotype
similar to that of Msx2-RBP-jCKO mice), we will conclude that BM-derived
immune cells are sufficient to mediate the effects of TSLP. On the other hand, if
Msx2-RBP-jCKO mice receiving IL7r"-/- BM show growth of the RBP-j-deleted
skin with appearance of spontaneous skin cancers, it will mean that TSLPresponsive immune cells are required for elimination of barrier-defective
epidermis and cancer prevention.
To substantiate the findings from these sets of experiments, we will take an
independent approach to investigate if immune cells are required for tumor
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prevention in Notch/RBP-j-deficient animals. In collaboration with Dr. Robert
Schreiber, we will eliminate specific subsets of immune cells in Msx2-RBP-jCKO
mice using neutralizing antibodies and determine if the tumor preventing effects
of TSLP are reversed.

II) We will examine the role of individual immune cells in this
immunosurveillance.
Given that reduced dermal inflammation is a hallmark of TSLP signaling
blockage in Msx2-RBP-jCKO;IL7r"-/- mice, we will compile a detailed list of
immune cells that are reduced in the dermis of Msx2-RBP-jCKO;IL7r"-/- relative
to Msx2-RBP-jCKO animals. By correlating the reduction in particular dermal
immune cell population to loss of immunosurveillance (i.e., the appearance of
skin cancers) in the skin of Msx2-RBP-jCKO;IL7r"-/- mice, we can identify
candidate cell types that are mediating the effects of TSLP. We will then use
genetic and lentiviral approaches to eliminate these candidate cell types in Msx2RBP-jCKO animals and determine if it would lead to a spontaneous tumor growth
and clone expansion similar to the phenotype seen in Msx2-RBP-jCKO;IL7r"-/mice.
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FIGURES
Figure 7.1
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Figure 7.1. Msx2-RBP-jCKO mice are resistant to treatment with chemical carcinogens.
(A) Treating 3-week-old Msx2-RBP-jCKO and their wild-type littermates with
DMBA/TPA chemical skin carcinogenesis model (described in Figure 4.2C; this
experiment is concluded at the end of TPA treatment period (week 15)) results in tumor
formation in majority (6/7) of wild-type mice in this susceptible genetic background. In
contrast, no persistent tumor is formed in the RBP-j-deficient littermates. Papillomas
appear starting 6 weeks after initiation in wild-type animals (n = 7 for each group; p
<0.0001, log-rank test). Note that one Msx2-RBP-jCKO mouse develops tumors, which
disappears later in week 11 of follow-up. (B) The average number of papillomas per each
tumor-bearing wild-type mouse increases progressively over the 15-week DMBA/TPA
treatment period. Beginning at 14 weeks post initiation, >50% of wild-type mice have
more than 20 papillomas.
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Figure 7.2
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Figure 7.2. Loss of RBP-j leads to growth disadvantage of RBP-j-deficient epidermis
compared to wild type. (A) RBP-j-deficient epidermal clones disappear as Msx2-RBPjCKO animals age. The red dotted line and arrows delineate the boundaries of RBP-jdeficient dorsal epidermis, which are determined based hair/epidermal phenotype and "RBP-j antibody staining on skin cross sections (data not shown). (B) Western blot
analysis of activity state of ERK/MARK signaling pathway as a major molecular
determinant of cell proliferation potential in epidermal samples from mice deficient in
Notch signaling. At P9, mice with minimal Notch loss (Msx2-N1CKO) and more
complete Notch deficiency (Msx2-N1N2CKO and Msx2-PSDCKO) show decrease in
Erk1, 2 activities. The reduction in Erk phosphorylation persists as mice age and is
evident in RBP-jCKO epidermis with a substantial decrease in Erk phosphorylation at
P60. Each graph shows the cumulative phosphorylated (or free) to total protein ratio for
any genotype as the percent of the ratio for normal animals, derived from three
independent experiments.
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Figure 7.3
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Figure 7.3. H-ras- and adeno-cre-infected RBP-jflox/flox keratinocytes (RBP-j-/-) are highly
tumorigenic in nude mice. (A) 1.5 x 106 H-ras-infected RBP-j-/- cells injected
subcutaneously into nude mice form a lage tumor after 30 days (red circle). Meanwhile,
1.5 x 106 H-ras-infected RBP-j+/- cells only grow to a small nodule. (B) Histological
analysis shows the tumor that is developed from RBP-j-/- cells is a poorly differentiated
squamous cell carcinoma (SCC; scale bar: 50µm). These findings are confirmed in
independent sets of experiments.
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Figure 7.4
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Figure 7.4. Intense immune cell infiltration is evident in the dermis of Msx2-RBP-jCKO
animals. Staining of P60 Msx2-RBP-jCKO and wild-type skins with CD45 pan-leukocyte
marker or toluidine blue shows a dramatic increase in leukocytes, and, in particular,
accumulation of mast cells in Msx2-RBP-jCKO dermis (scale bar: 50µm).
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Figure 7.5
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Figure 7.5. Deletion of TSLP signaling leads to expansion of Notch signaling-deficient
epidermal clones in the chimeric animals. (A) Red arrows are showing the boundaries of
RBP-j-deficient streak in dorsal skin of Msx2-RBP-jCKO animal at P60. The RBP-jdeficient skin territory, however, is much expanded in Msx2-RBP-jCKO;IL7r"-/animals at P60. The red dotted lines delineate the hairless areas of Msx2-RBPjCKO;IL7r"-/- skin. On close examination, the RBP-j-deficient epidermis extends into
the flank region of Msx2-RBP-jCKO;IL7r"-/- animals. (B) Loss of TSLPR arm of the
TSLP receptor phenocopies the effects of IL7r" deletion. !-secretase-deficient animals
that also lack TSLPR (Msx2-PSDCKO;TSLPR-/-) have a longer life span than Msx2PSDCKO animals (Chapter V) and show the expansion of hyperkeratotic Notch
signaling-deficient skin patch in adulthood. White arrows point to the remaining small
patches of wild-type skin in Msx2-PSDCKO;TSLPR-/- animal. Although no Msx2PSDCKO animal survives 50 days to be shown as a control, Msx2-PSDCKO animals
treated with bone marrow transplantation live up to 50 days and their skin phenotype is
described in chapter V (Figure 5.4).
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Figure 7.6
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Figure 7.6. Msx2-RBP-jCKO;IL7r"-/- animals develop spontaneous skin cancers as they
age. A 90-day-old animal with multiple lesions on its dorsal skin is shown. Histological
analysis of the skin of this animal demonstrates the presence of an invasive SCC that has
penetrated the subcutaneous muscle layer (scale bar: 50µm).
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CHAPTER VIII

The mechanism of thymic stromal lymphopoietin
overexpression by epithelial cells
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RATIONALE
Asthma and atopic dermatitis (AD) are common allergic disorders affecting
millions of Americans (Galli et al., 2007). Their chronic nature and lack of effective
treatment, have limited the therapeutic choices for treating asthma and AD to long-term
management of their symptoms. This has left the patients with a lifetime of suffering and
created a huge burden on the healthcare system in America. Importantly, asthma and AD
share many clinical and pathological features suggesting that advances in either field will
have implications for both disorders. In particular, thymic stromal lymphopoietin (TSLP)
has been identified as a common molecular etiology driving asthma and AD (Liu, 2006).
TSLP is an interleukin (IL)-7-like cytokine made by epithelial cells, which has been
shown to cause asthma or AD by triggering lung or skin inflammation, respectively.
Although the pathways linking TSLP to allergic inflammation and disease are well
understood, the exact mechanism by which epithelial cells make TSLP remains unclear.
Understanding how epithelial cells begin to overexpress TSLP is pivotal to
unraveling the underlying cause of asthma and AD. It is thought that insults from
allergens or pathogens penetrating through the compromised lung or skin barriers
stimulate TSLP overproduction by the epithelial cells (Liu, 2006). This view is
challenged by our recent findings showing that persistent epithelial differentiation defects
and the ensuing barrier malformation directly cause epithelial TSLP overexpression in
the sterile environment of the uterus (Demehri et al., 2008). This brings up a possibility
that intrinsic epithelial defects serve as the primary trigger for TSLP overproduction.
Therefore, the current chapter aims to dissect the mechanism by which epithelial
differentiation defects (intrinsic factors) are translated into TSLP readout (Aim I), and
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test whether or not extrinsic factors such as invading pathogens play any role in inducing
TSLP production by epithelial cells (Aim II). To tackle these questions, we will utilize
the mouse skin as the model organ that we have studied previously. Through this system,
we have demonstrated that deletion of Notch signaling components or fatty acid transport
protein (FATP)4 in epidermal keratinocytes leads to TSLP overexpression in these
epithelial cells (Demehri et al., 2008). Although FATP4 expression and Notch signaling
are not linked, loss of either one causes defective epidermal differentiation/barrier
formation, which is the common denominator. These, together with several other
knockout models shown to cause epidermal differentiation defects and TSLP
overexpression (Segre, 2006), strongly point to a common “sensor”, linking the defects in
differentiation/barrier formation to TSLP spike. Therefore, the proposed research will
attempt to identify the sensor underlying epithelial TSLP overexpression by addressing
the following specific aims.
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SPECIFIC AIMS
Aim I: Identify a cell autonomous molecular pathway mediating TSLP
overexpression by the epithelial cells that fail to differentiate. Culturing keratinocytes
on plastic, which leads to an improper differentiation has resulted in TSLP
overproduction by these cells (Demehri et al., 2008); this experiment has determined the
existence of a cell autonomous sensor inducing TSLP readout when it is activated by the
impaired epithelial differentiation. Using this robust in vitro effect, we have found that
TSLP expression in cultured keratinocytes requires active NF$B (Demehri et al., 2008),
which is a transcription factor known to bind and activate TSLP expression (Lee and
Ziegler, 2007). Therefore, we will test if NF$B regulates TSLP expression in vivo, in
which case the NF$B signaling pathway will be the sensing mechanism inducing TSLP
readout. Follow-up studies will attempt to discover the cell autonomous signal linking the
NF$B pathway to epithelial differentiation defect. However, if NF$B does not affect
TSLP expression in vivo, we will embark on an alternative approach. We have performed
microarray analysis on Notch- or FATP4-deficient skin and generated lists of genes that
are altered under either of these conditions. By comparing these lists, a subgroup of
candidate genes will be identified that are affected similarly in both knockout systems.
We will further narrow down the list by selecting the genes that follow the same trend
and are overexpressed in the same cells as TSLP. Subsequently, we will perform in silico
analysis on these TSLP-like transcripts to find a cluster of genes that share (a) regulatory
element(s) with TSLP. This group of genes will constitute the additional readouts of the
sensor, and the transcription factor that binds to their shared element(s) will lead us to the
sensor itself. After identifying the signaling pathway regulating this gene cluster, we will
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study its effect on TSLP overexpression in vitro and in vivo.

Aim II: Investigate the effect of extrinsic factors on TSLP overexpression by the
skin. Although we have shown that keratinocytes lacking Notch or FATP4 can
overexpress TSLP in the sterile uterine environment (Demehri et al., 2008), the
consequences of skin-barrier dysfunction could amplify the TSLP production after birth.
To address this possibility, we will test the role of water loss and allergen/pathogen
exposure on TSLP overexpression in vivo.
a) We will induce transient barrier dysfunction in wild-type animals to test if barrier
loss in the absence of any intrinsic epithelial abnormality can induce TSLP
overexpression. If so, we will try to prevent TSLP overexpression by occluding
the site of the acute barrier defect with water- or particle-impermeable tapes in
order to isolate the specific complication causing this effect.
b) To examine if water loss and allergen/pathogen exposure enhance TSLP
overproduction in the context of a preexisting epithelial differentiation/barrier
formation defect, we will measure the serum TSLP levels in the Notch-deficient
mice after occluding their skin with an artificial barrier restoring agents like a
physiologic lipid coat. In addition, we will test the specific contribution of
pathogens to TSLP overproduction by raising the Notch-deficient newborns in a
germ-free environment.
Completion of these aims will help identify the underlying mechanism governing TSLP
overexpression by epithelial cells. It will also clarify the role of extrinsic factors in
mediating this effect and the subsequent inflammation.
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BACKGROUND AND SIGNIFICANCE
Lung and skin are the two major metazoan organs, which are in direct contact
with the external environment. Therefore, these organs are susceptible to insults from
outside invaders, and have evolved elaborate mechanisms to counter these insults. Most
importantly, they have developed specialized epithelial structures that in a reciprocal
interaction with mesenchymal and hematopoietic cells sustain organ integrity (Morasso
and Tomic-Canic, 2005). The primary function of lung and skin epithelial cells is to form
a competent barrier preventing water loss and protecting the organism’s internal milieu
from outside pathogens and allergens (Segre, 2006). However, when this barrier is
compromised as in wounds, the epithelial cells are still able to launch a secondary
defense mechanism by recruiting the immune cells to the site of the defect, protecting the
internal environment until the barrier is restored. Despite its adaptive role in preventing
invading agents from harming the organism in an acute setting, the chronic activation of
such an inflammatory cycle can have adverse consequences.
Asthma and atopic dermatitis (AD) are common chronic inflammatory diseases
that develop at the site of persistent barrier defect in lung or skin, respectively, and thus
they have many similar features (Galli et al., 2007). Clinically, both asthma and AD are
highly prevalent especially among children (Asthma and Allergy foundation of America
(AAFA)). For instance, more than 20 million Americans suffer from Asthma and this
number has been growing since the early 1980s. Asthma accounts for one quarter of all
emergency room visits in the U.S. every year and its overall morbidity and mortality data
highlight a major public health problem; it places an $18 billion strain on the U.S.
economy each year (AAFA). AD has similar statistics with particularly high incidence
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during the first years of life; over 17% of American children are affected by AD (Spergel
and Paller, 2003). Notably, epidemiological studies have found that half of AD patients
will develop asthma, suggesting a direct link between these two disorders (Pourpak et al.,
2008; Spergel and Paller, 2003). With regard to disease pathogenesis, both asthma and
AD are caused by local allergic inflammations at epithelial surfaces (Holgate, 2007b).
Following an environmental trigger, activated dendritic cells leave the epithelium and
travel to the draining lymph nodes where they stimulate naïve CD4+ T-lymphocytes to
attain T helper 2 (Th2) cell fate. Th2 cells then migrate back to the site of the initial insult
and release various cytokines including interleukin (IL)-4 and IL-5. These factors in turn
activate B-lymphocytes, mast cells, eosinophils, and other resident cells to mount an
allergic inflammatory response. Based on these processes, several treatments like
corticosteroids and humanized anti-IgE antibodies are developed and being used to block
inflammation in asthma and AD (Holgate et al., 2005; Novak et al., 2005). Although the
current treatments can curtail the acute episodes of these diseases, they mainly target the
downstream effectors and fail to inhibit the early triggering events, leaving patients
poised to repeated episodes (Holgate et al., 2005). One such early event is activation of
dendritic cells, and in recent years it has become clear that thymic stromal lymphopoietin
(TSLP), a cytokine released by stressed/injured epithelia, is the main culprit in activating
these cells in humans (Soumelis et al., 2002). Epithelial-derived TSLP may also serve as
a direct stimulating signal for T cells (Lee et al., 2008; Liu et al., 2007).
TSLP is a ~16KDa polypeptide that functions as a four-helix bundle cytokine
(Sims et al., 2000). It belongs to IL-2 family of type I cytokines and has originally been
isolated from a murine thymic stromal cell line (Friend et al., 1994). TSLP is closely
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related to IL-7; it binds to a heterodimeric receptor (TSLPR) that shares one of its
subunits (IL-7r") with IL-7 receptor (Liu et al., 2007). TSLPR activates the STAT
signaling pathway, thus TSLP affects the development and/or activation of TSLPR
expressing cells like B, T and dendritic cells in various settings (Liu et al., 2007). The
TSLP promoter has several conserved vitamin D-, retinoic acid-responsive elements, and
NF$B binding sites (Li et al., 2006). Studies have shown that TSLP is predominantly
expressed by epithelial cells especially lung and skin epithelia, where its overexpression
is found to play a critical role in initiating asthma and AD, respectively (Al-Shami et al.,
2005; Leonard, 2002; Yoo et al., 2005). In addition to its local consequences, we have
found that high serum TSLP levels in neonates can cause a systemic Blymphoproliferative disorder (B-LPD) with mortality in its extreme form (Demehri et al.,
2008). The confinement of this disease to the neonatal period in mice points to a specific
proliferative effect of TSLP on fetal pre-B cells in vivo. Since we discovered this
phenotype in mice lacking Notch signaling exclusively in skin keratinocytes, we have
demonstrated that skin-derived factors can trigger systemic humoral and autoimmune
diseases. This finding supports the hypothesis that epithelial abnormalities are the
primary defects predisposing the lung or the skin to chronic inflammatory disorders:
asthma and AD (Holgate, 2007a).
How does loss of Notch signaling in the skin lead to TSLP overexpression? Notch
is a transmembrane transcription factor that mediates many developmental decisions
during metazoan organogenesis, and its activation requires cleavage by !-secretase
enzyme on the cell surface (Mumm and Kopan, 2000). In the epidermis, Notch signaling
regulates the proper differentiation of basal layer keratinocytes to form upper spinous and
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granular layers, and deletion of total Notch signaling in epidermal cells leads to loss of
these suprabasal layers (Blanpain et al., 2006; Pan et al., 2004). Although no direct
molecular link between Notch signaling and TSLP has been found, reduction in Notch
dosage in the skin triggers a chronic overproduction of TSLP in a dose-dependent manner
(Demehri et al., 2008). TSLP levels mirror the increase in severity of differentiation
defects arising when Notch signaling in the skin is decreased. The tight correlation
between Notch loss, differentiation defects and TSLP overproduction suggests that TSLP
expression could be dependent on the degree of skin-barrier defect seen in Notchdeficient animals. Support for this notion comes from the observation that differentiation
defects seen in fatty acid transport protein (FATP)4-deficient mice also lead to
overexpression of TSLP (Demehri et al., 2008). FATP4 is an enzyme important in lipid
biosynthesis and its deletion in wrfr-/- mice results in a severe epidermal differentiation
and skin-barrier defect, which leads to the animal’s death at birth due to rapid
dehydration (Moulson et al., 2003). Importantly, neither the loss of Notch signaling in
epidermal keratinocytes affect FATP4 expression nor does FATP4-deficient skin show
any sign of Notch signaling alteration (Demehri et al., 2008). Therefore, FATP4
deficiency provides an independent evidence that defective skin-barrier triggers
epidermal TSLP overexpression. These findings are consistent with the current view on
TSLP overexpression in asthma and AD; in which defective barrier function induces
TSLP overproduction by epithelial cells initiating the allergic inflammation (Holgate,
2007b). According to this view, however, the allergens and invading pathogens are the
main culprits triggering epithelial TSLP release by penetrating through the barrier breach
and stimulating the epithelial cells directly (Holgate, 2007b; Liu, 2006). In contrast, the
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embryonic overexpression of TSLP in Notch- or FATP4-deficient animals in utero, prior
to any exposure to allergens or pathogens, suggests an alternative explanation for TSLP
overproduction: an intrinsic epithelial defect, with an underlying genetic predisposition
(Demehri et al., 2008).
Given the current lack of knowledge regarding the exact mechanism mediating
epithelial TSLP expression, it is imperative that the molecular link between epithelial
differentiation/barrier formation defect and TSLP overexpression be explored to more
fully understand the potential role of genetics in the pathogenesis of asthma and AD. The
proposed research will address the complex regulation of TSLP expression and the role
of extrinsic factors in TSLP overproduction. It will provide insights into how epithelium
is prompted to release TSLP and if genetic predisposition plays an important role in this
disease-related process. Therefore, the outcome of this research can have an important
impact on defining the interplay between environment and genetics in the pathogenesis of
asthma and AD, leading to potential new therapeutic approaches to benefit a large group
of patients.

416

PRELIMINARY STUDIES
Loss of function studies on Notch signaling pathway in the skin have yielded a
comprehensive model for investigating the underlying cause of epithelial TSLP
overexpression (Demehri et al., 2008). To carry out these studies, we have used Msx2Cre line to remove Notch paralogs (N1, N2 and N3) or presenilins (PS1 and PS2; the
catalytic subunits of !-secretase) specifically from the skin keratinocytes. Msx2-Cre is
expressed in the dorsal and ventral midline ectoderm on embryonic day 9.5 (E9.5)
creating a chimeric pattern of Cre-mediated deletion in the skin (Pan et al., 2004).
Deletion of total Notch signaling by abolishing !-secretase function in the keratinocytes
(Msx2-Cre/+; PS1flox/flox; PS2-/- or PSDCKO) resulted in a severely impaired epidermal
differentiation and lipid deposition, which were highlighted by significant epidermal
hypoplasia and barrier defect at birth (Figure 5.18). Due to the clonal pattern of Msx2Cre activity, the consequences of Notch loss were confined only to a fraction of the
surface area, and therefore the mutant newborns did not suffer from dehydration and were
able to survive through birth. Nonetheless, the mice that lacked total Notch signaling in
their skin still died around the weaning time while their skin phenotype was mild (Pan et
al., 2004). A thorough necropsy on the moribund mice revealed a severe B-LPD in these
animals accompanied by white blood cell (WBC) count of >200,000 cells/ l and WBC
infiltration into vital organs, which was detected during the second week of life (Demehri
et al., 2008). On further analysis, we identified the expanding leukocytes as pre- and
immature B-lymphocytes. As confirmed by PCR and reporter lines, skin was the only
organ experiencing Cre-mediated Notch signaling loss, and therefore (a) skin-derived
factor(s) must have been the cause of this disorder.
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Comparing skin gene expression profiles of Notch-deficient animals and their
wild-type littermates identified a list of cytokines that were up-regulated upon loss of
Notch. Among all, TSLP was the only cytokine capable of supporting B cell
development, which maintained high systemic levels in the mutant animals. The
subsequent immunohistochemical analysis showed TSLP to be overexpressed by
suprabasal keratinocytes, which were unable to differentiate properly and retained some
of the basal-like characteristics as they migrated up toward the epidermal surface (Figure
8.1) (Pan et al., 2004). To demonstrate that epidermal-derived TSLP was sufficient to
cause neonatal B-LPD, TSLP was overexpressed in the epidermis of the wild-type
animals using a transgenic approach. Such an overexpression recapitulated the B-LPD
seen in Notch-deficient animals, and confirmed the proliferative effect of TSLP on fetal
pre-B cells in vivo (Demehri et al., 2008). Other TSLP overexpression studies, however,
have mainly focused on the local effects of TSLP in adult skin, which have found it to be
the initiating factor in AD in adult mice (Yoo et al., 2005). Indeed, Notch-deficient
animals also developed an AD-like skin phenotype shortly after birth highlighted by
hyperkeratosis, parakeratosis, spongiosis, acanthosis and dermal infiltration of
eosinophils and mast cells (Figure 8.2 and Chapter VI). Given these phenotypes, Notchdeficient animals present an invaluable tool to investigate the pathogenesis of allergic
disorders represented by AD in this model.
The remaining overarching question in describing the phenotypes observed in
mice lacking Notch signaling is how deletion of the Notch pathway in the epidermal
keratinocytes gets translated into TSLP overproduction by these cells. Although we
initially suspected that Notch signaling pathway might regulate TSLP expression directly,
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we were unable to find any evidence for such a molecular link. Instead, we focused on
the possibility that the skin-barrier defect caused by Notch loss is the main trigger for
TSLP overexpression (Segre, 2006). This hypothesis was substantiated when we cultured
wild-type and Notch-deficient primary keratinocytes on plastic plates, where they could
not form a stratified epithelium. Measuring TSLP levels in the medium collected from
these keratinocytes revealed that the Notch signaling status of the cultured cells had no
detectable impact on their TSLP expression (Figure 5.18E). More importantly, though,
the significant levels of TSLP released by both wild-type and Notch-deficient
keratinocytes into their surrounding medium pointed to the dominant effect of epidermal
differentiation defect in stimulating TSLP production. High serum TSLP levels in
FATP4-deficient animals (wrfr-/-) at birth solidified this conclusion. This was traced
back to elevated TSLP mRNA levels detectable even in the skin of E15.5 wrfr-/- embryos
(Demehri et al., 2008). Importantly, embryonic origin of TSLP overexpression in Notchdeficient mice was also confirmed by documenting the extremely high serum TSLP
levels in these mice at birth (Figure 8.3). The embryonic onset for TSLP overexpression
in these mouse models and its persistence in cultured keratinocytes underscores the
existence of a cell autonomous signaling pathway that somehow senses the defect in
epithelial differentiation/barrier formation and reports it as TSLP “alarm”.
One of the molecular pathways known to activate TSLP expression is NF$B
signaling, which is also directly involved in regulating epidermal differentiation and can
serve as the “sensor” (Kaufman and Fuchs, 2000; Lee and Ziegler, 2007). Therefore, we
tested if NF$B activity was required for TSLP production by cultured keratinocytes.
Addition of BAY 11-7082, a NF B pathway inhibitor, led to a dose-dependent reduction
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in TSLP concentration in culture medium, suggesting that NF B signaling pathway acts
upstream of TSLP (Figure 5.18E). Importantly, our preliminary studies showed that
NF$B pathway inhibition in the skin of Notch-deficient newborns also led to reduction in
serum TSLP levels (Figure 8.4). However, it is still unclear how NF$B pathway gets
activated. We will investigate this and other possible causes of TSLP overexpression in
vivo with an attempt to identify the initiating defects in asthma and AD. Our preliminary
studies have provided novel insights into the mechanism triggering TSLP overexpression
by epithelial cells, which we propose to examine further according to the research design
detailed in the following section.
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RESEARCH DESIGN AND METHODS
Aim I: Identify a cell autonomous molecular pathway mediating TSLP
overexpression by the epithelial cells that fail to differentiate.
Rationale: Our preliminary findings strongly suggest that epithelial cells possess an
autonomous sensing mechanism allowing them to report their intrinsic differentiation
defects to the surrounding environment by overexpressing TSLP as a readout. Therefore,
it is critical to identify the components of this sensor in order to understand how
epithelial cells detect their differentiation defect and translate it into TSLP
overexpression. Given that NF$B directly binds to TSLP promoter and regulates its
expression in cultured keratinocytes, NF$B signaling pathway is the likely candidate
regulating TSLP expression in vivo. Therefore, we will first confirm the effect of NF$B
on TSLP expression in mouse skin. In wake of a negative outcome, we will look for other
signaling pathways that can contribute to TSLP expression in vivo. The availability of
two independent mouse models with profound activation of the sensor overexpressing
TSLP has created a unique opportunity to discover novel candidates by comparing the
molecular changes in these models. We will identify the sensor by clustering the genes
that behave like TSLP in both Notch- and FATP4-deficent skin and ask if a common
regulatory element define this cluster. To identify a signaling pathway that meets the
criteria of a TSLP-producing sensor in the epithelial cells, the following approaches will
be taken.

Experimental approach (part 1):

We have identified NF$B as the likely cell

autonomous sensing mechanism inducing TSLP expression in epithelial cells that fail to

421

differentiate. To examine the importance of this in vitro finding, we will ask if NF$B
activity is increased in !-secretase-deficient skin using immunohistochemistry comparing
the nuclear phospho-NF$B staining (#3037, Cell Signaling, Danvers, MA) in wild-type
and mutant skin. If NF$B signaling is activated in the suprabasal keratinocytes, which
overexpress TSLP, we will inhibit its activity in vivo and check whether TSLP levels are
affected. Pyrrolidine dithiocarbamate (PDTC) is a potent inhibitor of NF$B, sequestering
it in cytoplasm by reversibly suppressing its release from I$B(Schreck et al., 1992).
Twice daily topical treatment of the skin with PDTC (in PBS) causes NF$B signaling
inhibition in epidermis and a clear epidermal thickening within 7 days (Seitz et al., 1998).
Therefore, we have used this chemical to inhibit NF$B in Notch- or !-secretase-deficient
skin by treating P4 animals for 5-7 days according to the published protocol (Seitz et al.,
1998) and check the mRNA levels of TSLP in the epidermis and serum TSLP levels at
the end of the treatment period. Our preliminary results shows a reduction in TSLP
expression (Figure 8.4). After confirming that NF$B signaling is required for TSLP
overexpression in vivo, we will compile a list of epithelial-associated NF$B activators
such as IL-1, TNF" and integrins using literature searches.
Any NF$B pathway activator that is elevated in cultured keratinocytes and, more
importantly, in Notch-deficient epidermis will be tested for its contribution to TSLP
overexpression. Primary keratinocytes will be cultured on plastic pates as previously
described (Missero et al., 1996). TSLP mRNA levels in keratinocytes will be measured
by qRT-PCR and its concentration in culture medium will be determined using TSLP
ELISA kit (R&D Systems, Minneapolis, MN)(Demehri et al., 2008). We will use siRNA
or neutralizing antibodies to reduce the levels of the candidate NF$B activator in vitro
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(Le Buanec et al., 2006; Nguyen et al., 2006). We will perform qRT-PCR, western blot,
and ELISA assays to confirm that significant knockdown/blocking is achieved. If
reduction in any of the candidate proteins replicates the effect of NF$B inhibition on
TSLP expression, that molecule will be inhibited or removed in Notch-deficient animals
to check for reduction in TSLP expression and reversal of B-LPD and AD phenotypes.
These will be determined by methods described previously (Demehri et al., 2008).

Anticipated outcomes and conclusions (part 1): The full execution of the experiments
proposed above depends on an initial confirmation that NF$B regulates TSLP in vivo.
Therefore, there are two possible outcomes.
-

NF$B is required for TSLP overexpression in !-secretase-deficient skin
(supported by our preliminary findings). This outcome will pave the way for the
follow-up studies to pinpoint the outside-in signal activating this sensor. In vitro
experiments have demonstrated that this signal is produced by keratinocytes
autonomously. Therefore, from the small pool of keratinocyte-derived molecules
known to activate the NF$B pathway, we hope to identify the one(s) relevant to
this paradigm.

-

NF$B is not required for TSLP overexpression in !-secretase-deficient skin. This
result will necessitate an alternative approach in search for TSLP-producing
sensor in the epidermis (part 2).

Caveats and solutions (part 1): The pivotal experiment in this section involves the
chemical inhibition of NF$B in !-secretase-deficient skin. To confirm the practicality of
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treating newborns twice daily with PDTC for 5-7 days, we have conducted some
preliminary studies and showed that the animals can tolerate this regimen. Nonetheless, if
a subtle effect is detected by chemical inhibition over a large pool of experimental
animals, we will genetically remove NF$B in !-secretase-deficient mice to substantiate
the role of the NF$B signaling pathway as a TSLP-producing sensor. This will also allow
us to examine the long-term effects of NF$B loss on TSLP-mediated phenotypes.

Experimental approach (part 2): If NF$B does not show the desired effects in vivo (part
1), a novel direction will be explored to identify the signaling pathways regulating TSLP
in the epidermis. Using in silico analysis, we will determine if there is a cluster of genes,
which are regulated by the sensor in a similar way to TSLP. This approach will allow us
to find the common transcription factor/signaling pathway that has (a) shared response
element(s) on the clustered genes. To that end, we will first use microarray analysis in
order to identify the genes with increased expression in both Notch- and FATP4-deficent
skin compared to their wild-type littermates. This candidate gene list will only include
genes that are up-regulated like TSLP in both models filtering out Notch- or FATP4specific alterations. Several independent microarray analysis on these animals have
already been performed, however, further gene expression profiling of the skin in various
developmental stages might be warranted. In addition, our previous studies on the
complete allelic series of Notch-deficient animals have shown that Notch dosage
inversely correlates with the level of the epidermal differentiation defect and TSLP
overexpression in the skin (Demehri et al., 2008). Such a tight correlation implies that the
genes regulated in a similar fashion to TSLP should be up-regulated to a lesser extent in
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mice lacking partial Notch signaling compared to those with no Notch signaling in their
skin. Therefore, using the data from the skin microarray analysis on mice with various
degrees of Notch signaling loss, we will perform a trend analysis on the common gene set
described above. This way, the number of candidate genes in the common gene set will
be reduced to those that follow the TSLP trend, and are highly elevated in !-secretasedeficient but only mildly in Notch1-deficient skin. We will further narrow down this gene
set by immunohistochemical or in situ hybridization analysis to pick out the genes
expressed in the suprabasal keratinocytes, where TSLP is overexpressed (Lee et al.,
2007). Combining TSLP with this refined group of TSLP-like genes, we will look for any
common

regulatory

element

among

them

using

PhyloCon

(http://ural.wustl.edu/~twang/PhyloCon/) and D.I.R.E. (http://dire.dcode.org/) softwares.
We will also identify the evolutionarly-conserved regions of these genes as an additional
reference point. If TSLP falls within a cluster of genes that have shared regulatory
sequences, the transcription factor(s) that binds to these CIS elements will be sought.
Next, we will identify an epidermal signaling pathway upstream of this transcription
factor using literature searches and ingenuity pathway analysis (IPA) software (Ingenuity
Systems, Redwood City, CA). Such a signaling pathway is likely to be the TSLPproducing sensor and will be tested in cultured keratinocytes and Notch-deficient animals
in a sequence described for NF$B.

Anticipated outcomes and conclusions (part 2): According to our initial investigation,
we are confident that there are a significant number of genes altered similarly in both
Notch- and FATP4-deficient skins. Therefore, it is likely that we will have several TSLP-
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like genes. From testing this group of genes, we will arrive at one of the following
results:
-

There is a shared regulatory element between TSLP and a number of TSLP-like
genes, which has a known transcription factor binding to it. This will lead us to a
signaling pathway that will be tested for its ability to regulate TSLP expression in
vitro and in vivo.

-

There is a shared regulatory element between TSLP and other TSLP-like genes,
but no known transcription factor binds to it. This outcome is unlikely due to the
analysis method. Nonetheless, we will examine the significance of such common
sequence(s).

-

None of the genes has a regulatory sequence shared with TSLP. This result will
hinder our ability to pursue this aim any further.

Caveats and solutions (part 2): Although we have devised several criteria to narrow
down the list of TSLP-like genes, the large number of genes that may still meet these
criteria is a major issue. If necessary, we will examine other mouse models of skin-barrier
defect (Segre, 2006; Segre et al., 1999), several of which are being analyzed by
laboratories at Washington University. After determining which models overexpress
TSLP, we will compare their skin microarray data with our candidate gene list in a
manner described above. This will further narrow down our list to the genes that are also
affected in these additional mouse models.
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Aim II: Investigate the effect of extrinsic factors on TSLP overexpression by the
skin.
Rationale: The embryonic origin of TSLP overexpression in mice lacking Notch
signaling or FATP4 enzyme emphasizes the importance of intrinsic epidermal defects to
induce such a response in the sterile uterine environment. However, these findings cannot
rule out the effect that extrinsic factors might have on boosting TSLP response, as
impaired epidermal differentiation/barrier formation in these models causes barrier
dysfunction and exposes the epithelial cells to various harmful agents. Notably, allergens
and pathogens are currently thought to be the main culprit in driving TSLP production in
asthma and AD (Liu, 2006). Our preliminary studies have also demonstrated that the
consequences of barrier dysfunction are required for development of an AD-like
phenotype in Notch-deficient skin. This requirement is highlighted by the clear transition
from a hypoplastic epidermis and normal dermal structures at birth (Figure 5.18) to a
severe hyperplasia and an AD-like skin phenotype at postnatal day 9 (P9) in the !secretase-deficient animals (Figure 8.2). Although this observation can be interpreted to
support the role of extrinsic agents like pathogens in amplifying epithelial TSLP
overproduction, it also introduces a novel possibility. It suggests that exposure to harmful
agents serve as a secondary signal to fully activate TSLP-primed immune cells and
initiate disease. If true, this can explain why half of AD patients develop asthma overtime
(Spergel and Paller, 2003). We will address these possibilities in the following sub-aims
by examining the specific effects of extrinsic factors on TSLP production and disease
progression.
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Aim IIa: To isolate the possible effect of extrinsic factors on epithelial TSLP
overexpression, an acute model of skin-barrier loss will be used in which no intrinsic
epithelial defect is present (Grubauer et al., 1989a). If such an effect exists, it will be
important to figure out which specific factor(s) mediate(s) it. Therefore, the role of the
two main consequences of skin-barrier dysfunction, water loss and allergen/pathogen
exposure, will be examined separately. To accomplish this goal, the following methods
will be applied.

Experimental approach (part 1): Adult hairless (Foxn1-/-) mice will be used to study if
acute skin-barrier removal with chemical or mechanical means induces TSLP
overexpression. Acetone is an organic solvent, which disrupts the lipid barrier in the
cornified layer of the epidermis (Grubauer et al., 1989b). Tape stripping is also used for
removing the cornified layer of the epidermis and causing acute barrier loss (Jiang et al.,
1998). A cohort of 30 mice will be divided into test and control groups. The test groups
will be treated on their back skin either by rolling acetone-soaked cotton balls for 10
minutes or tape stripping for eight times using Scotch-tape. These procedures have been
shown to induce epidermal cytokine production (e.g. GM-CSF) due to a significant
transepidermal water loss (TEWL), which is measured with an electrolytic water analyzer
(Meeco, Warrington, PA, USA)(Wood et al., 1996; Wood et al., 1992). The control group
will be treated with sterile PBS-soaked cotton balls for 10 minutes. It takes 24 hours for
the skin to reconstitute a competent barrier (Man et al., 1993). Therefore, at 2, 6, 12 and
24 hours after tape stripping, acetone or PBS treatment, a subgroup of the test and control
animals will be sacrificed. The serum and epidermal mRNA from these mice will be
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harvested as described (Demehri et al., 2008; Lee et al., 2007). Subsequently, TSLP
mRNA levels in the epidermis of the test mice will be compared to that in the control
group at designated time points after treatment using qRT-PCR. Likewise, the serum
TSLP levels of the mice in the three groups will be measured by TSLP ELISA kit (R&D
Systems).

Anticipated outcomes and conclusions (part 1): this experiment can yield two different
results.
-

There is a TSLP surge in barrier-defective skin detectable at the level of mRNA.
This elevation may also result in increased serum TSLP levels. Such an outcome
will support the hypothesis that extrinsic factors play a significant role in inducing
TSLP expression. The time course of mRNA surge will show whether TSLP
overexpression constitutes an early or a late response, which will provide an
insight into which consequence of barrier dysfunction may be playing a dominant
role; an early surge will favor the dominance of water loss but a late surge will
point more toward the importance of allergen/pathogen exposure. Nonetheless,
the significance of either conclusion needs to be examined in the follow-up
experiments described in part 2 of this sub-aim.

-

TSLP expression is not altered in mice with acute barrier loss. Although the
transient nature of acute barrier loss limits our ability to reach a solid conclusion
from this result, it will suggest that the effect of extrinsic factors on TSLP
production by otherwise normal epithelium is insignificant. In light of this result,
we will move on to aim IIb.
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Experimental approach (part 2): If the results from the previous section show TSLP upregulation in the skin with acute barrier loss, the specific cause of such an up-regulation
will be tested by separating the effects of water loss and allergen/pathogen exposure.
Three groups of tape-stripped, acetone- or PBS-treated mice will be set up as in part 1
with 30 mice in each group. However, immediately after acetone/PBS treatment, each
group will be divided into three subgroups, (1) wrapped tightly into water vaporimpermeable tapes, (2) wrapped tightly into particle-impermeable tapes, and (3) kept
unwrapped (Grubauer et al., 1989a; Proksch et al., 1991). Sterile latex membrane (Fisher
Scientific, Pittsburgh, PA) will be used as the water vapor-impermeable tape. This
membrane is also impermeable to particles. Its proper placement on the skin to prevent
TEWL will be confirmed on each mouse (Proksch et al., 1991). For particle-impermeable
tape, sterile Op-Site adhesive drape (Medical Action Industries Inc., Arden, NC), which
is permeable to water vapor will be used (Grubauer et al., 1989a). The mice in all
subgroups will be sacrificed at a single time point after tape stripping/acetone treatment,
which is found in part 1 of this sub-aim to be associated with peak TSLP mRNA levels in
the barrier-defective animals. The epidermal mRNA and serum from all the treated
animals will be prepared and TSLP measurements will be performed as outlined above.

Anticipated outcomes and conclusions (part 2): This follow-up study will determine the
isolated effect of water loss and allergen/pathogen exposure on epidermal TSLP
production. The possible outcomes are:
-

Occlusion with water vapor-impermeable tape inhibits the epidermal TSLP
overexpression in the barrier-defective skin while skins wrapped in particle-
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impermeable tape or kept unwrapped continue to overexpress TSLP. This result
will point to water loss as the main driver of TSLP response in acute skin-barrier
loss.
-

Both vapor- and particle-impermeable tapes suppress TSLP overexpression in the
barrier-defective skin to the same degree. Based on such an outcome, the invading
particles (or factors other than water loss) will be the primary culprit in causing
TSLP overexpression in this paradigm. However, if the level of suppression is
less pronounced in particle-impermeable tape occlusion, the outcome will suggest
that both consequences of barrier dysfunction contribute to TSLP overexpression.

-

No difference is observed between the three groups, and TSLP surge in barrierdefective skin is not affected by artificial barrier replacement. This outcome will
fail to support the role of water loss and allergen/pathogen exposure in inducing
epidermal TSLP overexpression. It will suggest that direct stress and injury to
epidermal cells during the process of barrier destruction induces TSLP response
in the context of acute barrier loss.

Caveats and solutions: To demonstrate that the effects observed with artificial barrier
restoration are not specific to mechanical tape occlusion, we will repeat some of the key
experiments in aim IIa (part 2) using a physiologic lipid coat as the barrier-restoring
agent.
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Aim IIb: It is possible that the consequences of barrier dysfunction act to amplify the
epithelial TSLP overexpression, which is first triggered by intrinsic epithelial defects. To
investigate this possibility, we will attempt to reduce TSLP overproduction in the Notchdeficient epidermis by restoring the skin barrier, as in aim IIa. To achieve this aim, we
will conduct the following experiments.

Experimental approach: Epidermal TSLP expression will be monitored after partial or
complete skin-barrier restoration in Notch-deficient animals. E18.5-19.0 embryos that
lack !-secretase in their skin and maintain extremely high levels of TSLP will be
delivered by cesarean section (6 mice for each experimental condition)(Koch et al.,
2000). Prior to the onset of TEWL or allergen/pathogen exposure, the affected skin will
be covered by exogenous physiologic lipids or carrier alone, and TSLP changes at the
level of epidermal mRNA and serum protein will be measured at 6, 12 and 24 hours post
lipid treatment, as outlined in aim IIa. Physiologic lipid mix is an equimolar combination
of three main barrier-forming lipids (cholesterol, fatty acids, and ceramides) in propylene
glycol:ethanol (7:3 vol/vol) solvent, which is shown to restore the barrier function (Choi
et al., 2005). As an alternative to lipid treatment, the mutant embryos will be occluded
with water vapor-impermeable tape, particle-impermeable tape or kept unwrapped
according to the procedure described in aim IIa. The rest of the assay will be the same as
above.

Anticipated outcomes and conclusions: Restoring the skin barrier in !-secretasedeficient animals using the methods outlined will elucidate the role of water loss and
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allergen/pathogen exposure in augmenting epidermal TSLP overproduction individually
and in combination. These experiments will yield one of the following outcomes.
-

Repairing the skin-barrier defect with lipid coat and vapor-impermeable tape
lowers TSLP levels in the !-secretase-deficient embryos. Regardless of the degree
of reduction, this outcome will demonstrate that the consequences of barrier
dysfunction collectively play a significant role in amplifying epithelial TSLP
production. The specific contribution of each extrinsic factor will then be realized
based on the results obtained from the mice wrapped in particle-impermeable
tapes. On one hand, if occlusion with particle-impermeable tape causes reduction
in TSLP levels similar to water vapor-impermeable tape, allergen/pathogen
exposure will be considered as the main effector in augmenting TSLP
overexpression. On the other hand, if the effect of water vapor-impermeable tape
is absent in particle-impermeable tape, water loss will be the mediator boosting
TSLP production.

-

Repairing the skin-barrier defect with lipid coat and water vapor-impermeable
tapes has no effect on TSLP overexpression by !-secretase-deficient
keratinocytes. Therefore, we are unable to attribute any importance to extrinsic
factors in affecting TSLP expression. Although this outcome will reemphasize the
dominant role of epidermal differentiation/barrier formation defect in stimulating
TSLP overexpression, due to its limitations, it will not rule out the effect of
barrier dysfunction conclusively.

Caveats and solutions: The design of the proposed experiments will prevent us from
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reaching a solid conclusion in wake of a negative outcome. First, if the barrier-restoring
methods require more than 24 hours to show their effect on TSLP production,
experimentation with !-secretase-deficient embryos will be impractical. The reasons are:
1) the embryos cannot be kept away from foster mother for more than 24 hours, 2) if
together, mother will remove the lipid coat or tapes from the skin of the newborns, and 3)
these mice die at weaning (Pan et al., 2004), excluding the possibility of testing them in
adulthood. To circumvent these problems, we will repeat the experiments in adult mice
lacking partial Notch signaling in their skin (Msx2-Cre/+; N1flox/flox; N2flox/+; N3-/- or
N1N2hN3CKO), which produce high levels of TSLP (Demehri et al., 2008). We will add
additional time points to the analysis so that we can be confident our conclusions are
accurate.
The second issue is the extent to which skin barrier can be restored exogenously
with lipid or tape. Although the skin coverage with lipid coat is likely to be more
inclusive, both methods risk leaving a significant stretch of barrier-defective skin
uncovered, hindering our ability to detect a subtle yet significant effect of water loss
and/or particle exposure on TSLP overexpression. To address this issue, we will conduct
additional experiments in which 5mm diameter skin patches from E18.5 !-secretasedeficient embryos will be transplanted on back of the nude mice (Blanpain et al., 2006),
and 7 days later, the barrier reconstitution assays will be performed on the engrafted
mutant skins as above. The subsequent timetables for TSLP measurement and data
analysis will also be the same as above.
Although covering the skin with protective lipid or water vapor-impermeable
tapes prevents water loss and entry of new allergens and pathogens to the site of the
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barrier defect, the persistence of existing pathogens can introduce a confounding factor
for interpreting the results obtained from the long-term experiments described above. To
avoid this, an independent approach will be taken. We will specifically test the role of
pathogens in boosting TSLP overexpression by maintaining a cohort of !-secretasedeficient animals in a germ-free environment before any microbial community is formed
on the skin. For that, E18.5-19.0 mutant embryos will be delivered by cesarean section
and kept with a foster mother in plastic gnotobiotic isolators (Hooper et al., 2001). At P9,
the skin mRNA and serum of these mice will be collected. TSLP mRNA and protein
levels in germ-free mutant animals will then be compared to those of P9 mutant mice
kept in a regular housing facility. If epidermal TSLP overexpression in germ-free animals
is reduced, this will strongly suggest that pathogens influence epithelial cells to increase
their TSLP production.
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FIGURES
Figure 8.1
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Figure 8.1. TSLP is produced by suprabasal keratinocytes in !-secretase-deficient skin.
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Figure 8.2
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Figure 8.2. Mice lacking total Notch signaling in their skin develop an AD-like skin
disease shortly after birth. (A) H&E staining shows AD-like changes including
hyperkeratosis, parakeratosis and acanthosis in !-secretase-deficient skin at postnatal day
9 (P9). (B) Toluidine blue staining highlights the increased number of mast cells in
dermis of PSDCKO mice, which are also significantly larger than their counterparts in
wild-type skin.
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Figure 8.3
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Figure 8.3. TSLP overexpression begins during embryonic life and is readily detectable
in serum of animals with !-secretase- or FATP4-deficient skin at P0 (n = 3).
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Figure 8.4
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Figure 8.4. NF$B signaling inhibition in Notch-deficient skin reduces TSLP
overexpression in vivo. Pyrrolidine dithiocarbamate (PDTC) is a potent inhibitor of
NF$B, and twice daily topical treatment of the skin with PDTC (in PBS) causes NF$B
signaling inhibition in epidermis and a clear epidermal thickening within 7 days (Seitz et
al., 1998). Treating the skin of P4 Msx2-Cre/+; N1flox/flox; N2flox/flox (N1N2CKO) mice
with 20mM PDTC or control (0.05% SDS) according to this protocol (Seitz et al., 1998)
leads to marked reduction in serum TSLP levels after 7 days (n = 2 for each group).
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